drug	genes	question	answer	incorrect_recommendations	concurring_recommendation	llm_answer	oai_embedding_ref_vs_llm	oai_embedding_ref_vs_concurring	oai_embedding_adversarial_vs_llm	oai_embedding_concurring_vs_llm	negation_mpnet_ref_vs_llm	negation_mpnet_ref_vs_concurring	negation_mpnet_adversarial_vs_llm	negation_mpnet_concurring_vs_llm	base_mpnet_ref_vs_llm	base_mpnet_ref_vs_concurring	base_mpnet_adversarial_vs_llm	base_mpnet_concurring_vs_llm	roberta_ref_vs_llm	roberta_ref_vs_concurring	roberta_adversarial_vs_llm	roberta_concurring_vs_llm	gte_ref_vs_llm	gte_ref_vs_concurring	gte_adversarial_vs_llm	gte_concurring_vs_llm	gpt4_ref_vs_llm
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 positive for HLA-B with regards to taking abacavir? Give a 2-3 sentence summary.	Abacavir is not recommended	['Proceed taking abacavir as normal. There is no recommendation.', 'Take abacavir with a reduced dose.', 'Take abacavir with an increased dose.']	Avoid abacavir. Take an alternate therapy.	Individuals who are HLA-B*57:01 positive should avoid taking abacavir due to a significantly increased risk of developing a potentially life-threatening hypersensitivity reaction. Clinical guidelines recommend using alternative antiretroviral agents for these patients to prevent this severe adverse effect.	0.696917441070123	0.7591085217163046	0.7478930202531574	0.6671486114452181	0.765963	0.7781518	0.6934752	0.65761715	0.72145957	0.83611435	0.7775479	0.67424357	0.62724	0.81410533	0.7101601	0.63107073	0.67407906	0.8348719	0.68389004	0.6955916	1
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 negative for HLA-B with regards to taking abacavir? Give a 2-3 sentence summary.	Use abacavir per standard dosing guidelines	['Avoid abacavir. Take an alternate therapy.', 'Take abacavir with a reduced dose.', 'Take abacavir with an increased dose.']	Proceed taking abacavir as normal. There is no recommendation.	If an individual tests negative for the HLA-B*57:01 allele, they have a significantly lower risk of developing a hypersensitivity reaction to abacavir. Therefore, it is generally considered safe for them to take abacavir as part of their antiretroviral therapy regimen. However, all patients should still be monitored for adverse reactions according to standard clinical guidelines.	0.6250543377087445	0.7425463294048439	0.7393050470573677	0.6008858598627939	0.59157044	0.6159381	0.63718647	0.63080525	0.6611116	0.81842065	0.70092964	0.6707627	0.56543297	0.7709747	0.7008068	0.5092694	0.61912507	0.6778212	0.68626267	0.5813097	1
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 positive for HLA-B with regards to taking allopurinol? Give a 2-3 sentence summary.	Allopurinol is contraindicated	['Proceed taking allopurinol as normal. There is no recommendation.', 'Take allopurinol with a reduced dose.', 'Take allopurinol with an increased dose.']	Avoid allopurinol. Take an alternate therapy.	Individuals who test positive for HLA-B*58:01 are at a significantly increased risk of developing severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), when taking allopurinol. Clinical guidelines recommend that allopurinol be avoided in these patients, and alternative treatments should be considered for managing conditions like gout.	0.5939881878249901	0.7545144589685137	0.7085670824596689	0.5468308249933829	0.71925104	0.76679975	0.6530146	0.55745727	0.67729163	0.8266746	0.66951466	0.64183176	0.45064908	0.70286465	0.5987668	0.5284201	0.66443044	0.6549113	0.6174964	0.6480142	1
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 negative for HLA-B with regards to taking allopurinol? Give a 2-3 sentence summary.	Use allopurinol per standard dosing guidelines	['Avoid allopurinol. Take an alternate therapy.', 'Take allopurinol with a reduced dose.', 'Take allopurinol with an increased dose.']	Proceed taking allopurinol as normal. There is no recommendation.	For a patient who tests negative for the HLA-B*58:01 allele, there is no increased genetic risk for allopurinol-induced severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Therefore, allopurinol can be prescribed according to standard dosing guidelines without additional genetic-related precautions.	0.6205782079138522	0.7484103453525945	0.7186908948710595	0.590790774150585	0.50049126	0.6815679	0.65257436	0.6010473	0.61443716	0.8328961	0.7034953	0.55171	0.44067684	0.78210455	0.6806982	0.40853247	0.6342876	0.71530896	0.6425888	0.6047678	1
amikacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking amikacin as normal. There is no recommendation.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Avoid amikacin. Take an alternate therapy.	Individuals with variants in the MT-RNR1 gene are at increased risk of aminoglycoside-induced hearing loss, including with the antibiotic amikacin. Clinical guidelines recommend avoiding aminoglycosides in these patients if possible, and if an aminoglycoside must be used, close monitoring of hearing function and consideration of alternative antibiotics are advised to minimize ototoxicity risk.	0.7037837859068501	0.5695837331112267	0.4648830871229456	0.45947459107328703	0.7027945	0.60226387	0.47815537	0.5770043	0.7359313	0.48981178	0.48967484	0.5349655	0.758261	0.5031077	0.46382198	0.4726851	0.63541025	0.6614421	0.53816634	0.59817934	1
amikacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid amikacin. Take an alternate therapy.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Proceed taking amikacin as normal. There is no recommendation.	For individuals at normal risk of aminoglycoside-induced hearing loss, as determined by MT-RNR1 genotyping, there are no specific mitochondrial-related contraindications for the use of amikacin. However, standard clinical precautions should still be followed, including monitoring for ototoxicity and renal function, as aminoglycosides generally carry a risk of hearing loss, regardless of genetic predisposition. Regular auditory assessments may be advisable during prolonged treatment.	0.6291742975060788	0.47580446717636815	0.4859188850444213	0.5363555192911402	0.62575155	0.4669419	0.4909214	0.6479404	0.6556586	0.5265164	0.54872555	0.6001933	0.66804606	0.5102065	0.49971142	0.49038553	0.5897565	0.54797655	0.5869781	0.5542149	0
amikacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid amikacin. Take an alternate therapy.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Proceed taking amikacin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss due to variants in the MT-RNR1 gene, clinical guidance typically involves exercising caution with the use of aminoglycosides like amikacin. Preemptive genetic testing for MT-RNR1 variants (such as the m.1555A>G mutation) should be considered, as these variants can significantly increase the risk of irreversible hearing loss. If such variants are present or if testing is not feasible, alternative antibiotics should be considered to mitigate this risk.	0.624964082932096	0.47580446717636815	0.4859188850444213	0.4695622733294591	0.5354043	0.4669419	0.4909214	0.49491078	0.6850283	0.5265164	0.54872555	0.4987583	0.68547535	0.5102065	0.49971142	0.40636903	0.5982249	0.54797655	0.5869781	0.4728806	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	For individuals with G6PD deficiency, caution is advised when prescribing aminosalicylic acid due to the risk of hemolytic anemia. Clinical guidelines suggest that alternative treatments should be considered to avoid triggering hemolysis in these patients. Always consult with a healthcare provider for personalized medical advice.	0.6361459073286551	0.44172620650463	0.32037267961495025	0.5950503809702138	0.68186367	0.57132834	0.38750115	0.6712954	0.68603545	0.48404753	0.32936177	0.6733134	0.66247743	0.42687207	0.34347174	0.6249775	0.556034	0.48436835	0.38195375	0.5893825	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	For individuals who are indeterminate for glucose-6-phosphate dehydrogenase (G6PD) deficiency, caution is advised when considering the use of aminosalicylic acid. Given the potential risk of hemolysis in G6PD-deficient individuals, close monitoring for hemolytic reactions is recommended, and alternative medications with a safer profile for G6PD deficiency should be considered if possible.	0.6301317129359288	0.36518252963585807	0.290232986552188	0.576061537929234	0.578608	0.27695686	0.3095455	0.63390684	0.6795411	0.35385722	0.31128815	0.6326134	0.5870654	0.2328999	0.22736825	0.5226345	0.566956	0.39969903	0.3975958	0.52076524	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, taking aminosalicylic acid is generally contraindicated due to the increased risk of hemolysis and resultant hemolytic anemia. Clinical guidance would typically recommend avoiding the medication and considering alternative treatments that do not pose a risk to red blood cell integrity. Consulting with a healthcare provider is essential for personalized treatment options.	0.4679217150431	0.4006416696819361	0.41775495424629056	0.5981893507621001	0.52819717	0.46784836	0.487771	0.66218966	0.48901796	0.4492486	0.45345166	0.6577474	0.53539217	0.41248125	0.39447236	0.6011859	0.54757714	0.37057325	0.4644723	0.5881655	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) levels, taking aminosalicylic acid does not typically carry an increased risk of hemolytic anemia associated with G6PD deficiency. Therefore, standard dosing and administration protocols for aminosalicylic acid can be followed safely for these individuals. It is always advisable to monitor for any adverse reactions and consult with a healthcare provider for personalized medical advice.	0.6012608401762574	0.3817372014394566	0.25350288918969843	0.6376988814943791	0.5147323	0.39697912	0.20935781	0.69231546	0.46770558	0.27556524	0.16035241	0.74212754	0.39838395	0.17489599	0.10831696	0.6210497	0.5652516	0.4079968	0.2952974	0.64074284	1
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer (UM) with an activity score of ≥3.0 for CYP2D6 and an Intermediate Metabolizer (IM) for CYP2C19, clinical guidelines suggest considering an alternative medication not primarily metabolized by CYP2D6 or starting amitriptyline at a low dose with careful monitoring. This is because UM status for CYP2D6 may lead to subtherapeutic levels of amitriptyline, reducing efficacy, while IM status for CYP2C19 may also affect drug metabolism, necessitating dose adjustments and close monitoring for therapeutic response and side effects.	0.6811265005595589	0.6949423861638112	0.651481370625492	0.5865340187241121	0.62728584	0.65050733	0.5732424	0.675334	0.6062173	0.6533343	0.5974688	0.6383921	0.4556159	0.5631736	0.5388899	0.4149181	0.50375944	0.6366815	0.53334093	0.54929286	1
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For a patient identified as a Poor Metabolizer (PM) with an activity score of 0.0 for CYP2D6 and an Intermediate Metabolizer (IM) for CYP2C19, consider starting amitriptyline at a reduced dose and titrating carefully while monitoring for side effects. Amitriptyline is metabolized by both CYP2D6 and CYP2C19, and impaired metabolism can increase the risk of adverse effects. The use of an alternative medication not extensively metabolized by these enzymes may also be considered.	0.7214348723938503	0.698769571228788	0.6955279047742459	0.6092240435354512	0.7181563	0.6797541	0.6347178	0.5434297	0.7106274	0.72943014	0.6795208	0.6708062	0.5797754	0.6338296	0.6091957	0.5598885	0.60037446	0.64152896	0.546624	0.5959343	0
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer with an activity score of ≥4.0 for CYP2D6 and no result for CYP2C19, clinical guidance would generally suggest avoiding the use of amitriptyline due to the increased risk of subtherapeutic levels and decreased efficacy. Alternative medications not metabolized by CYP2D6 should be considered. If amitriptyline use is necessary, a higher dose might be needed, but this requires careful monitoring and potentially genetic testing for CYP2C19 to inform dosing adjustments.	0.6852910228633489	0.5743861857306282	0.5258918246350636	0.6336494649572293	0.6550688	0.5125287	0.48056582	0.6526831	0.6551964	0.39688072	0.400237	0.6620855	0.6943084	0.3816344	0.41306093	0.5289784	0.6330719	0.49497038	0.44446456	0.60942894	1
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For an individual identified as an Ultrarapid Metabolizer (activity score = 2.5) for CYP2D6 and a Rapid Metabolizer for CYP2C19, alternative medications not primarily metabolized by CYP2D6 and CYP2C19 should be considered, as amitriptyline's efficacy and safety might be compromised. If amitriptyline must be used, a reduction in dose with careful monitoring for efficacy and side effects is recommended.	0.6547652338214021	0.6949423861638112	0.651481370625492	0.6013926607842875	0.6358682	0.65050733	0.5732424	0.62551504	0.65262675	0.6533343	0.5974688	0.6734081	0.49475625	0.5631736	0.5388899	0.49146068	0.53505933	0.6366815	0.53334093	0.5605128	0
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of aspirin can pose a risk of hemolytic anemia, especially at high doses. Clinical guidance typically advises caution or avoidance of aspirin to prevent potential hemolytic episodes. Alternative treatments or the lowest effective dose under medical supervision might be recommended depending on the clinical scenario.	0.5980695700660056	0.4459196450676884	0.3442451989461756	0.5416198095181982	0.60699695	0.50565726	0.29768896	0.5550779	0.5870613	0.3899839	0.20185107	0.54977584	0.4769876	0.30249068	0.20275861	0.48867524	0.5291674	0.47129795	0.35572088	0.58010453	0
aspirin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	In individuals with an indeterminate G6PD status, caution should be exercised when prescribing aspirin due to the potential risk of hemolysis, particularly in patients with undiagnosed G6PD deficiency. It may be advisable to perform a confirmatory G6PD test or consider alternative treatments to avoid the risk of hemolytic anemia. Consultation with a healthcare provider is essential to tailor the safe use of aspirin based on individual patient risk factors.	0.6373406352573681	0.3329144969915283	0.2828750497858906	0.4966847716558397	0.55711544	0.15246582	0.13569383	0.5668705	0.62734556	0.14822075	0.043561343	0.5332	0.5797596	0.10093915	0.072764836	0.48556143	0.56323326	0.39109543	0.3770856	0.55816644	0
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	For individuals who are Glucose-6-phosphate dehydrogenase (G6PD) deficient, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), clinical guidance typically advises caution with aspirin use. Aspirin can potentially trigger hemolysis in G6PD-deficient individuals, so it should be used only if clearly necessary, and alternative medications with a safer profile for these patients should be considered. Monitoring for signs of hemolysis is important if aspirin is administered.	0.5030198925666638	0.3629086447441852	0.4316698491535371	0.4965047611460742	0.59469867	0.5096383	0.49232772	0.5476377	0.6113917	0.5230757	0.43451044	0.51988083	0.5831615	0.37750256	0.35231495	0.49013582	0.5645478	0.46096954	0.49368557	0.5241562	0
aspirin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) enzyme activity, there are no specific pharmacogenomic concerns regarding the use of aspirin. These patients can generally take aspirin as prescribed without an increased risk of hemolysis, a concern typically associated with G6PD deficiency. It's still important, however, for all patients to follow general clinical guidelines and consult their healthcare provider for personalized recommendations, especially if they have other underlying health conditions.	0.6580262956752627	0.3801122209271646	0.26357460814829503	0.5729318150665988	0.5686396	0.37381068	0.1668359	0.5599599	0.51218474	0.24273352	0.09404408	0.5413653	0.39823005	0.088122815	0.028731108	0.5137367	0.565189	0.4127048	0.295844	0.6121048	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Normal Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	For individuals who are normal metabolizers of UGT1A1 taking atazanavir, no dosage adjustment is typically necessary. Standard dosing can be followed, as these individuals are likely to have normal bilirubin levels and a lower risk of hyperbilirubinemia, a common side effect associated with atazanavir. Clinical monitoring should continue as per standard guidelines for antiretroviral therapy.	0.7408979993956968	0.5711183341636629	0.5767997077611658	0.6695387767251573	0.7098064	0.6421217	0.52521557	0.6116527	0.7325765	0.6135973	0.54535013	0.6448213	0.6595931	0.45971864	0.41235915	0.5380957	0.65259105	0.4662697	0.5388937	0.5600089	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Poor Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).	['Proceed taking atazanavir as normal. There is no recommendation.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Avoid atazanavir. Take an alternate therapy.	For patients identified as Poor Metabolizers for UGT1A1, clinical guidance suggests caution when prescribing atazanavir. These individuals may have an increased risk of developing hyperbilirubinemia due to reduced UGT1A1 enzyme activity, which impairs bilirubin conjugation and clearance. Monitoring bilirubin levels and considering alternative antiretroviral therapy could be necessary to manage this risk.	0.7480065061035152	0.6557665948866161	0.6045642846820268	0.6468846975430577	0.65589553	0.63117003	0.51049376	0.5430056	0.579939	0.7025749	0.5682924	0.52722275	0.5290589	0.51187485	0.4455293	0.4551995	0.64995426	0.6169579	0.556464	0.59705967	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Indeterminate for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	No recommendation	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	For an individual who is Indeterminate for UGT1A1 when considering atazanavir, clinical guidelines recommend monitoring for hyperbilirubinemia. While routine UGT1A1 genotyping is not standard before initiating atazanavir, patients with indeterminate status should be aware of the potential for increased bilirubin levels, and healthcare providers might consider alternative medications if jaundice or other bilirubin-related issues occur. It is essential to weigh the benefits and potential risks in these cases.	0.22728172203909008	0.48173100566612415	0.23318251202327814	0.5595833790711184	0.16555928	0.39350763	0.21344809	0.4921808	0.09406	0.25891978	0.13633974	0.5578721	-0.00030493364	0.3284822	0.11475738	0.391984	0.27614206	0.51323426	0.3697779	0.52196413	0
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Intermediate Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	For someone who is an Intermediate Metabolizer for UGT1A1, caution is advised when prescribing atazanavir due to the increased risk of hyperbilirubinemia. It may be necessary to consider alternative antiretroviral therapies or closely monitor bilirubin levels during treatment to manage potential side effects.	0.7733924801709392	0.5711183341636629	0.5767997077611658	0.5911506934140879	0.6846993	0.6421217	0.52521557	0.50872767	0.7429049	0.6135973	0.54535013	0.6119797	0.6846429	0.45971864	0.41235915	0.5142806	0.69766754	0.4662697	0.5388937	0.52910364	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For an individual identified as a Normal Metabolizer with an activity score of 1.25 for the CYP2D6 enzyme, the standard clinical guidance for taking atomoxetine would typically apply. Such patients are expected to metabolize atomoxetine at a regular rate, suggesting that they should follow standard dosing recommendations. However, clinical decisions should also consider other patient-specific factors such as overall health, concurrent medications, and any other potential drug interactions.	0.5087836234453521	0.42715668847227034	0.4024412384359093	0.6171500379049251	0.46649727	0.36949787	0.3471994	0.5241489	0.41190398	0.28713918	0.31679457	0.55572426	0.5220786	0.4850908	0.42077208	0.5385659	0.35597396	0.40467218	0.29155576	0.6358026	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For an individual who is an Ultrarapid Metabolizer (UM) with a CYP2D6 activity score of ≥3.75, the clinical guidance would be to use an alternative medication. Ultrarapid Metabolizers can metabolize atomoxetine much faster, potentially leading to subtherapeutic drug levels and reduced efficacy. Therefore, selecting a medication not primarily metabolized by CYP2D6 would be more appropriate for ensuring therapeutic effectiveness.	0.5095750683366158	0.42715668847227034	0.4024412384359093	0.5659361998252007	0.41920593	0.36949787	0.3471994	0.56383127	0.36491126	0.28713918	0.31679457	0.53922004	0.39685988	0.4850908	0.42077208	0.4632706	0.34640443	0.40467218	0.29155576	0.63338625	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For an individual identified as a CYP2D6 Ultrarapid Metabolizer with an activity score of ≥4.0, clinical guidance suggests that atomoxetine may be less effective due to increased metabolism leading to lower plasma drug levels. Consideration should be given to alternative treatments or increased monitoring of response and potential dose adjustments to achieve the desired therapeutic effect.	0.5479478843723998	0.42715668847227034	0.4024412384359093	0.6243289054503832	0.41221166	0.36949787	0.3471994	0.61747396	0.35343722	0.28713918	0.31679457	0.59196854	0.43580538	0.4850908	0.42077208	0.48903325	0.42702338	0.40467218	0.29155576	0.6869892	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For someone identified as a Normal Metabolizer with an activity score of 1.5 for CYP2D6, clinical guidance typically suggests that they can take atomoxetine at the standard recommended dosage. Normal metabolizers generally have the typical enzyme activity, meaning the drug will be processed by their body as expected, leading to usual therapeutic outcomes and side effect profiles. However, individual monitoring for efficacy and side effects is still advised.	0.520176122793214	0.42715668847227034	0.4024412384359093	0.5727942601633768	0.44834164	0.36949787	0.3471994	0.45301902	0.44299364	0.28713918	0.31679457	0.51205134	0.51507664	0.4850908	0.42077208	0.48389894	0.34950712	0.40467218	0.29155576	0.6580351	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	For individuals with increased function variants of the SLCO1B1 gene, which encodes the transporter protein OATP1B1, atorvastatin may be taken at standard doses without any adjustments. This genetic variant typically results in enhanced hepatic uptake and potentially lower plasma concentrations of atorvastatin, which may reduce the risk of statin-associated muscle symptoms. However, the clinical significance of increased function variants is not fully established and does not usually necessitate changes in atorvastatin dosing.	0.2823963000177937	0.3523187039537286	0.36646681329051006	0.48916422556175737	0.39297557	0.27986246	0.3984175	0.50428754	0.36747074	0.47312072	0.35083434	0.5725349	0.29653895	0.37909073	0.32316342	0.5039601	0.36529443	0.5329314	0.59090626	0.5234478	1
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	Individuals with Normal Function for the SLCO1B1 gene typically do not have an increased risk of atorvastatin-associated myopathy. Therefore, standard dosing of atorvastatin is appropriate for these patients, and they can be treated according to general clinical guidelines for atorvastatin use without the need for special modifications or additional monitoring.	0.3476107935529165	0.3523187039537286	0.36646681329051006	0.5912938299126315	0.37661335	0.27986246	0.3984175	0.6282626	0.39539027	0.47312072	0.35083434	0.6104459	0.3112222	0.37909073	0.32316342	0.47161746	0.45498973	0.5329314	0.59090626	0.5793258	1
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	For individuals with an indeterminate SLCO1B1 genotype, clinical guidance would suggest following standard procedures for atorvastatin prescription, as no specific genotype-based recommendations can be made. It may be beneficial, however, to monitor for potential adverse effects like myopathy, especially if other risk factors are present. In such cases, dose adjustments or considering alternative statins could be explored based on clinical response and tolerability.	0.2946276559473076	0.47622299017767583	0.21799617205276686	0.6034864301209368	0.24111666	0.30401453	0.14507087	0.626758	0.0849942	0.20310934	0.078651264	0.5960745	0.02280802	0.27278835	0.06812026	0.5674124	0.36782545	0.5326432	0.41531742	0.59206563	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	['Proceed taking atorvastatin as normal. There is no recommendation.', 'Avoid atorvastatin. Take an alternate therapy.']	Take atorvastatin with an altered dose.	For individuals with Possible Decreased Function of the SLCO1B1 gene taking atorvastatin, clinical guidelines suggest starting with a low dose and considering alternative statins, such as pravastatin or rosuvastatin, which have a lower risk of muscle toxicity. Enhanced vigilance for signs of myopathy is recommended with any dose increases.	0.7311426795756972	0.6585139763767641	0.6054158908619628	0.615818288954725	0.752185	0.6618069	0.59806365	0.6540268	0.6873561	0.6170747	0.6731684	0.59180856	0.60080856	0.5733377	0.54448944	0.5576222	0.6580214	0.66922385	0.5752127	0.6299232	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Take azathioprine with a reduced dose.', 'Take azathioprine with an increased dose.']	Avoid azathioprine. Take an alternate therapy.	For a patient who is a normal metabolizer for TPMT but a poor metabolizer for NUDT15, clinical guidelines suggest starting azathioprine at approximately 30-80% of the standard dose while monitoring closely for toxicity. This is due to the significant risk of myelosuppression associated with NUDT15 poor metabolizers, even if TPMT function is normal. Regular blood count monitoring is essential to manage potential adverse effects.	0.6778297208129728	0.6419905906519379	0.6083212357836375	0.5074642475118171	0.6305897	0.671346	0.5922713	0.5265686	0.6134924	0.6836008	0.5990632	0.53337294	0.6602183	0.63224715	0.58392835	0.59223074	0.60418206	0.6212602	0.57314605	0.56368047	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For a patient identified as a Possible Intermediate Metabolizer for TPMT (Thiopurine S-methyltransferase) and a Normal Metabolizer for NUDT15 (Nudix Hydrolase 15), it is recommended to start azathioprine at 30-70% of the standard dose. Close monitoring of hematologic parameters and adjusting the dose based on tolerance and therapeutic response is crucial to avoid potential toxicity.	0.6891534908461507	0.6416023522801692	0.5998024512284732	0.591385521202587	0.6456936	0.5624113	0.47381184	0.52999884	0.6984258	0.59944177	0.65054864	0.5113602	0.62200195	0.5782251	0.5763185	0.5472891	0.65475184	0.60769624	0.53516483	0.559835	1
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For a patient who is a Normal Metabolizer for TPMT and an Intermediate Metabolizer for NUDT15, it is recommended to start azathioprine at 30-80% of the target dose and then adjust based on the patient's tolerance and clinical response. This approach minimizes the risk of myelosuppression due to the intermediate NUDT15 metabolism status. Frequent monitoring of blood counts is advised to promptly identify any adverse effects.	0.7008471086844753	0.6416023522801692	0.5998024512284732	0.5899554903543001	0.75588423	0.5624113	0.47381184	0.5503368	0.7099882	0.59944177	0.65054864	0.49795365	0.68366647	0.5782251	0.5763185	0.5626057	0.6982197	0.60769624	0.53516483	0.6183353	1
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For a patient identified as an intermediate metabolizer for TPMT and a possible intermediate metabolizer for NUDT15, clinical guidelines suggest considering a lower starting dose of azathioprine, accompanied by close monitoring for adverse effects like myelosuppression. Additionally, frequent blood count checks are recommended to ensure safe and effective dosing, to mitigate the risk of severe toxicity.	0.6844262329480588	0.6416023522801692	0.5998024512284732	0.5947340989803671	0.7094172	0.5624113	0.47381184	0.5694286	0.60770947	0.59944177	0.65054864	0.48487765	0.6147468	0.5782251	0.5763185	0.58029133	0.5800358	0.60769624	0.53516483	0.6420466	1
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	['Proceed taking capecitabine as normal. There is no recommendation.', 'Avoid capecitabine. Take an alternate therapy.']	Take capecitabine with an altered dose.	For an individual who is an intermediate metabolizer with an activity score of 1.5 for DPYD, clinical guidelines recommend considering a reduced starting dose of capecitabine due to the decreased enzymatic activity and potential for increased toxicity. Close monitoring for adverse effects is essential, with dosage adjustments based on tolerance and response.	0.5238023389394757	0.47863677882165445	0.40844301278868717	0.6236943539613079	0.59925604	0.42999864	0.33372468	0.5535352	0.56577694	0.40511233	0.3683068	0.5487788	0.528757	0.4880396	0.39713836	0.5395011	0.60106796	0.6063859	0.4190805	0.7112998	0
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	['Proceed taking capecitabine as normal. There is no recommendation.', 'Take capecitabine with a reduced dose.', 'Take capecitabine with an increased dose.']	Avoid capecitabine. Take an alternate therapy.	For individuals identified as Poor Metabolizers with an activity score of 0.0 for the DPYD gene, clinical guidelines recommend avoiding the use of capecitabine due to a significantly increased risk of severe or even life-threatening toxicities. Alternative chemotherapy agents that do not rely on DPYD metabolism should be considered for these patients.	0.465209000044506	0.5414726767739763	0.49672553406270065	0.5622400954879795	0.67706436	0.6247767	0.4920834	0.6007852	0.486214	0.5851306	0.5618895	0.5555553	0.43918937	0.51412904	0.5186717	0.5508374	0.54505193	0.714998	0.6033118	0.6738856	0
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	['Proceed taking capecitabine as normal. There is no recommendation.', 'Avoid capecitabine. Take an alternate therapy.']	Take capecitabine with an altered dose.	For a patient who is an intermediate metabolizer (activity score = 1.0) of DPYD, clinical guidelines suggest considering a dose reduction of capecitabine by 25-50%. This adjustment is recommended to minimize the risk of severe toxicity, as intermediate metabolizers have a reduced capacity to metabolize the drug, potentially leading to an increased exposure to the active metabolites. Close monitoring for adverse effects is also advised.	0.5950618602269211	0.5324344790903448	0.45300515097499244	0.6503567638656991	0.6958638	0.4706911	0.3992529	0.5738093	0.5942382	0.41999757	0.4116537	0.56330705	0.56906325	0.4618656	0.3852155	0.5622139	0.491672	0.44198045	0.31433272	0.72283745	0
capecitabine	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	['Avoid capecitabine. Take an alternate therapy.', 'Take capecitabine with a reduced dose.', 'Take capecitabine with an increased dose.']	Proceed taking capecitabine as normal. There is no recommendation.	For a patient who is a normal metabolizer with an activity score of 2.0 for DPYD, it is generally recommended to follow the standard dosing guidelines for capecitabine. This indicates the patient has typical DPYD enzyme activity and is expected to metabolize capecitabine normally, thus not at an increased risk for severe toxicity. However, as with all patients, clinical monitoring for adverse effects is still advised.	0.44806846052259847	0.5113245277554628	0.42944674198200233	0.5939131592725075	0.55061895	0.69324726	0.42168808	0.5389703	0.54299355	0.6017656	0.42015585	0.63994026	0.50877106	0.54416347	0.4992672	0.57007354	0.4355398	0.60580325	0.44000736	0.58211875	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For individuals who are HLA-A*31:01 negative and HLA-B*15:02 negative, the risk of severe cutaneous adverse reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis) associated with carbamazepine is significantly reduced. Therefore, carbamazepine can be prescribed with standard dosing guidelines, but clinicians should still monitor for any adverse reactions and consider other individual patient factors.	0.5905510365360565	0.7277817176648592	0.7105334996948726	0.5529309447044857	0.50544494	0.7026914	0.746233	0.56806654	0.5097373	0.84202725	0.861857	0.5729523	0.48576617	0.7945945	0.74495906	0.51094604	0.6519507	0.7673427	0.7796819	0.5899737	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For individuals who are negative for HLA-A*31:01 and HLA-B*15:02, the risk of severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) associated with carbamazepine is significantly reduced. Clinical guidance would generally support the use of carbamazepine in these patients, albeit with continuous monitoring for any signs of adverse reactions, as these genetic markers do not eliminate the risk entirely.	0.560704571772552	0.7277817176648592	0.7105334996948726	0.5459920003915847	0.46518135	0.7026914	0.746233	0.5221888	0.48738003	0.84202725	0.861857	0.49547493	0.3869072	0.7945945	0.74495906	0.4229609	0.5626618	0.7673427	0.7796819	0.54010457	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For an individual who is HLA-A*31:01 negative but does not have a result for HLA-B, the risk of hypersensitivity reactions to carbamazepine is reduced but not entirely eliminated. Particularly, without HLA-B genotyping, it cannot be confirmed if the person carries the HLA-B*15:02 allele, which is associated with a high risk of severe skin reactions such as Stevens-Johnson syndrome (SJS). Additional genotyping for HLA-B*15:02 should be considered before starting carbamazepine, especially in individuals of Asian descent, where this allele is more prevalent.	0.48443469545663714	0.7277817176648592	0.7105334996948726	0.4992385103498958	0.3524804	0.7026914	0.746233	0.49728358	0.48890534	0.84202725	0.861857	0.5528671	0.3945626	0.7945945	0.74495906	0.4458841	0.45594388	0.7673427	0.7796819	0.46765172	0
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For an individual with no HLA-A result and who is HLA-B*15:02 negative, there is no increased genetic risk of carbamazepine-induced Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN specifically linked to HLA-B*15:02. Clinical guidance would generally suggest that carbamazepine can be prescribed, but it is important to monitor for adverse reactions, as other non-genetic factors could still contribute to risks.	0.5080545732363099	0.7277817176648592	0.7105334996948726	0.5393383181137481	0.39702168	0.7026914	0.746233	0.6056575	0.4955366	0.84202725	0.861857	0.5637542	0.35391203	0.7945945	0.74495906	0.43769574	0.54905355	0.7673427	0.7796819	0.5655095	1
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For an individual who is a Normal Metabolizer with a CYP2C9 activity score of 2.0, standard dosing of celecoxib is typically appropriate. Clinical guidelines indicate that no dose adjustment is needed, as these patients are expected to metabolize the drug at a usual rate, minimizing the risk of adverse effects or sub-therapeutic response. Always ensure to review individual patient factors and consult with a healthcare provider for personalized recommendations.	0.44618306622353343	0.40567257225714715	0.42770531724059974	0.6595980285151642	0.4877096	0.38638705	0.39478818	0.5908956	0.46282762	0.45445698	0.36048612	0.68963075	0.47290996	0.37312865	0.36061966	0.6449906	0.52638304	0.46683076	0.45701364	0.6857164	1
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	Individuals who are intermediate metabolizers of CYP2C9 with an activity score of 1.5 may show reduced enzyme activity, leading to higher plasma concentrations of celecoxib when taken at standard dosages. Clinical guidance often includes recommending a dose reduction of up to 50% to minimize the risk of adverse effects while achieving therapeutic benefits. Monitoring for efficacy and side effects should also be considered to further tailor the dosage to the individual's response.	0.46889520332173007	0.40567257225714715	0.42770531724059974	0.5547347901926273	0.43705374	0.38638705	0.39478818	0.5133992	0.3911864	0.45445698	0.36048612	0.65172863	0.3664438	0.37312865	0.36061966	0.56971896	0.5252763	0.46683076	0.45701364	0.6048375	0
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	No recommendation	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For individuals identified as Indeterminate for CYP2C9, clinical guidance for taking celecoxib is not well-defined due to the uncertainty in their enzyme activity. Physicians should monitor the patient closely for adverse drug reactions or therapeutic efficacy and consider alternative medications or dosing adjustments based on clinical response and tolerability. Consulting with a pharmacogenomics specialist may also be beneficial for personalized recommendations.	0.2770975474931281	0.4503348200569034	0.204086610726694	0.6319126543634103	0.16806911	0.30769557	0.16489118	0.61286163	0.08939478	0.16374862	0.082905285	0.64783657	-0.008466868	0.31693703	0.07523396	0.55584455	0.35646975	0.54835063	0.43558237	0.6703348	0
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For an individual identified as an Intermediate Metabolizer with a CYP2C9 activity score of 1.0, it is recommended to consider using an alternative medication to celecoxib. If celecoxib is used, a reduced dosage is advised due to an increased risk of adverse effects and reduced drug clearance associated with CYP2C9 intermediate metabolism. Monitoring for efficacy and adverse effects is essential to ensure safe and effective treatment.	0.4642837313958715	0.3892830671369341	0.4244849987563771	0.5733283465546138	0.5323963	0.5151078	0.4857378	0.6040561	0.4727004	0.4742775	0.36415294	0.67376256	0.36808154	0.37362063	0.35958537	0.5705465	0.40952238	0.37028444	0.40010867	0.5923212	0
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	For a patient with an indeterminate G6PD status, caution is advised when prescribing chloramphenicol due to the potential risk of hemolytic anemia. It may be prudent to confirm the patient's G6PD status through further testing before initiating treatment, or consider alternative antibiotics that do not pose this risk. Clinical decisions should be guided by a careful risk-benefit assessment.	0.6424873472157486	0.39246547575067464	0.3245106801493239	0.5550492010759895	0.5441728	0.19861542	0.20102336	0.56689703	0.58424765	0.2068566	0.117397964	0.5445278	0.5760517	0.21180902	0.17144549	0.61775154	0.62861365	0.45501253	0.41476402	0.5890251	0
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	For an individual with G6PD deficiency, particularly those with Chronic Nonspherocytic Hemolytic Anemia (CNSHA), the use of chloramphenicol should generally be avoided. Chloramphenicol has the potential to trigger hemolytic episodes in G6PD-deficient patients, leading to severe hemolysis and related complications. It is essential to consult a healthcare professional for alternative antibiotics that are safer for individuals with G6PD deficiency.	0.4733408349245048	0.4178523072839911	0.45615212154559687	0.5186494780404164	0.57477593	0.51649576	0.50096565	0.6010643	0.5589199	0.5041229	0.42528483	0.54835755	0.46450174	0.39991066	0.35830283	0.576615	0.5359909	0.47981247	0.4969966	0.5782883	0
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	For individuals with a normal G6PD enzyme activity, taking chloramphenicol generally does not pose an increased risk of hemolysis. Thus, standard dosing can typically be administered without specific concerns related to G6PD deficiency. However, it is always important to monitor for other potential side effects of chloramphenicol and to follow clinical guidelines and physician recommendations.	0.6100494498477342	0.43317725481527186	0.29243096024329013	0.5831285030631631	0.5310255	0.36942506	0.17954536	0.5834326	0.49497908	0.25685412	0.10079092	0.5444861	0.3907299	0.17106257	0.09560957	0.5654341	0.5234991	0.428042	0.3108426	0.59974617	1
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	For individuals who are variable for G6PD (glucose-6-phosphate dehydrogenase) deficiency, caution is advised when prescribing chloramphenicol. G6PD deficiency can increase the risk of hemolytic anemia, and while chloramphenicol is not a known major trigger, monitoring for signs of hemolysis is important. Consider alternative antibiotics where possible and ensure close clinical follow-up if chloramphenicol is used.	0.6337796051649888	0.4898280820656678	0.36499620457823706	0.5529493942747996	0.6055153	0.4934541	0.2918487	0.44931474	0.6548661	0.38766325	0.18482666	0.4455553	0.62981343	0.41142672	0.30628744	0.5163362	0.5517149	0.5183808	0.3895975	0.5399206	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	For individuals with G6PD deficiency and chronic non-spherocytic hemolytic anemia (CNSHA), the use of chloroquine can be risky due to the increased potential for hemolysis. Clinical guidance generally advises against the use of chloroquine in these patients due to the risk of severe hemolytic episodes. Alternative medications that do not induce hemolysis should be considered.	0.49007266042859543	0.37153311495852165	0.4390726087515146	0.5267623321824539	0.5719696	0.48956993	0.48323813	0.61155325	0.54368734	0.459889	0.4264392	0.6352034	0.5349158	0.3573649	0.28844643	0.56135815	0.5962796	0.4705147	0.5014475	0.48723477	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	For individuals who have normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity, there are no specific contraindications or adjusted dosing recommendations for taking chloroquine based on their G6PD status. Therefore, they can generally be prescribed chloroquine according to standard clinical guidelines without additional concerns related to G6PD deficiency.	0.6290386993663132	0.4151865088686798	0.29257253602601274	0.6069871042785764	0.51340723	0.38358575	0.19254194	0.60635716	0.44937682	0.2540765	0.12516873	0.6100791	0.37317726	0.1273699	0.059261054	0.59973925	0.58510417	0.4453672	0.3172803	0.5862398	1
chloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	For an individual who is variable for glucose-6-phosphate dehydrogenase (G6PD) deficiency, caution is advised when prescribing chloroquine. This genetic condition can increase the risk of hemolytic anemia when exposed to certain medications, including chloroquine. It is essential to closely monitor for signs of hemolysis and consider alternate treatment options if clinically appropriate.	0.601456506792861	0.46968323126720896	0.36489734562844683	0.510695641699107	0.54207355	0.5186051	0.31381693	0.51427567	0.5711131	0.4105274	0.23366332	0.5392921	0.48913977	0.3348913	0.21829455	0.54101497	0.49044877	0.50255424	0.3728218	0.46633336	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	For individuals who are G6PD-deficient, chloroquine use carries an increased risk of hemolytic anemia. Clinical guidance typically recommends either avoiding chloroquine or using it with caution, closely monitoring for signs of hemolysis. Alternatives to chloroquine should be considered, particularly for those with severe G6PD deficiency.	0.5982958708560091	0.46968323126720896	0.36489734562844683	0.5389401800085861	0.5956008	0.5186051	0.31381693	0.60512215	0.6183264	0.4105274	0.23366332	0.63588154	0.5411047	0.3348913	0.21829455	0.6047013	0.53948927	0.50255424	0.3728218	0.50495297	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking ciprofloxacin due to the increased risk of hemolytic anemia. Clinical guidance would typically recommend selecting an alternative antibiotic that is safer for G6PD-deficient patients to prevent potential adverse effects such as hemolysis.	0.5835620494071097	0.4438475122381718	0.3257868643846184	0.5001126852515265	0.61681086	0.49022415	0.29601064	0.5774348	0.60078895	0.35601187	0.17014761	0.5508518	0.5830039	0.4138652	0.28979284	0.5788416	0.5554474	0.48706716	0.3765311	0.595484	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For individuals who are indeterminate for G6PD deficiency, ciprofloxacin should be used with caution due to the potential risk for hemolysis, even though this risk is generally lower compared to those with confirmed G6PD deficiency. Clinical monitoring for signs of hemolysis is recommended, and alternative antibiotics should be considered if feasible.	0.5833422276118275	0.3360311875783908	0.25992283892784585	0.5161997912460675	0.52101105	0.1779981	0.18765672	0.61135656	0.5642098	0.19115603	0.08984924	0.6506854	0.51692855	0.21838915	0.17383742	0.60260224	0.52859926	0.42345944	0.4001079	0.548435	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is categorized under chronic nonspherocytic hemolytic anemia (CNSHA), the use of ciprofloxacin is generally not recommended. Ciprofloxacin can potentiate oxidative stress, leading to hemolysis in G6PD-deficient individuals. Alternative antibiotics that have a safer profile in G6PD deficiency should be considered.	0.45104614150508837	0.38208821088783307	0.42924361795224675	0.4746901710955125	0.55521196	0.5047884	0.5085552	0.54186016	0.5220197	0.50199807	0.40826872	0.54537654	0.50521874	0.42412663	0.36324444	0.5017745	0.49327382	0.4018524	0.46376386	0.547083	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For an individual who is normal for G6PD (glucose-6-phosphate dehydrogenase) enzyme activity, there are generally no specific restrictions on taking ciprofloxacin. G6PD deficiency is a concern because it can lead to hemolytic anemia when exposed to certain drugs, but since the individual is normal for G6PD, ciprofloxacin can be prescribed and used according to standard clinical guidelines without an increased risk of hemolytic complications.	0.6197245919199069	0.38276692008015645	0.25177241089872665	0.5421740596306333	0.5021092	0.37021354	0.19452894	0.5254999	0.47417933	0.22637795	0.10209319	0.5240791	0.4223509	0.14614059	0.068949364	0.5380987	0.53116125	0.42934164	0.32436523	0.6089622	1
citalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	['Avoid citalopram. Take an alternate therapy.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Proceed taking citalopram as normal. There is no recommendation.	For individuals who are rapid metabolizers of CYP2C19, clinical guidance typically suggests monitoring the effectiveness and tolerability of citalopram, as these patients may have lower plasma concentrations of the drug. Dose adjustment may be necessary, and alternative SSRIs that are not primarily metabolized by CYP2C19, such as sertraline or escitalopram, may be recommended to achieve optimal therapeutic outcomes.	0.6696834991651088	0.5316032710002577	0.5966979122789285	0.5973932814928614	0.7838711	0.53916734	0.5473874	0.56250775	0.77623993	0.580556	0.46466854	0.65088135	0.6704715	0.5730628	0.5569536	0.60054237	0.7100134	0.5798676	0.6025488	0.632482	0
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	['Proceed taking citalopram as normal. There is no recommendation.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Avoid citalopram. Take an alternate therapy.	For individuals identified as likely poor metabolizers of CYP2C19, clinical guidance typically recommends considering an alternative medication to citalopram or starting at a lower dose and closely monitoring for adverse effects. Poor metabolizers have a higher risk of increased drug levels, which can lead to side effects such as QT prolongation. Consulting with a healthcare provider to tailor the treatment plan based on metabolic status is essential.	0.8121571014077048	0.6401034118884491	0.6272478425140092	0.6596924780386387	0.7356276	0.628373	0.54530865	0.588002	0.7501395	0.64336944	0.5497703	0.5917245	0.7781549	0.6504354	0.5842876	0.5983827	0.73523515	0.67197365	0.6417776	0.65299416	1
citalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	['Proceed taking citalopram as normal. There is no recommendation.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Avoid citalopram. Take an alternate therapy.	Ultrarapid Metabolizers (UMs) of CYP2C19 generally have an increased metabolic rate for citalopram, potentially resulting in lower plasma levels and reduced therapeutic efficacy. Clinical guidelines often recommend considering an alternative antidepressant not primarily metabolized by CYP2C19 or monitoring the patient closely for efficacy and side effects, with potential dose adjustments as necessary.	0.7188989880136426	0.6738976936913412	0.6058469264630334	0.6098095704871875	0.7307484	0.65306926	0.5437373	0.6091897	0.78674847	0.62100977	0.54659015	0.6446853	0.8018229	0.6746069	0.6136	0.5849154	0.7608199	0.7099127	0.65166336	0.6384265	1
citalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	No recommendation	['Avoid citalopram. Take an alternate therapy.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Proceed taking citalopram as normal. There is no recommendation.	For a patient with an indeterminate CYP2C19 genotype taking citalopram, it may be prudent to start the medication at the standard dosage while closely monitoring for efficacy and side effects. Without conclusive genotype information, clinicians should use clinical judgment and potentially consider therapeutic drug monitoring to ensure effective and safe medication levels. If adverse effects or suboptimal response occurs, dose adjustments or alternative treatments may be explored.	0.20665445904577467	0.4305902258140802	0.1971014363581738	0.6011709095612687	0.10977992	0.3139183	0.15235092	0.5447515	0.05330781	0.19333221	0.09381477	0.6040941	-0.044896945	0.31026813	0.077434786	0.52745736	0.29983172	0.5449865	0.4306178	0.617315	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For a patient who is an intermediate metabolizer with an activity score of 1.0 for CYP2D6 and a rapid metabolizer for CYP2C19, dose adjustments for clomipramine may be required due to variations in drug metabolism. The reduced CYP2D6 activity may lead to higher plasma concentrations of clomipramine and its active metabolite, potentially increasing the risk of side effects, while rapid CYP2C19 metabolism might lead to faster clearance of the drug. Therefore, close monitoring and possibly a reduction in the starting dose of clomipramine should be considered to avoid adverse effects.	0.7984249593386766	0.743199199857198	0.6899615499319122	0.6484132284368087	0.7225296	0.6226829	0.5216868	0.5146604	0.83614093	0.6405431	0.53945464	0.68790257	0.82376444	0.638971	0.61448556	0.6425497	0.76997256	0.66807246	0.6294661	0.60117424	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For a patient who is an intermediate metabolizer (activity score = 0.5) for CYP2D6 and a poor metabolizer for CYP2C19, clinical guidance for taking clomipramine would include initiating treatment at a lower dose and titrating slowly while monitoring for side effects. This is due to the reduced metabolic activity of both enzymes, which could lead to higher plasma concentrations of the drug and an increased risk of adverse effects. Regular therapeutic drug monitoring is recommended to ensure safe and effective dosing.	0.7940319222786997	0.758487090255069	0.723638229420449	0.6717087505385101	0.6132337	0.6844407	0.5856779	0.5620453	0.6980987	0.70384324	0.6105506	0.67525244	0.64235944	0.65684545	0.6160593	0.6201898	0.6151572	0.6555844	0.5484403	0.65261537	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For a patient with indeterminate CYP2D6 metabolizer status (No Result) and confirmed CYP2C19 Rapid Metabolizer status, it is generally advised to approach clomipramine therapy with caution. The unknown CYP2D6 status suggests that the patient could experience unpredictable drug levels and side effects. As a rapid metabolizer of CYP2C19, the patient might clear the drug more quickly, potentially necessitating dose adjustments. Close monitoring for efficacy and side effects is recommended, and alternative medications that are less influenced by these enzymes might be considered.	0.598708010887863	0.5670832207503633	0.49539212724239884	0.5900639563560032	0.66908777	0.54132766	0.46458408	0.605853	0.6405617	0.46163166	0.4087923	0.70940244	0.5601537	0.4565104	0.4474328	0.62909925	0.51459247	0.54319793	0.45833254	0.5881325	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For a patient who is a Poor Metabolizer (activity score = 0.0) for CYP2D6 and a Normal Metabolizer for CYP2C19, clinical guidance would suggest avoiding clomipramine due to the increased risk of adverse effects and toxicity. If clomipramine must be used, dose reduction and careful therapeutic drug monitoring are recommended to manage potential side effects and ensure safe and effective treatment.	0.7697176055763388	0.7746458766533457	0.7528115651192664	0.6783433397116452	0.7061636	0.7208367	0.6305043	0.6393712	0.73155457	0.75810313	0.6774829	0.7179689	0.6448494	0.70352703	0.6572676	0.66778773	0.67248267	0.69235593	0.59332865	0.6850083	1
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	No recommendation	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	For individuals identified as Ultrarapid Metabolizers (UMs) of CYP2C19, the clinical guidance regarding clopidogrel suggests that standard dosing can typically be maintained. UMs are expected to convert clopidogrel to its active metabolite more efficiently, potentially enhancing its effectiveness. Regular monitoring for bleeding risks and efficacy is recommended to ensure optimal therapeutic outcomes.	0.21524207040441726	0.45688150306617453	0.21610690458159412	0.5670082464677116	0.10645701	0.31816393	0.17449729	0.52831	0.09620495	0.21856642	0.11721446	0.5878009	-0.03143537	0.28515077	0.08993647	0.5294951	0.2983426	0.526283	0.40348768	0.6225618	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	No recommendation	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	For individuals identified as Ultrarapid Metabolizers of CYP2C19, clopidogrel is generally considered to be more effective because they convert the prodrug to its active form more efficiently. Clinical guidance typically suggests that these individuals can continue with the standard dosage of clopidogrel, as their heightened enzymatic activity ensures adequate therapeutic levels of the active metabolite, thereby reducing the risk of major adverse cardiovascular events. However, individual clinical factors should always be considered.	0.1932942431692194	0.45688150306617453	0.21610690458159412	0.5897518272019852	0.041257236	0.31816393	0.17449729	0.47074288	0.09307763	0.21856642	0.11721446	0.6244836	-0.023647657	0.28515077	0.08993647	0.5604968	0.31963265	0.526283	0.40348768	0.5939682	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	If considering clopidogrel, use at standard dose (75 mg/day)	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	For individuals identified as Ultrarapid Metabolizers (UMs) of CYP2C19, the clinical guidance regarding clopidogrel suggests that standard dosing can typically be maintained. UMs are expected to convert clopidogrel to its active metabolite more efficiently, potentially enhancing its effectiveness. Regular monitoring for bleeding risks and efficacy is recommended to ensure optimal therapeutic outcomes.	0.6334769543786428	0.6522205944630053	0.6815597261727898	0.5670082464677116	0.65306324	0.6645943	0.6399111	0.52831	0.57609534	0.80417114	0.67431617	0.5878009	0.57851666	0.8246283	0.7503503	0.5294951	0.6317059	0.63629496	0.6103577	0.6225618	1
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	If considering clopidogrel, use at standard dose (75 mg/day)	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	For a patient who is a normal metabolizer (also known as an *extensive metabolizer*) for CYP2C19, standard dosing of clopidogrel is recommended. This is because the patient's metabolic capacity will allow for the effective activation of clopidogrel, thus providing the expected antiplatelet effect. The typical dosage should suffice to achieve the desired therapeutic outcomes.	0.665475658229374	0.6522205944630053	0.6815597261727898	0.6074196633477194	0.73618054	0.6645943	0.6399111	0.56103516	0.6913289	0.80417114	0.67431617	0.6309203	0.77105576	0.8246283	0.7503503	0.6603319	0.716534	0.63629496	0.6103577	0.67358464	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	For someone who is an ultrarapid metabolizer with a CYP2D6 activity score of ≥3.75, it is typically recommended to avoid the use of codeine. This is because ultrarapid metabolizers can convert codeine to its active metabolite, morphine, more quickly and extensively, increasing the risk of toxicity and serious side effects such as respiratory depression. Alternative pain management strategies or the use of non-opioid analgesics should be considered for these individuals.	0.6640018705843947	0.6601620868945094	0.587413750423559	0.5874800168139775	0.7178227	0.68523335	0.6014889	0.55028313	0.6883585	0.70542294	0.6193411	0.59691	0.706344	0.6926102	0.6553331	0.62785494	0.65996486	0.7587913	0.6651764	0.6143734	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	For individuals who are classified as Poor Metabolizers with an activity score of 0.0 for CYP2D6, it is strongly recommended to avoid using codeine. These patients lack the functional enzyme required to convert codeine into its active form, morphine, resulting in insufficient pain relief and potential accumulation of codeine itself, leading to adverse effects. Alternative analgesics that do not rely on CYP2D6 metabolism should be considered.	0.6039027238728677	0.6712189997506207	0.6157128084482854	0.5867823810466858	0.67069685	0.70070213	0.6140154	0.5163512	0.70175165	0.7190798	0.62698156	0.5935184	0.67490727	0.7003821	0.6592577	0.58244306	0.7079932	0.7284867	0.61820257	0.6662129	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Use codeine label recommended age- or weight-specific dosing.	['Avoid codeine. Take an alternate therapy.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Proceed taking codeine as normal. There is no recommendation.	An individual with a normal metabolizer status and an activity score of 1.25 for the CYP2D6 enzyme is likely to metabolize codeine into morphine effectively, providing typical therapeutic effects. Clinical guidance would generally indicate that standard dosing regimens of codeine can be used, but as always, patient response and potential side effects should be monitored. Adjustments to dosing may be necessary based on individual efficacy and tolerability.	0.5424998618595347	0.5709305889327287	0.599952295885271	0.5491534641621905	0.5139122	0.49087286	0.48797438	0.51194733	0.5513367	0.6813124	0.55925846	0.6020743	0.5577907	0.6714886	0.5974271	0.5270656	0.6099495	0.59692234	0.6480749	0.6092216	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	For individuals identified as ultrarapid metabolizers (UMs) with an activity score of ≥5.0 for CYP2D6, it is recommended to avoid prescribing codeine. Ultrarapid metabolizers convert codeine to its active metabolite, morphine, more rapidly and extensively, which increases the risk of potentially severe toxicity and adverse effects, such as respiratory depression. Alternative analgesics that do not rely on CYP2D6 metabolism should be considered.	0.6139192691437685	0.6601620868945094	0.587413750423559	0.5626770412722063	0.6930377	0.68523335	0.6014889	0.54248804	0.6879755	0.70542294	0.6193411	0.5627891	0.69435877	0.6926102	0.6553331	0.63130474	0.64343596	0.7587913	0.6651764	0.62769467	1
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	Avoid use	['Proceed taking dapsone as normal. There is no recommendation.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Avoid dapsone. Take an alternate therapy.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with the Central Nervous System Hemolytic Anemia (CNSHA) variant, the use of dapsone is typically contraindicated. This is because dapsone can induce hemolysis in G6PD-deficient patients, potentially leading to severe hemolytic anemia. Therefore, alternative medications should be considered for these patients.	0.2356419902591706	0.3185163774677721	0.2651758360971103	0.614368351564044	0.2823539	0.37868088	0.32521656	0.5655269	0.13760236	0.21554653	0.25289652	0.59655744	0.16598082	0.24950446	0.23950267	0.52850336	0.40344948	0.5749198	0.47583222	0.5753914	1
dapsone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid dapsone. Take an alternate therapy.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Proceed taking dapsone as normal. There is no recommendation.	For an individual with indeterminate G6PD status, clinical guidance would typically recommend caution when prescribing dapsone. Due to the risk of hemolytic anemia in individuals with G6PD deficiency, a genetic test or enzyme assay should ideally be conducted to determine G6PD activity before initiating treatment. If testing is not feasible, the patient should be closely monitored for signs of hemolysis, and alternative therapies should be considered if necessary.	0.7157252300908783	0.4076634399606662	0.3359090140281565	0.5801894055581637	0.6404181	0.28339827	0.30463564	0.56053925	0.6928764	0.35237035	0.29692048	0.58880734	0.7046055	0.23821466	0.19378132	0.42232123	0.6364142	0.41301382	0.40812746	0.5217791	0
dapsone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid dapsone. Take an alternate therapy.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Proceed taking dapsone as normal. There is no recommendation.	For a person with normal G6PD enzyme activity, taking dapsone typically carries a lower risk of hemolytic anemia compared to individuals with G6PD deficiency. However, it is still important to monitor for potential side effects like methemoglobinemia and hemolysis, as dapsone can cause oxidative stress on red blood cells. Regular follow-ups with healthcare providers are recommended to ensure safe use.	0.5931701807681528	0.4354732367062862	0.3210860465313764	0.6067491683914825	0.46281317	0.41541058	0.21241479	0.5686714	0.46689135	0.33054855	0.17866246	0.6660555	0.40088663	0.20539324	0.12723547	0.49228275	0.4618301	0.44612318	0.31890652	0.47345597	0
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	Avoid use	['Proceed taking dapsone as normal. There is no recommendation.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Avoid dapsone. Take an alternate therapy.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of dapsone is generally contraindicated due to the risk of hemolytic anemia, a serious adverse reaction. Clinical guidance suggests that alternative medications should be considered, and if dapsone use is unavoidable, it should be administered under close supervision with careful monitoring of hemoglobin and reticulocyte counts.	0.2657106989705113	0.3185163774677721	0.2651758360971103	0.6510820601881387	0.31568143	0.37868088	0.32521656	0.6240745	0.1664265	0.21554653	0.25289652	0.6392927	0.23058254	0.24950446	0.23950267	0.53629375	0.44157422	0.5749198	0.47583222	0.61026716	0
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid desflurane. Take an alternate therapy.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Proceed taking desflurane as normal. There is no recommendation.	For an individual with Uncertain Susceptibility for RYR1 and No Result for CACNA1S, the potential risk for malignant hyperthermia (MH) when taking desflurane cannot be fully determined due to the incomplete genetic information. Clinical guidance would generally advise careful monitoring for signs of MH during and after anesthesia with desflurane and consider the use of alternative anesthetic agents with lower MH risk if feasible. Malignant hyperthermia experts or a specialist in medical genetics may provide additional guidance based on a comprehensive clinical evaluation.	0.6050144376055588	0.38577120250986685	0.3307412787379272	0.5861492210443339	0.6729915	0.4609391	0.30815086	0.49839422	0.6532708	0.3084973	0.28907695	0.48861393	0.49820337	0.3462964	0.27809054	0.51553434	0.66772896	0.42528605	0.3634113	0.52879995	0
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking desflurane as normal. There is no recommendation.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Avoid desflurane. Take an alternate therapy.	For individuals with malignant hyperthermia susceptibility (MHS) associated with RYR1 mutations, desflurane is contraindicated due to the significant risk of triggering a malignant hyperthermia episode. The absence of a result for CACNA1S does not change this recommendation, as the known RYR1 susceptibility already necessitates avoidance of desflurane and other potent volatile anesthetics and depolarizing muscle relaxants.	0.7937187248384815	0.4877120702202649	0.40759720523702586	0.5600374234994671	0.78747547	0.540203	0.44405654	0.53796333	0.75840366	0.40028316	0.34460056	0.5596168	0.8007554	0.4101717	0.39421642	0.51906747	0.80245566	0.53125346	0.5231835	0.5488432	1
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking desflurane as normal. There is no recommendation.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Avoid desflurane. Take an alternate therapy.	For individuals with Malignant Hyperthermia Susceptibility (MHS) due to RYR1 mutations and Uncertain Susceptibility related to CACNA1S, desflurane should be avoided. Desflurane is a known trigger for malignant hyperthermia, and using it could provoke a life-threatening hypermetabolic reaction. Therefore, alternative anesthetic agents that do not pose a risk for MH should be selected.	0.7570484167736383	0.48249697404395686	0.4065796318743214	0.5964718362208838	0.6976708	0.5509429	0.4551545	0.5928286	0.7746176	0.41915092	0.3681922	0.58856297	0.7797392	0.42118034	0.40452838	0.5714025	0.67379785	0.5364594	0.5282536	0.58413535	0
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid desflurane. Take an alternate therapy.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Proceed taking desflurane as normal. There is no recommendation.	"For a patient with ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S, clinical guidance suggests caution when using desflurane. Desflurane is a known trigger for malignant hyperthermia (MH), and while uncertainty or lack of result does not confirm susceptibility, the potential risk may necessitate considering alternative anesthetics and readiness for MH management."	0.6698629907830388	0.39608846965848793	0.34405547355692284	0.5898950092086604	0.6128776	0.46003866	0.2944893	0.5524611	0.57044595	0.30627367	0.28438205	0.51078993	0.51124835	0.383938	0.31790766	0.5443057	0.63739467	0.4284476	0.36899507	0.53335	0
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	For individuals identified as CYP2D6 ultrarapid metabolizers with an activity score of ≥3.5, clinical guidance suggests they may experience subtherapeutic levels of desipramine, leading to decreased efficacy. It is recommended to consider an alternative medication not metabolized by CYP2D6 or to closely monitor the patient with possible dose adjustments to achieve the desired therapeutic effect.	0.6491386794119799	0.5791451332775236	0.5373567198918817	0.6367380890884301	0.6960524	0.44016337	0.40424857	0.5998235	0.66260165	0.29443657	0.290827	0.59673846	0.6196604	0.4245695	0.42618787	0.5945082	0.6346297	0.4605885	0.41130963	0.62672645	1
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid desipramine. Take an alternate therapy.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Proceed taking desipramine as normal. There is no recommendation.	For a patient who is a Normal Metabolizer with a CYP2D6 activity score of 1.75 taking desipramine, standard dosing guidelines can be followed. This pharmacogenomic profile suggests typical enzyme activity, leading to expected therapeutic drug levels and standard risk for side effects. Therefore, no dosage adjustments based on CYP2D6 metabolizer status are necessary.	0.4435250753539591	0.4970514938181248	0.49951174077425575	0.6508113899463862	0.31987223	0.3279334	0.33902714	0.5749191	0.2875992	0.3715319	0.26033115	0.59557074	0.35663506	0.3783283	0.36477098	0.5750949	0.44166404	0.5207515	0.5412411	0.62202114	1
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	For individuals identified as Ultrarapid Metabolizers (UMs) with a CYP2D6 activity score of 2.75, taking desipramine may lead to subtherapeutic drug levels and reduced efficacy due to faster metabolism of the drug. Clinical guidelines generally recommend considering alternative medications not metabolized by CYP2D6 or using a higher starting dose of desipramine, with close monitoring to achieve therapeutic drug levels while minimizing potential side effects.	0.6079588987484621	0.5791451332775236	0.5373567198918817	0.6175258492676545	0.6537261	0.44016337	0.40424857	0.58452016	0.5936372	0.29443657	0.290827	0.6133045	0.55308217	0.4245695	0.42618787	0.5659785	0.6033341	0.4605885	0.41130963	0.62809753	1
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	For an individual identified as an Ultrarapid Metabolizer (UM) with an activity score of ≥ 6.0 for the CYP2D6 enzyme, the use of desipramine is generally not recommended. This is because UM individuals metabolize the drug very quickly, leading to significantly lower plasma concentrations, which may result in subtherapeutic effectiveness. Alternative medications that do not heavily depend on CYP2D6 for metabolism should be considered.	0.5868085785056286	0.5791451332775236	0.5373567198918817	0.6018308551963464	0.6410371	0.44016337	0.40424857	0.60854006	0.6226491	0.29443657	0.290827	0.63780534	0.5861701	0.4245695	0.42618787	0.538366	0.56268936	0.4605885	0.41130963	0.57702667	1
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	For individuals identified as rapid metabolizers of CYP2C19, clinical guidance typically suggests that they may clear proton pump inhibitors (PPIs) like dexlansoprazole more quickly, potentially leading to reduced therapeutic efficacy. In such cases, clinicians may consider adjusting the dosage or exploring alternative medications that are not significantly impacted by CYP2C19 metabolism to ensure effective acid suppression. Regular monitoring and clinical assessment are advised to optimize treatment outcomes.	0.4577324277620916	0.4319553597895283	0.42233968245783043	0.6185250617213788	0.42066485	0.5244644	0.4231161	0.5805131	0.3942411	0.45668057	0.45661736	0.5316266	0.3139377	0.3934011	0.36267322	0.5040917	0.36731526	0.5162315	0.40365982	0.63534254	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	For individuals identified as likely poor metabolizers for CYP2C19, standard dosing of dexlansoprazole can generally be maintained. Dexlansoprazole is primarily metabolized by CYP2C19; however, the altered metabolism does not typically necessitate dosing adjustments. Monitoring for therapeutic efficacy and potential adverse effects is still advised as a precaution.     References:  - Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines  - FDA-approved prescribing information for dexlansoprazole	0.4106773211856797	0.42523775097561367	0.42684894270648566	0.654929498094624	0.44011828	0.44282916	0.42134076	0.55543697	0.3891797	0.41426593	0.4479003	0.53487694	0.44357795	0.40671661	0.422625	0.58556646	0.4103468	0.5007438	0.40314394	0.6400449	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	For individuals identified as Ultrarapid Metabolizers (UMs) of CYP2C19, clinical guidelines suggest that standard doses of dexlansoprazole may be less effective due to increased metabolic clearance. It may be recommended to use an alternative proton pump inhibitor (PPI) that is less dependent on CYP2C19 metabolism, such as rabeprazole or esomeprazole, to ensure effective acid suppression therapy.	0.3756699100798746	0.4635054827851051	0.4026219676626276	0.6598527111838592	0.42840376	0.65926266	0.5000261	0.5814669	0.3776583	0.6434663	0.5377309	0.5565068	0.3810481	0.53986955	0.46074867	0.5513816	0.35333404	0.54229647	0.3703695	0.6918699	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid dexlansoprazole. Take an alternate therapy.', 'Take dexlansoprazole with a reduced dose.', 'Take dexlansoprazole with an increased dose.']	Proceed taking dexlansoprazole as normal. There is no recommendation.	For individuals who are indeterminate for CYP2C19 status and need dexlansoprazole, current clinical guidance suggests starting with the standard recommended dose. This recommendation is based on the fact that dexlansoprazole, a proton pump inhibitor (PPI), does not have significant clinically relevant differences in efficacy or safety among various CYP2C19 metabolizer statuses. As always, clinical response and tolerability should be monitored, and adjustments made as necessary.	0.28831782048043403	0.486250059442504	0.24026405407688708	0.680699134139306	0.21306904	0.31074408	0.17201191	0.6416479	0.07872464	0.20862237	0.104758225	0.62959635	0.024710622	0.2978906	0.08362041	0.6276053	0.3543153	0.5100925	0.38946712	0.69608724	0
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking dibekacin as normal. There is no recommendation.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Avoid dibekacin. Take an alternate therapy.	Individuals with genetic variants in the MT-RNR1 gene, which are associated with an increased risk of aminoglycoside-induced hearing loss, should generally avoid the use of aminoglycosides, including dibekacin, unless no alternatives are available and the clinical benefits outweigh the risks. If administration is necessary, it should be done with caution, close monitoring, and potential consideration of therapeutic drug monitoring to minimize the risk of ototoxicity.	0.6804088487796882	0.35741944163104894	0.2734635264132587	0.43318711155774076	0.76769143	0.48581654	0.4086357	0.52357	0.6911311	0.28585368	0.31050727	0.4831337	0.67822105	0.3569748	0.36481377	0.49608445	0.671055	0.5829945	0.43764806	0.54250824	1
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid dibekacin. Take an alternate therapy.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Proceed taking dibekacin as normal. There is no recommendation.	Individuals who are at normal risk for aminoglycoside-induced hearing loss based on MT-RNR1 genetic testing can typically be administered aminoglycosides, including dibekacin, without an increased risk of ototoxicity. Clinical guidelines would suggest standard dosing and monitoring of auditory function as per usual practice without additional precautions specific to MT-RNR1 genotypic variations.	0.6461611748902273	0.27616468966216273	0.3249936539066184	0.42856699869048404	0.61640096	0.44967836	0.4379379	0.5375525	0.652363	0.46886286	0.39527568	0.47895056	0.6990396	0.43930098	0.41773668	0.45837992	0.5632779	0.42932752	0.4826897	0.43961474	1
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid dibekacin. Take an alternate therapy.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Proceed taking dibekacin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss due to the MT-RNR1 genetic variant, it is generally recommended to avoid aminoglycosides like dibekacin if possible, due to the potential for irreversible ototoxicity. However, if aminoglycoside use is deemed necessary, it should be done under close monitoring for hearing loss and considering alternative antibiotics where appropriate to mitigate risk. Genetic counseling may also be beneficial to better understand and manage this risk.	0.6353856785403353	0.27616468966216273	0.3249936539066184	0.3738435751321978	0.5161549	0.44967836	0.4379379	0.56900346	0.6742299	0.46886286	0.39527568	0.47655755	0.7368206	0.43930098	0.41773668	0.45382917	0.61054254	0.42932752	0.4826897	0.44003305	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	For an individual who is normal for G6PD (Glucose-6-Phosphate Dehydrogenase), there are typically no special clinical restrictions or adjustments needed when taking dimercaprol. However, healthcare providers should still monitor all patients closely for any adverse reactions, as dimercaprol can cause side effects regardless of G6PD status.	0.6170380315460431	0.4504761207348548	0.31438179236277985	0.6794363495631034	0.53163725	0.43337488	0.25049815	0.6176002	0.54203504	0.36993873	0.22432745	0.6795262	0.45129475	0.16816781	0.09049007	0.5455294	0.5382228	0.42321077	0.31795502	0.55563205	1
dimercaprol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	For individuals with indeterminate G6PD status, there is a potential risk when taking dimercaprol, as it could cause hemolytic anemia. The best clinical guidance would be to avoid dimercaprol if possible and consider alternative chelation therapies that do not carry the same risk. G6PD testing should be performed before administration if the use of dimercaprol is deemed necessary.	0.5956835159727257	0.4110698869674558	0.3466776430264691	0.6517664448530208	0.50603426	0.29013315	0.33482385	0.6827576	0.58785063	0.40234423	0.33091676	0.66800904	0.5539105	0.20922032	0.1590218	0.52932364	0.4625011	0.42118466	0.41460478	0.52764374	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	For patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), the use of dimercaprol (BAL) is generally contraindicated. Dimercaprol can induce hemolysis in individuals with G6PD deficiency, leading to severe anemia and other associated complications. Alternative chelating agents that do not pose such risks should be considered in these patients.	0.4819011808743516	0.4422433961350855	0.47727765551118423	0.6107333599205597	0.57598615	0.51419854	0.5208659	0.5911805	0.58831316	0.5395808	0.48958275	0.6089186	0.48392043	0.37105876	0.32608926	0.5480007	0.564328	0.43311268	0.5046956	0.5133523	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	Clinical guidance for someone who is deficient in glucose-6-phosphate dehydrogenase (G6PD) would advise against using dimercaprol due to the risk of hemolysis. G6PD deficiency can lead to severe oxidative stress in red blood cells when exposed to certain medications, including dimercaprol, potentially causing significant hemolytic anemia. Alternative chelation therapies should be considered in these patients.	0.6148642478733038	0.5035624175943788	0.39459110939654013	0.5976472399235986	0.6147751	0.58485574	0.41781464	0.6443001	0.643663	0.56316566	0.39363757	0.6534104	0.5559981	0.4273458	0.3047075	0.5294862	0.53169	0.5044765	0.40088812	0.520636	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	For a patient who is an Intermediate Metabolizer with an activity score of 0.25 for CYP2D6 and a Rapid Metabolizer for CYP2C19, the clinical guidance for taking doxepin would generally suggest caution and a possible dosage adjustment. Doxepin is metabolized by CYP2D6, so decreased CYP2D6 activity may lead to higher drug levels and an increased risk of side effects. Regular monitoring and potentially starting with a lower dose may be recommended to avoid adverse effects.	0.7979672971511901	0.7151476117280727	0.6841688238371783	0.6434845520721352	0.77959543	0.6404857	0.528271	0.5717631	0.8500489	0.6326013	0.5126578	0.67416495	0.8110507	0.63504755	0.6258844	0.6261901	0.73732746	0.6596959	0.6257886	0.62694067	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Avoid doxepin. Take an alternate therapy.']	Take doxepin with an altered dose.	For a patient identified as an intermediate metabolizer with an activity score of 0.75 for CYP2D6 and a normal metabolizer for CYP2C19, there may be a need to adjust the dosage of doxepin. Given that CYP2D6 is involved in the metabolism of doxepin, reduced enzyme activity could lead to higher plasma levels of the drug, increasing the risk of adverse effects. Therefore, a lower starting dose and careful monitoring for side effects may be recommended.	0.5240524030921788	0.5067308901633374	0.4210325149398224	0.6803586256993436	0.5013661	0.316517	0.2795415	0.5232401	0.49427688	0.351068	0.36093313	0.52892053	0.51192147	0.44490945	0.3686589	0.5797271	0.6155129	0.69863254	0.5398863	0.67317873	1
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	"For individuals with ""No Result"" for CYP2D6 and ""Rapid Metabolizer"" for CYP2C19, there is insufficient information to provide specific guidance related to CYP2D6-related metabolism of doxepin, which could impact drug efficacy and risk of side effects. Given that doxepin is primarily metabolized by CYP2D6, clinical decisions should involve close monitoring and potentially genetic testing to determine CYP2D6 status. Adjustments might be needed based on observed therapeutic response and tolerability."	0.5220013872917466	0.5239138713048924	0.4260355713058504	0.6046769289334111	0.6193233	0.50593096	0.43306768	0.5639998	0.5529287	0.38745186	0.36487615	0.6171571	0.44697973	0.3161475	0.34714463	0.53323823	0.5470284	0.5577876	0.46976265	0.6189391	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	For a patient identified as a Poor Metabolizer (PM) with an activity score of 0.0 for CYP2D6 and a Normal Metabolizer for CYP2C19, the clinical guidance for taking doxepin includes avoiding or using an alternative medication not metabolized by CYP2D6, as the compromised CYP2D6 function can lead to increased plasma levels and potential toxicity of doxepin. If doxepin must be used, significant dose reduction and careful monitoring are recommended to manage and minimize adverse effects.	0.7219444044565482	0.7373097702350665	0.7523437184471442	0.6617891862594227	0.68470526	0.65722984	0.5717569	0.6841206	0.68397003	0.6700948	0.6165454	0.67131066	0.61906374	0.66437507	0.6668616	0.5904863	0.6119535	0.7283124	0.64521545	0.68412656	1
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), caution is advised when administering doxorubicin. Although doxorubicin's risk of causing hemolysis in G6PD-deficient patients is not well-documented, the potential for oxidative stress should be considered, and patients should be monitored closely for signs of hemolysis and other adverse effects. Consulting a healthcare provider for personalized management and possible alternative treatments is recommended.	0.6128986358318147	0.4973267699533063	0.38687022842202695	0.5759149083308748	0.62363046	0.5219781	0.3436304	0.6039235	0.5848713	0.4361492	0.26921847	0.6335886	0.5465074	0.4062026	0.29904422	0.5643838	0.542789	0.48584712	0.3683913	0.54968077	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	For an individual with an indeterminate G6PD status, caution is advised when considering doxorubicin. While doxorubicin is not a known strong inducer of hemolysis in G6PD-deficient individuals, it is crucial to conduct a comprehensive assessment of the patient's G6PD activity before administration. If the deficiency is confirmed, close monitoring for hemolytic reactions and alternative therapies should be considered.	0.6448125570805554	0.37680744257423426	0.3029007959726204	0.5487401751112451	0.5341654	0.24444607	0.24107237	0.6152101	0.62305117	0.28558215	0.19955266	0.59980685	0.6382481	0.19736032	0.17089064	0.41977534	0.5338248	0.44028217	0.4201783	0.52812314	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and chronic non-spherocytic hemolytic anemia (CNSHA) should be closely monitored when treated with doxorubicin due to the potential risk of hemolytic anemia. While doxorubicin is not explicitly contraindicated, it is essential to evaluate the risk-benefit ratio and consider alternative therapies where possible, ensuring to monitor hemoglobin levels and signs of hemolysis.	0.5008091638212699	0.37513214718029997	0.4063589796439111	0.5369442067586107	0.6115991	0.5013409	0.47825193	0.60151505	0.543948	0.45784482	0.3945907	0.58865345	0.57571495	0.42531055	0.38260412	0.4607753	0.5963965	0.46916938	0.49619785	0.5695485	1
doxorubicin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	For a patient with normal glucose-6-phosphate dehydrogenase (G6PD) activity, there are no specific pharmacogenomic concerns related to the use of doxorubicin. Clinical guidance would focus on the general monitoring and management of doxorubicin's known side effects, such as cardiotoxicity and myelosuppression, rather than any G6PD deficiency-related considerations.	0.633315961228812	0.43744437762768595	0.3199766120215332	0.5977190364727493	0.48302168	0.39323217	0.22587413	0.64294183	0.4155476	0.286873	0.17024352	0.62307376	0.3558069	0.13009338	0.061870933	0.5202652	0.48373634	0.4238915	0.30855498	0.49262503	1
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals who are Ultrarapid Metabolizers (UMs) of CYP2B6, clinical guidelines typically recommend caution with the use of efavirenz, as increased metabolism may lead to subtherapeutic drug levels and reduced efficacy. Dose adjustments are generally not well-established for UMs; therefore, an alternative antiretroviral agent that is not extensively metabolized by CYP2B6 may be considered to ensure effective treatment outcomes.	0.6472257929587819	0.7055012761560941	0.7464661979655807	0.6036191678667576	0.6412246	0.6818854	0.714722	0.52702105	0.5894841	0.8309308	0.7367101	0.51807183	0.6210368	0.7354766	0.7257293	0.5507347	0.5755787	0.6453185	0.6786318	0.6097528	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals identified as rapid metabolizers (RM) of CYP2B6 when considering efavirenz, standard dosing is typically recommended as they may have lower plasma concentrations of the drug, reducing the likelihood of toxicity. However, clinical monitoring for therapeutic drug levels and efficacy is still crucial due to the variability in response among patients. Genetic testing results should be combined with clinical judgment and patient response to guide therapy.	0.62970806377276	0.7055012761560941	0.7464661979655807	0.5747268936473628	0.59162444	0.6818854	0.714722	0.46344966	0.5866907	0.8309308	0.7367101	0.5393725	0.6510067	0.7354766	0.7257293	0.54841983	0.6222139	0.6453185	0.6786318	0.6041949	1
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	No recommendation	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals who are indeterminate for CYP2B6 genotype, clinical guidance for efavirenz use typically remains cautious. Given that CYP2B6 polymorphisms can significantly affect efavirenz metabolism and increase the risk of adverse effects, close monitoring for drug toxicity and therapeutic efficacy is recommended. Alternative antiretroviral therapies may be considered if adverse reactions occur.	0.2242935744978805	0.4569317113924403	0.22062542305999888	0.5991935431572861	0.17788096	0.3323083	0.15975553	0.5295019	0.07266246	0.21319598	0.07932254	0.53556	0.00095831236	0.38391602	0.1689954	0.5283142	0.24241601	0.51199925	0.36884865	0.5059909	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals identified as normal metabolizers of CYP2B6, the clinical guidance for taking efavirenz is to follow the standard dosing regimen, as their metabolic capacity allows for effective and predictable drug metabolism without an increased risk of side effects or reduced efficacy. In this case, no dosage adjustment or alternative treatment is typically necessary.	0.660004398565085	0.7055012761560941	0.7464661979655807	0.6734392100534299	0.64001995	0.6818854	0.714722	0.6355089	0.6967894	0.8309308	0.7367101	0.66406417	0.73058915	0.7354766	0.7257293	0.6354259	0.7053422	0.6453185	0.6786318	0.68578523	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	For a patient with Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S, it is recommended to avoid the use of enflurane. Enflurane is a trigger for malignant hyperthermia, a potentially life-threatening condition, and individuals with variants in RYR1 and CACNA1S genes may be at an increased risk. Alternative anesthetic agents that do not trigger malignant hyperthermia should be considered.	0.6620471609511601	0.46037955059589064	0.37812824480627377	0.5627713944222957	0.6940224	0.54551834	0.44166663	0.64008814	0.696673	0.4112589	0.35429028	0.61781776	0.697645	0.47659156	0.4368042	0.5662185	0.59249496	0.5346017	0.5189058	0.53421766	0
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	For an individual with no mutations detected in the RYR1 gene but with a variant in the CACNA1S gene associated with malignant hyperthermia susceptibility, clinical guidance would generally advise against the use of enflurane. Enflurane is a known trigger for malignant hyperthermia, and caution is merited even with a single predisposing variant. Alternative anesthetic agents not associated with malignant hyperthermia risk should be considered.	0.6938582173515068	0.4671850765489417	0.3878358153190092	0.5299898992110474	0.7378105	0.5281074	0.423934	0.53263706	0.74551815	0.39498058	0.33109835	0.5365635	0.78897935	0.4626712	0.4183828	0.5530251	0.6348249	0.52395153	0.51317805	0.47882676	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	For a patient with Malignant Hyperthermia Susceptibility (MHS) due to RYR1 mutations and Uncertain Susceptibility due to CACNA1S, clinicians should avoid using enflurane. Enflurane, like other volatile anesthetics and succinylcholine, can trigger malignant hyperthermia in susceptible individuals. Alternative anesthetic agents that do not pose this risk should be considered.	0.7837314694042177	0.46037955059589064	0.37812824480627377	0.5608684940020814	0.7594355	0.54551834	0.44166663	0.57935786	0.7888701	0.4112589	0.35429028	0.57283974	0.8188999	0.47659156	0.4368042	0.5630421	0.70924026	0.5346017	0.5189058	0.5661814	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid enflurane. Take an alternate therapy.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Proceed taking enflurane as normal. There is no recommendation.	For a patient with no result for the RYR1 gene and uncertain susceptibility for the CACNA1S gene, standard clinical guidance would still recommend cautious use of enflurane due to the risk of malignant hyperthermia (MH). Despite the uncertain genetic results, the potential for MH should prompt close monitoring and consideration of alternative anesthesia options where feasible.	0.7455858950004286	0.4147813483935868	0.358039535973299	0.54852018829007	0.6822011	0.47012547	0.30272052	0.5372545	0.6892651	0.32209712	0.30513763	0.49772173	0.5342705	0.3831002	0.33377448	0.534117	0.7676233	0.42923912	0.3765669	0.55111456	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	['Avoid escitalopram. Take an alternate therapy.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Proceed taking escitalopram as normal. There is no recommendation.	For individuals identified as Rapid Metabolizers of CYP2C19, standard doses of escitalopram might be less effective due to increased metabolism leading to lower drug levels. Clinical guidance often suggests monitoring for decreased therapeutic effect and considering dose adjustments or an alternative medication that is not predominantly metabolized by CYP2C19. Consultation with a healthcare provider for personalized management is recommended.	0.6264138027575592	0.5075781156939725	0.5583226065780807	0.5966722303141975	0.705545	0.5094775	0.4746802	0.5151814	0.67186564	0.4981856	0.32803962	0.6069541	0.6177263	0.56714845	0.5543556	0.57170033	0.69201505	0.57716674	0.57637185	0.6252272	1
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	['Proceed taking escitalopram as normal. There is no recommendation.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Avoid escitalopram. Take an alternate therapy.	For individuals identified as likely poor metabolizers of CYP2C19, clinical guidelines suggest a lower starting dose of escitalopram. This is because reduced CYP2C19 activity can lead to higher plasma levels of the drug, increasing the risk of side effects. Close monitoring of the patient's response and any adverse effects is also recommended.	0.7955982672868371	0.6059810641106896	0.6188451460871146	0.6208669392506002	0.7632794	0.5525944	0.46171078	0.5404913	0.7418299	0.50769186	0.3985671	0.608448	0.79601926	0.654592	0.5856943	0.6302294	0.77847743	0.6138301	0.5987987	0.6817028	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	['Proceed taking escitalopram as normal. There is no recommendation.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Avoid escitalopram. Take an alternate therapy.	For someone identified as an Ultrarapid Metabolizer (UM) for CYP2C19, it is recommended to consider alternative medications that are not metabolized by CYP2C19 due to the likelihood of reduced efficacy of escitalopram. If escitalopram is still the preferred choice, monitoring the patient for therapeutic effectiveness and adjusting the dosage if necessary may be required. Always consult with a healthcare provider for personalized medical advice.	0.7386943883029612	0.6528372547404452	0.611068164202671	0.6552638331811965	0.80912524	0.58640766	0.47000778	0.6030985	0.73432696	0.50446117	0.40657008	0.59773606	0.6863808	0.6770981	0.6127477	0.5050053	0.7682171	0.66057587	0.61762315	0.6361103	1
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	No recommendation	['Avoid escitalopram. Take an alternate therapy.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Proceed taking escitalopram as normal. There is no recommendation.	For individuals with an indeterminate CYP2C19 genotype taking escitalopram, current clinical guidelines suggest standard dosing as there is insufficient evidence to make specific dosing recommendations. However, routine clinical monitoring for efficacy and adverse effects is still recommended, and dose adjustments can be made based on the patient's response and tolerability.	0.27157748722417313	0.450018056083929	0.2083545670540976	0.6386096407898622	0.13194418	0.3081905	0.13594498	0.5933066	0.037918303	0.16049233	0.043031152	0.63737136	0.004936785	0.29398826	0.074059986	0.5995822	0.28612334	0.53346795	0.42430457	0.64577794	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Avoid fluorouracil. Take an alternate therapy.']	Take fluorouracil with an altered dose.	For a patient who is an intermediate metabolizer with an activity score of 1.5 for DPYD, it is recommended to reduce the starting dose of fluorouracil by 25-50% to mitigate the risk of severe toxicity. The dose adjustment allows for better tolerance and reduces the risk of adverse effects while maintaining efficacy. Close monitoring and potential further dose modifications based on the patient's response and tolerance are essential.	0.5877784024445764	0.4710406124520722	0.4086666431197318	0.6473696351497904	0.64282984	0.4059437	0.32531244	0.49643236	0.5883082	0.3628539	0.34309623	0.41852158	0.618807	0.4564225	0.34486917	0.578058	0.67307687	0.5977499	0.43774837	0.6763421	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Take fluorouracil with a reduced dose.', 'Take fluorouracil with an increased dose.']	Avoid fluorouracil. Take an alternate therapy.	For a patient identified as a poor metabolizer with an activity score of 0.0 for the DPYD gene, it is recommended to avoid the use of fluorouracil (including related drugs like capecitabine). This genetic profile significantly increases the risk of severe, life-threatening toxicity due to impaired drug metabolism. Alternative treatments that do not depend on DPD enzyme activity should be considered.	0.564590594387554	0.6363807078965129	0.6013557767904428	0.570417675283639	0.6828671	0.64294964	0.54377013	0.54940796	0.5539602	0.7841388	0.6695526	0.4375612	0.54910225	0.7166225	0.68770903	0.55104744	0.64779603	0.82438254	0.7336395	0.66612256	1
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Avoid fluorouracil. Take an alternate therapy.']	Take fluorouracil with an altered dose.	For a patient who is an intermediate metabolizer with a DPYD activity score of 1.0, clinical guidance suggests a reduced dose of fluorouracil to mitigate the risk of severe toxicity. Specifically, it is recommended to initiate fluorouracil at 50% of the standard dose while closely monitoring for adverse effects. Adjustments should be made based on patient tolerance and response to the therapy.	0.5614283332900923	0.48060659295076996	0.42034116169133706	0.6537540005450634	0.73074174	0.43045583	0.38388374	0.5043737	0.649967	0.3628479	0.38803425	0.4079304	0.5675571	0.4147477	0.32485503	0.5681184	0.5364351	0.46764675	0.36165646	0.67149276	1
fluorouracil	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	['Avoid fluorouracil. Take an alternate therapy.', 'Take fluorouracil with a reduced dose.', 'Take fluorouracil with an increased dose.']	Proceed taking fluorouracil as normal. There is no recommendation.	For individuals identified as normal metabolizers (activity score = 2.0) of the DPYD gene, clinical guidance typically recommends standard dosing of fluorouracil. These individuals are expected to exhibit typical enzyme activity and are likely to metabolize the drug as intended, leading to standard efficacy and risk profiles. Therefore, no dose adjustment is generally needed for these patients when administering fluorouracil.	0.46769445831470535	0.4782238902673939	0.3833564023397967	0.6241015974158272	0.65772	0.6445161	0.3959833	0.51556987	0.57368904	0.5520111	0.3715272	0.50193554	0.49593723	0.50641716	0.44197294	0.488371	0.5614068	0.61629343	0.4629691	0.63488513	1
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For an individual identified as a Normal Metabolizer with an activity score of 2.0 for the CYP2C9 enzyme, the clinical guidance for taking flurbiprofen is generally to use the standard dosing regimen. Since this metabolic phenotype indicates typical CYP2C9 enzyme activity, no dose adjustments are necessary, and the individual is expected to process the drug normally, reducing the likelihood of adverse effects or reduced efficacy.	0.4120357027811158	0.39321415262206366	0.4285082952552643	0.6572678064325138	0.45949942	0.3423517	0.33949637	0.51691014	0.4254885	0.39875072	0.27121535	0.5282898	0.35634717	0.36041084	0.34209514	0.5455743	0.50069016	0.47378537	0.46098462	0.6887325	1
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For someone identified as an Intermediate Metabolizer with a CYP2C9 activity score of 1.5, clinical guidance for taking flurbiprofen would typically involve careful consideration due to potentially slower metabolism of the drug. The healthcare provider may recommend using a lower dose of flurbiprofen and monitor for adverse effects, adjusting dosage as needed to minimize the risk of toxicity and ensure therapeutic effectiveness. Always consult with a healthcare professional for personalized recommendations.	0.4336088366631287	0.39321415262206366	0.4285082952552643	0.6285805388877984	0.48395336	0.3423517	0.33949637	0.47152588	0.46810907	0.39875072	0.27121535	0.5547114	0.455444	0.36041084	0.34209514	0.59489244	0.52764654	0.47378537	0.46098462	0.6629407	0
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	No recommendation	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For a patient with an indeterminate CYP2C9 genotype taking flurbiprofen, clinical guidance typically includes using the lowest effective dose for the shortest duration to reduce potential adverse effects. Since CYP2C9 metabolizes flurbiprofen, and the indeterminate status implies uncertainty in metabolic capacity, careful monitoring for efficacy and toxicity is essential.	0.224936575521929	0.44451550026558473	0.22525894588730652	0.5994487538655735	0.1456189	0.2772925	0.14221925	0.47754845	0.05299307	0.13851252	0.051738933	0.46052656	-0.02053772	0.294111	0.100122064	0.50461733	0.25947085	0.5312631	0.39120016	0.5916566	0
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For an individual who is an intermediate metabolizer with an activity score of 1.0 for CYP2C9, taking flurbiprofen may result in higher plasma concentrations of the drug compared to normal metabolizers. Clinical guidance suggests using caution with dosing, potentially starting at the lower end of the dosing range to avoid adverse effects. Monitoring for signs of toxicity and adjusting the dose as necessary is recommended.	0.46221279941231064	0.3798003381723816	0.4327170944504029	0.6332896697538933	0.46843374	0.43295488	0.37236837	0.46184653	0.40842152	0.37317118	0.23944336	0.5466593	0.3750394	0.34830803	0.33611223	0.565741	0.5182632	0.3862069	0.4123571	0.6349525	1
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For a patient with indeterminate CYP2C9 status and possible decreased function of SLCO1B1, it would be prudent to monitor for signs of reduced drug metabolism and increased risk of statin-associated muscle symptoms (SAMS) when taking fluvastatin. Consider starting with a lower dose and titrate cautiously while closely monitoring lipid levels and any adverse effects. Alternative lipid-lowering therapies may also be considered based on clinical judgment.	0.8239498568063532	0.6064781273496315	0.6521096009458823	0.5801975227890274	0.7681392	0.5956504	0.5552284	0.56287277	0.826637	0.6790964	0.539539	0.6238139	0.6343273	0.54763275	0.51577735	0.5293839	0.7974714	0.6026437	0.6182136	0.6233114	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	n/a	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	"For individuals with ""No Result"" for CYP2C9 and ""Indeterminate"" for SLCO1B1 regarding fluvastatin use, clinical actions will generally be guided by standard dosing recommendations rather than genotype-specific adjustments. Given the lack of genetic information, providers should monitor for efficacy and adverse effects as they would for any patient starting fluvastatin, adjusting the dose based on clinical response and patient tolerance. Comprehensive clinical monitoring remains essential."	0.15919806337282502	0.20474682946536557	0.10894521055019962	0.6190146622999914	0.21411648	0.12301877	0.092413835	0.60179037	0.057413064	0.038634017	0.042194594	0.6269722	0.015516691	0.016649766	-0.006094717	0.49971768	0.34533077	0.3559772	0.37700883	0.644412	1
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For an individual who is a normal metabolizer (activity score = 2.0) for CYP2C9 and carries decreased function in SLCO1B1, fluvastatin can generally be administered at standard doses. However, due to the decreased function in SLCO1B1, there may be an increased risk for statin-associated myopathy. Clinical monitoring for signs of muscle toxicity is recommended, and dose adjustments may be necessary if muscle symptoms occur.	0.6951359646032282	0.6367757620343362	0.6899546755355092	0.5927805162215872	0.64505994	0.50806934	0.53615195	0.5770756	0.6461271	0.6572926	0.4876262	0.64165866	0.6681768	0.52920747	0.515023	0.5707414	0.6810838	0.5800475	0.60205317	0.615929	1
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	In the absence of specific CYP2C9 genotyping results, standard dosing of fluvastatin may be initiated, as clinical decisions would typically rely on therapeutic goals and patient response. Given the possible decreased function in SLCO1B1, careful monitoring for statin-associated side effects such as myopathy is advised, and dosage adjustments may be considered based on tolerance and therapeutic efficacy. Regular follow-up and possibly considering alternative statins could be prudent if adverse effects occur.	0.8645970968731536	0.6176859495097352	0.6645208434567201	0.611425537380061	0.8180122	0.59110093	0.5367722	0.5711643	0.82191885	0.67734224	0.52115065	0.60677785	0.7415588	0.5533289	0.521245	0.5104482	0.8068387	0.61240405	0.623084	0.6541309	1
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For a patient identified as an Intermediate Metabolizer with a CYP2D6 activity score of 0.5, clinical guidelines suggest close monitoring or considering alternative medications due to potential increased risk of adverse effects or reduced efficacy when taking fluvoxamine. Dose adjustments might be necessary to manage side effects effectively and achieve the desired therapeutic outcomes. Consulting with a healthcare provider for personalized advice is recommended.	0.42569282725778895	0.4769947583084961	0.49449161103990885	0.6206602858945139	0.43015686	0.39972264	0.4494815	0.5819342	0.38205987	0.5182947	0.4310929	0.65178615	0.4938814	0.48154306	0.4874611	0.5279742	0.507669	0.51965314	0.5779416	0.6699445	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	No recommendation due to lack of evidence	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For individuals identified as CYP2D6 ultrarapid metabolizers (with an activity score of 4.0), clinical guidance generally advises caution when prescribing fluvoxamine. Although fluvoxamine is primarily metabolized by CYP1A2, its interaction with other drugs metabolized by CYP2D6 may necessitate careful monitoring. Physicians might consider alternative medications or adjust the dosing to mitigate potential adverse effects and ensure therapeutic efficacy.	0.27079306609831627	0.4218766925953058	0.2753222920876771	0.6277146231124355	0.248548	0.36573133	0.21147163	0.5592557	0.1970516	0.32147405	0.16616675	0.5942561	0.050134867	0.26190105	0.08319646	0.42484346	0.3451309	0.53878886	0.36661777	0.6594327	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	No recommendation due to lack of evidence	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For an individual identified as an Ultrarapid Metabolizer with an activity score of ≥3.75 for CYP2D6, clinical guidance generally suggests caution when prescribing fluvoxamine. These patients may experience increased metabolism of fluvoxamine, leading to potentially reduced therapeutic effects. Alternative medications that are not primarily metabolized by CYP2D6 should be considered, or careful dose adjustment and monitoring may be necessary.	0.26644524134517966	0.4218766925953058	0.2753222920876771	0.6248111481644719	0.3121781	0.36573133	0.21147163	0.6046114	0.25400636	0.32147405	0.16616675	0.58963346	0.07737172	0.26190105	0.08319646	0.45721045	0.34555516	0.53878886	0.36661777	0.6219311	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For a patient with an intermediate metabolizer status and a CYP2D6 activity score of 0.25, there is potential for reduced metabolism of drugs that are substrates of CYP2D6, like fluvoxamine. This reduced metabolism may lead to higher plasma levels of the drug, increasing the risk of side effects. It is advisable to start at a lower dose and monitor the patient closely for efficacy and adverse effects, adjusting the dose accordingly.	0.41483817108133847	0.4769947583084961	0.49449161103990885	0.5344845325249847	0.33598787	0.39972264	0.4494815	0.497492	0.35854644	0.5182947	0.4310929	0.5594608	0.4354899	0.48154306	0.4874611	0.47158465	0.40944767	0.51965314	0.5779416	0.57451826	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Take fosphenytoin with a reduced dose.', 'Take fosphenytoin with an increased dose.']	Avoid fosphenytoin. Take an alternate therapy.	For individuals who are HLA-B*15:02 positive, it is generally recommended to avoid fosphenytoin due to a significantly increased risk of developing serious adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Alternative medications that do not pose this risk should be considered for these patients.	0.6030153390714182	0.6702755159184737	0.6107443987024547	0.6675014332020704	0.63359505	0.59464526	0.4982821	0.66550756	0.6007836	0.57391894	0.5386757	0.6542461	0.6002836	0.7290294	0.6978836	0.6765536	0.65249085	0.66946775	0.5832608	0.7023129	1
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Avoid fosphenytoin. Take an alternate therapy.']	Take fosphenytoin with an altered dose.	For individuals with no HLA-B result considering fosphenytoin, clinical guidance typically suggests proceeding with caution, as the risk of hypersensitivity reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), might not be predictable without this genetic information. Regardless of HLA-B status, it is essential to monitor for signs of adverse skin reactions, especially in patients of Asian descent, where the HLA-B*15:02 allele presence is more prevalent and significantly increases the risk.	0.658634031502838	0.501226012451486	0.5279686776720288	0.4956907506685644	0.5684875	0.52785814	0.52631456	0.41154492	0.5387741	0.46483022	0.49385822	0.39922097	0.5568348	0.493664	0.46575844	0.3481876	0.6485881	0.53713393	0.49919698	0.4953374	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Avoid fosphenytoin. Take an alternate therapy.']	Take fosphenytoin with an altered dose.	For a patient with no HLA-B result available, standard clinical guidelines recommend prescribing fosphenytoin while carefully monitoring for adverse reactions, particularly signs of drug hypersensitivity. It is advisable to consider genetic testing for HLA-B variants, such as HLA-B*15:02 in Asian populations, to better assess the risk of severe cutaneous adverse reactions associated with phenytoin and fosphenytoin.	0.6872284929379497	0.501226012451486	0.5279686776720288	0.5686995900553848	0.5759789	0.52785814	0.52631456	0.4163776	0.62380075	0.46483022	0.49385822	0.47483155	0.61966425	0.493664	0.46575844	0.46855024	0.6566334	0.53713393	0.49919698	0.58535403	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	['Avoid fosphenytoin. Take an alternate therapy.', 'Take fosphenytoin with a reduced dose.', 'Take fosphenytoin with an increased dose.']	Proceed taking fosphenytoin as normal. There is no recommendation.	For individuals who are HLA-B*15:02 positive, it is generally recommended to avoid fosphenytoin due to a significantly increased risk of developing serious adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Alternative medications that do not pose this risk should be considered for these patients.	0.6073935988002649	0.48824529050027937	0.47294060571268814	0.6228476198615179	0.50285876	0.50990474	0.45730594	0.6697331	0.45588523	0.46680757	0.40350342	0.65989226	0.48308808	0.45731217	0.45889673	0.6320086	0.44574088	0.45130447	0.46494862	0.6502721	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	For individuals with G6PD deficiency, the use of furazolidone is generally contraindicated. G6PD deficiency increases the risk of hemolytic anemia when taking drugs like furazolidone, which can induce oxidative stress on red blood cells. Clinical guidance would typically recommend avoiding furazolidone and considering alternative treatments.	0.6385487204109712	0.47913669049993196	0.35253250497545424	0.5699613631232191	0.6135466	0.48758852	0.25889498	0.57770777	0.6467015	0.3791599	0.16561508	0.56908846	0.64351434	0.3970475	0.26155618	0.52358747	0.62574697	0.5409147	0.41668686	0.6150868	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when considering furazolidone due to the risk of hemolytic anemia. It is recommended to either test for G6PD deficiency or choose an alternative antibiotic that poses less risk to G6PD-deficient patients. Consulting a healthcare provider for appropriate diagnostic and therapeutic guidance is strongly advised.	0.6288102786684746	0.3773792634833346	0.30732528260765085	0.5927726053054407	0.5726185	0.21883878	0.229263	0.5610791	0.5827142	0.25067353	0.14510423	0.62709427	0.5758001	0.21878554	0.16820498	0.5825935	0.55071414	0.46202555	0.42795384	0.58919156	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, especially those with Chronic Nonspherocytic Hemolytic Anemia (CNSHA), are at increased risk of hemolysis when exposed to certain oxidative drugs, including furazolidone. Clinical guidance would advise against the use of furazolidone in these patients to avoid potentially severe hemolytic episodes. Alternative therapies should be considered, and any medication use should be closely monitored by a healthcare provider.	0.4817004185838496	0.35920067335988476	0.36998925309527014	0.4994690490969522	0.56244916	0.4745068	0.42660522	0.54106826	0.59108317	0.4559514	0.34154233	0.5002314	0.5684832	0.4212205	0.35976788	0.4796467	0.57597136	0.41092572	0.46192658	0.5718416	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	For an individual with normal glucose-6-phosphate dehydrogenase (G6PD) activity, there are generally no specific pharmacogenomic contraindications to taking furazolidone. However, as with any medication, it is important to follow dosing recommendations and monitor for adverse reactions. Always consult with a healthcare provider for personalized medical advice.	0.6000062158046472	0.40583018558805406	0.2756435379268424	0.6316966435331953	0.4695525	0.3701698	0.14049484	0.64074004	0.44441178	0.2350072	0.06022823	0.6610774	0.29455185	0.1464956	0.059222415	0.6325602	0.55403054	0.4469264	0.32621247	0.6331075	1
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking gentamicin as normal. There is no recommendation.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Avoid gentamicin. Take an alternate therapy.	For individuals at increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants, it is clinically recommended to avoid the use of gentamicin and other aminoglycosides. Alternative antibiotics that do not carry the same risk of ototoxicity should be considered to prevent irreversible hearing loss.	0.7626206700236798	0.5727240540413857	0.4999290832437488	0.5782317536294967	0.83402246	0.5789478	0.4776456	0.6313567	0.8021335	0.5039189	0.48770854	0.58949876	0.82933074	0.4621089	0.43198887	0.53095865	0.70572954	0.64363265	0.561553	0.60321444	1
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid gentamicin. Take an alternate therapy.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Proceed taking gentamicin as normal. There is no recommendation.	For individuals assessed to be at normal risk of aminoglycoside-induced hearing loss based on their MT-RNR1 genotype, standard clinical guidance generally recommends proceeding with the use of gentamicin according to established pharmacological protocols. Routine monitoring of renal function and auditory status is still advisable to manage potential adverse effects, but no genotype-specific alterations in dosing or administration are typically required.	0.7107966484845074	0.490414452354216	0.5102863961167895	0.6426415882317982	0.66684306	0.51108366	0.50961554	0.5317729	0.68421906	0.5786553	0.54718715	0.5448807	0.68938684	0.4842328	0.4831772	0.54857963	0.6807947	0.57890636	0.6105881	0.6442206	1
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid gentamicin. Take an alternate therapy.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Proceed taking gentamicin as normal. There is no recommendation.	For individuals at uncertain risk of aminoglycoside-induced hearing loss due to variants in the MT-RNR1 gene, it is recommended to consider alternative antibiotics to avoid potential ototoxicity. Genetic testing can help confirm the presence of deleterious variants in MT-RNR1, which are associated with a significantly increased risk of hearing loss when exposed to aminoglycosides such as gentamicin. If genetic testing is not feasible, clinicians should weigh the risks and benefits, considering other safer antibiotic options.	0.600602295002078	0.490414452354216	0.5102863961167895	0.4869234221711017	0.5364486	0.51108366	0.50961554	0.41234592	0.6236901	0.5786553	0.54718715	0.43761206	0.6905461	0.4842328	0.4831772	0.41304728	0.5941818	0.57890636	0.6105881	0.50573444	0
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	Clinical guidance for a patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency would advise caution when prescribing glyburide, as this medication may increase the risk of hemolytic anemia in such individuals. Alternative diabetes medications with a lower risk profile for hemolysis should be considered for managing blood glucose levels in patients with G6PD deficiency.	0.6385483259128147	0.5059322248389749	0.38436230227362467	0.5243563613213011	0.6145304	0.63096577	0.44991803	0.59887516	0.6416545	0.58356655	0.41665685	0.5902746	0.66411793	0.55687624	0.45458207	0.57939667	0.5553226	0.5694796	0.4480128	0.5116353	0
glyburide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	For individuals who are classified as Indeterminate for G6PD deficiency, clinical guidance suggests exercising caution with the use of glyburide. This is because glyburide, a sulfonylurea used to manage blood glucose levels in type 2 diabetes, has the potential to cause hemolytic anemia in patients with G6PD deficiency. Close monitoring for any signs of hemolysis, such as jaundice, dark urine, or fatigue, is advised, and alternative diabetes medications may be considered to avoid this risk.	0.6113266772486531	0.3998292587178428	0.33707966123279814	0.5310472569046552	0.5196719	0.33047724	0.33726558	0.626024	0.62684155	0.40882063	0.3365035	0.65897053	0.6003398	0.3728444	0.3463533	0.5580232	0.519235	0.46678153	0.45682272	0.48029813	0
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	For patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), the use of glyburide should be approached with caution. Glyburide is a sulfonylurea which has been associated with hemolytic anemia in patients with G6PD deficiency. Clinical guidance typically recommends considering alternative non-sulfonylurea antidiabetic medications to mitigate the risk of hemolysis.	0.4357203903573945	0.36733386981728566	0.3981281133812886	0.5143222429883982	0.5382262	0.48771554	0.4872537	0.6053501	0.48428348	0.4324181	0.42766428	0.6053307	0.41802517	0.42212665	0.39028063	0.5755661	0.4820076	0.38036668	0.46689287	0.46822447	0
glyburide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	Individuals with a normal G6PD (glucose-6-phosphate dehydrogenase) status generally do not face increased risk of hemolysis when taking glyburide. Therefore, clinical guidance for them would typically not require special precautions related to G6PD deficiency. However, standard clinical monitoring for glyburide's effectiveness and side effects, such as hypoglycemia, remains essential.	0.6534729256126895	0.44756236119760623	0.32030727867000786	0.5987666371177305	0.54334027	0.45541766	0.2555867	0.66583866	0.49638072	0.3578021	0.21604638	0.6708135	0.5063089	0.2883242	0.21600156	0.5786573	0.62099653	0.49520373	0.36960807	0.5523622	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	Individuals with Malignant Hyperthermia Susceptibility due to RYR1 mutations should avoid exposure to halothane, as it can trigger a life-threatening hypermetabolic reaction in skeletal muscles. While the susceptibility related to CACNA1S is uncertain, it does not negate the significant risk associated with RYR1 mutations, and thus, halothane and other potent inhalational anesthetics should be avoided. Non-triggering anesthetic alternatives should be used instead.	0.6644574016670776	0.5125833701259792	0.436373501116472	0.4781567154787475	0.69004315	0.6434366	0.5418251	0.55784905	0.7662424	0.5877565	0.4985808	0.55829346	0.6962981	0.47715402	0.41892657	0.5259126	0.66909105	0.593848	0.5662722	0.5793295	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	Individuals with Malignant Hyperthermia Susceptibility (MHS) due to RYR1 or CACNA1S gene mutations should avoid halothane, as it is a known trigger for malignant hyperthermia (MH) episodes. Clinical guidelines recommend the use of alternative anesthetic agents that do not pose a risk for MH, such as intravenous anesthetics like propofol, to ensure safe perioperative care.	0.7619069073672996	0.5125833701259792	0.436373501116472	0.5104367238359251	0.8380839	0.6434366	0.5418251	0.66355425	0.8448514	0.5877565	0.4985808	0.6053687	0.82374907	0.47715402	0.41892657	0.5727199	0.6994851	0.593848	0.5662722	0.5610749	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid halothane. Take an alternate therapy.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Proceed taking halothane as normal. There is no recommendation.	Patients with uncertain susceptibility for RYR1 and no available results for CACNA1S should be managed cautiously with regard to halothane administration due to the risk of malignant hyperthermia (MH). It is generally advisable to avoid halothane and consider alternative anesthesia options, while ensuring that protocols for managing MH are readily available if exposure cannot be avoided.	0.7020123280979881	0.43087132781590964	0.37226282698796437	0.5780540886625776	0.6814902	0.5207521	0.37978888	0.60013634	0.6746369	0.39891043	0.40849724	0.57710683	0.599938	0.3723084	0.32514384	0.53509516	0.7120019	0.4512371	0.41108957	0.53924894	0
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	Clinical guidance for a patient who has no result for RYR1 testing and is susceptible to Malignant Hyperthermia (MH) due to a CACNA1S variant would include avoiding halothane and other potent volatile anesthetics, as they pose a significant risk for triggering MH. Alternative anesthetic agents that do not precipitate MH, such as intravenous agents, should be considered instead. Additionally, preoperative planning with an anesthesiologist familiar with MH protocols is essential.	0.7651207891276047	0.5192424969053808	0.4447830076105678	0.542682656672343	0.84039396	0.6295587	0.53317004	0.64978045	0.8421959	0.5611591	0.46712592	0.4999186	0.7879909	0.45054677	0.39339378	0.4703385	0.7163135	0.57862145	0.5561028	0.5074701	1
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For individuals identified as CYP2D6 ultrarapid metabolizers (activity score ≥ 5.0), clinical guidance typically recommends avoiding hydrocodone for pain management. This is due to the increased risk of rapid conversion of hydrocodone to hydromorphone, potentially enhancing opioid-related side effects and toxicity. Alternative pain management strategies or non-CYP2D6-metabolized opioids should be considered.	0.5743425965012086	0.6161507282885375	0.5686107654364894	0.5676490762297928	0.6257133	0.58620346	0.42646375	0.63637966	0.71893495	0.7300503	0.63213	0.61361283	0.6561753	0.7018526	0.6028943	0.579603	0.5971826	0.798659	0.62215155	0.5909262	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For individuals identified as CYP2D6 Ultrarapid Metabolizers with an activity score of 2.5, clinical guidance suggests that they may convert hydrocodone to its active metabolite, hydromorphone, more rapidly and extensively than individuals with normal metabolism. This can increase the risk of adverse effects such as respiratory depression. Given these risks, alternative analgesics that are not metabolized by CYP2D6 or close monitoring for adverse effects may be recommended.	0.5059678532770956	0.6161507282885375	0.5686107654364894	0.5327323290525326	0.34772897	0.58620346	0.42646375	0.45005688	0.64464456	0.7300503	0.63213	0.5657235	0.57303923	0.7018526	0.6028943	0.52355045	0.5510948	0.798659	0.62215155	0.55861855	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	Use hydrocodone label recommended age- or weight-specific dosing.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For someone identified as a normal metabolizer with an activity score of 1.5 for CYP2D6, the clinical guidance for taking hydrocodone generally would not involve any adjustments to the standard dosing. This genotype suggests that they have typical CYP2D6 enzyme activity, implying hydrocodone can be effectively metabolized without significant risk of altered drug response or toxicity. However, clinical judgment should consider other patient-specific factors to ensure safe and effective treatment.	0.5502990307980821	0.6090451225031737	0.6433887561233885	0.6011357287357454	0.4324907	0.47603956	0.54207224	0.53003436	0.5017756	0.66232723	0.63483906	0.5526708	0.5603931	0.7024995	0.5987571	0.5374361	0.54518545	0.67024654	0.6824866	0.6476572	1
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For an individual who is an ultrarapid metabolizer (activity score ≥6.0) of CYP2D6, clinical guidance typically advises against prescribing hydrocodone. This is because ultrarapid metabolizers convert hydrocodone to its active metabolite, hydromorphone, more quickly and extensively than normal metabolizers, which may increase the risk of side effects or toxicity. Alternative analgesics that are not predominantly metabolized by CYP2D6 should be considered.	0.5650498081073644	0.6161507282885375	0.5686107654364894	0.5883236434448063	0.55211645	0.58620346	0.42646375	0.6091572	0.6756591	0.7300503	0.63213	0.6241247	0.64248645	0.7018526	0.6028943	0.6065863	0.5703976	0.798659	0.62215155	0.59261125	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	Individuals with variable glucose-6-phosphate dehydrogenase (G6PD) enzyme activity could be at an increased risk for hemolytic anemia when taking hydroxychloroquine. Close monitoring for signs of hemolysis, such as dark urine, jaundice, and pallor, is advised, and alternative treatments should be considered where appropriate. It may also be prudent to assess G6PD enzyme levels prior to initiating therapy.	0.5987465242286553	0.45205065480352546	0.3323417258016147	0.47845525346735307	0.48752132	0.5309878	0.31695506	0.55114794	0.46341452	0.42106065	0.23939104	0.6119953	0.49397418	0.38040987	0.23393212	0.5495176	0.4581562	0.52370197	0.3827801	0.4689313	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) levels, hydroxychloroquine can be prescribed without significant concerns related to hemolytic anemia, a risk associated with G6PD deficiency. However, clinical use should still consider other factors such as potential side effects and contraindications specific to hydroxychloroquine. Regular monitoring and adherence to dosing guidelines are recommended to ensure patient safety.	0.6317573932525608	0.3887950861137486	0.25870312161007675	0.5618500448038892	0.54193306	0.39236608	0.19392107	0.62633294	0.447954	0.257026	0.12544477	0.64540786	0.3702116	0.14875	0.05898493	0.60063463	0.5567971	0.46030128	0.32393625	0.5520788	1
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	For individuals with an indeterminate Glucose-6-phosphate dehydrogenase (G6PD) status, caution is advised when prescribing hydroxychloroquine. While the indeterminate status may not conclusively indicate a deficiency, there remains a potential risk for hemolysis. Clinical guidelines often recommend closely monitoring the patient for signs of hemolysis, such as jaundice or dark urine, and considering an alternative medication if possible.	0.6272293479126342	0.3572291636238882	0.2946983749619397	0.5315922109343545	0.58584887	0.24435943	0.266636	0.5650738	0.62189853	0.2771159	0.21064825	0.5913505	0.5180493	0.20778732	0.14779188	0.59958595	0.57694805	0.45534867	0.41669604	0.4931893	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	Individuals with a deficiency in glucose-6-phosphate dehydrogenase (G6PD) are at an increased risk for hemolytic anemia when taking hydroxychloroquine. Clinical guidance generally advises against the use of hydroxychloroquine in G6PD-deficient patients due to this risk. Alternative treatments that pose a lower risk of hemolysis should be considered for these individuals.	0.6048870762599009	0.45205065480352546	0.3323417258016147	0.50935481577427	0.55617595	0.5309878	0.31695506	0.5967704	0.5132741	0.42106065	0.23939104	0.6030827	0.5100098	0.38040987	0.23393212	0.56629205	0.5344146	0.52370197	0.3827801	0.50938207	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For individuals identified as Normal Metabolizers with an activity score of 2.0 for CYP2C9, standard dosing guidelines for ibuprofen are typically recommended. This means that the individual can metabolize ibuprofen at a normal rate, and no dosing adjustments are necessary. It is still important to monitor for the usual side effects and to follow general medical advice regarding ibuprofen use.	0.40081483549878083	0.4006584357188238	0.4396917121283619	0.5895030970935515	0.44988504	0.32480732	0.31108817	0.4976978	0.43594134	0.35875928	0.24688198	0.49190882	0.40753213	0.33359322	0.30585048	0.5171697	0.4029973	0.4845922	0.44641066	0.5888261	1
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For an individual who is an intermediate metabolizer with a CYP2C9 activity score of 1.5, clinical guidelines suggest that caution should be exercised when prescribing ibuprofen. This metabolizer status may lead to slower clearance of the drug, increasing the risk of adverse effects. It might be advisable to start with a lower dose and monitor the patient closely for efficacy and toxicity, adjusting the dosage as necessary.	0.4677326243042204	0.4006584357188238	0.4396917121283619	0.510091458131128	0.40468058	0.32480732	0.31108817	0.48802793	0.384174	0.35875928	0.24688198	0.4802146	0.40483427	0.33359322	0.30585048	0.5487837	0.4619534	0.4845922	0.44641066	0.5808832	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	No recommendation	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	If a patient has an indeterminate CYP2C9 genotype, clinical guidance generally suggests exercising caution when using ibuprofen. Since CYP2C9 plays a role in metabolizing ibuprofen, the uncertainty in metabolizer status may affect drug efficacy and safety. It is advisable to start with the lowest effective dose and closely monitor for adverse effects, adjusting the dosage as needed based on clinical response and tolerability.	0.2466812191185104	0.48599801094480516	0.2182767175546251	0.49842411867736347	0.09968253	0.23385403	0.100331865	0.4971684	0.030847963	0.09324747	0.015746238	0.46197498	-0.033715926	0.27112207	0.069338076	0.45019597	0.26808536	0.5637174	0.40936735	0.5339767	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For individuals identified as Intermediate Metabolizers with an activity score of 1.0 for the CYP2C9 enzyme, caution is recommended when taking ibuprofen. They may experience slower drug metabolism, potentially leading to higher plasma levels of the drug, which increases the risk of adverse effects. It is advisable to consider a lower dose or increased monitoring for side effects, and consult with a healthcare provider for personalized guidance.	0.4658622078894805	0.39285660678716616	0.4442933924759782	0.49491485156551523	0.4083526	0.4101101	0.34259138	0.46998006	0.30498335	0.3405758	0.22255297	0.48321477	0.34965652	0.3271477	0.30738145	0.53349316	0.4547648	0.39364275	0.39321008	0.6034697	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	For a patient identified as an Ultrarapid Metabolizer with a CYP2D6 activity score of ≥3.25 and an Intermediate Metabolizer for CYP2C19, clinical guidance would suggest avoiding the use of imipramine due to the high likelihood of subtherapeutic plasma concentrations caused by rapid metabolism via CYP2D6. Alternative therapies not primarily metabolized by CYP2D6, or dose adjustments monitored through therapeutic drug monitoring, should be considered to optimize treatment efficacy and safety.	0.7425730221113802	0.7450422613076159	0.7134930859317925	0.6570953483697409	0.61790776	0.64964586	0.5529227	0.5600567	0.5634568	0.65750116	0.5660723	0.5387068	0.507108	0.56931394	0.53625494	0.5397315	0.6303918	0.6534099	0.5688579	0.6739478	1
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid imipramine. Take an alternate therapy.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Proceed taking imipramine as normal. There is no recommendation.	For someone who is a Normal Metabolizer with an activity score of 2.25 for CYP2D6 and an Intermediate Metabolizer for CYP2C19, standard dosing of imipramine is typically appropriate. Although CYP2C19 metabolizes imipramine into its active metabolite, desipramine, the primary metabolism of imipramine occurs via CYP2D6. Therefore, no specific dosage adjustment is recommended based on their CYP2D6 and CYP2C19 metabolizer status. However, clinical monitoring for efficacy and adverse effects is always advised.	0.4087524175480004	0.4908741748286966	0.5123352083304534	0.6533743426511112	0.45994282	0.38066065	0.41784343	0.4612288	0.3886653	0.5019479	0.3961862	0.6203164	0.35584953	0.4548648	0.47493827	0.5921054	0.39533538	0.5462582	0.5904767	0.55640334	1
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	For a patient identified as an Ultrarapid Metabolizer with an activity score of ≥4.0 for CYP2D6 and no available result for CYP2C19, caution is advised when prescribing imipramine. Ultrarapid metabolizers of CYP2D6 can experience reduced therapeutic effects due to increased metabolism and lower plasma levels of the drug. Consider alternative medications not predominantly metabolized by CYP2D6, or if imipramine is necessary, close monitoring and possible dose adjustment are recommended.	0.6221764035779459	0.5578426613906001	0.5193132654916947	0.6442487780112685	0.7147132	0.44053555	0.40628043	0.5042588	0.6915465	0.32613507	0.3218074	0.5148557	0.65147835	0.40993163	0.41416633	0.51375055	0.5996171	0.4719266	0.4182336	0.58452266	1
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	For a patient who is an Ultrarapid Metabolizer (UM) with an activity score of 3.0 for CYP2D6, there is an increased risk of subtherapeutic levels of imipramine, which may result in reduced efficacy. Considering the indeterminate status for CYP2C19, careful monitoring is advised. It may be recommended to select an alternative medication not metabolized by CYP2D6 or to adjust the imipramine dosage based on therapeutic drug monitoring and clinical response. Consulting a clinical pharmacogenomics specialist might also be beneficial.	0.6457613424741145	0.5578426613906001	0.5193132654916947	0.6426661426726493	0.7184177	0.44053555	0.40628043	0.5043074	0.6630202	0.32613507	0.3218074	0.53111696	0.57213026	0.40993163	0.41416633	0.45658296	0.5768071	0.4719266	0.4182336	0.56680727	1
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	Individuals with uncertain susceptibility for RYR1 and confirmed malignant hyperthermia susceptibility for CACNA1S should avoid the use of isoflurane. Isoflurane is a known trigger for malignant hyperthermia, a potentially life-threatening condition. Alternative anesthetic agents that do not pose this risk should be used instead.	0.6852216580620082	0.4495130904628476	0.3617350067114547	0.548180868244594	0.7860975	0.53825134	0.442722	0.68960017	0.73236144	0.4140642	0.36374617	0.6655641	0.6902744	0.37577188	0.38502988	0.5927916	0.5913304	0.5462868	0.524697	0.5799896	0
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	"If a patient has ""No Result"" for RYR1 and is ""Malignant Hyperthermia Susceptibility"" for CACNA1S, clinical guidance generally indicates avoiding the use of isoflurane and other potent volatile anesthetics, as well as succinylcholine. This is because the CACNA1S mutation can still pose a risk for malignant hyperthermia, a life-threatening condition triggered by these agents. It is advisable to use alternative anesthetics and to ensure proper precautions are in place, such as dantrolene availability, to manage any potential adverse reactions."	0.7718448249364998	0.45614978682644847	0.37056933441858364	0.5229145798554817	0.7903838	0.5214989	0.43131432	0.5670476	0.8034309	0.3956143	0.33795953	0.5251323	0.74771076	0.3587199	0.36191645	0.47017664	0.76066476	0.5345819	0.5182881	0.5795612	1
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	For individuals with Malignant Hyperthermia Susceptibility (MHS) associated with RYR1 genetic variants and Uncertain Susceptibility for CACNA1S, the clinical guidance is to avoid using isoflurane and other known triggering agents like certain volatile anesthetics and succinylcholine. Alternative anesthetics that do not trigger malignant hyperthermia should be considered to ensure patient safety.	0.790005437062135	0.4495130904628476	0.3617350067114547	0.520248944807624	0.8470069	0.53825134	0.442722	0.62325203	0.8298544	0.4140642	0.36374617	0.4773752	0.79848266	0.37577188	0.38502988	0.45602602	0.71440953	0.5462868	0.524697	0.5934943	1
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid isoflurane. Take an alternate therapy.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Proceed taking isoflurane as normal. There is no recommendation.	If a patient has No Result for the RYR1 gene and Uncertain Susceptibility for the CACNA1S gene, caution is advised when considering isoflurane due to the potential risk of malignant hyperthermia (MH). Although the genetic findings are inconclusive, the safest approach would be to avoid isoflurane and opt for alternative anesthetics that do not trigger MH, ensuring patient safety. Consultation with a specialist in pharmacogenomics or an anesthesiologist is recommended for tailored advice.	0.7305710192767348	0.40895507371181516	0.3593131329637432	0.5385052020162732	0.7758504	0.47162196	0.31851384	0.6279271	0.75811267	0.30084196	0.31226307	0.51316756	0.61264205	0.38888192	0.3407664	0.5360439	0.7270542	0.4430562	0.40123078	0.57952505	0
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor responsive in CF patients for CFTR with regards to taking ivacaftor? Give a 2-3 sentence summary.	Use ivacaftor according to the product label	['Avoid ivacaftor. Take an alternate therapy.', 'Take ivacaftor with a reduced dose.', 'Take ivacaftor with an increased dose.']	Proceed taking ivacaftor as normal. There is no recommendation.	For cystic fibrosis patients with CFTR mutations that are ivacaftor-responsive, clinical guidance recommends initiating treatment with ivacaftor. This medication should be taken at a dose of 150 mg every 12 hours with fat-containing food to enhance its absorption and efficacy. Regular follow-up to monitor liver function and pulmonary improvements is also advised.	0.6736213727407996	0.7318675888562056	0.7403879963197788	0.6309285205444586	0.6077002	0.6627078	0.682622	0.5159738	0.5725572	0.7752967	0.7427501	0.61345226	0.37981832	0.48500445	0.42284766	0.56824017	0.63903064	0.6062356	0.7029137	0.47919905	1
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor non-responsive in CF patients for CFTR with regards to taking ivacaftor? Give a 2-3 sentence summary.	Ivacaftor is not recommended	['Proceed taking ivacaftor as normal. There is no recommendation.', 'Take ivacaftor with a reduced dose.', 'Take ivacaftor with an increased dose.']	Avoid ivacaftor. Take an alternate therapy.	For CF patients who are ivacaftor non-responsive due to specific CFTR mutations not being targets of ivacaftor, clinical guidance generally recommends discontinuation of ivacaftor, as continued use would not provide therapeutic benefit. Alternative treatments, such as other CFTR modulators or combination therapies that are effective for their specific CFTR mutation, should be considered under the guidance of a healthcare professional.	0.6422708033682837	0.6982744309840512	0.72880598182411	0.6278794864229246	0.55787504	0.72865677	0.6260349	0.61000246	0.53698254	0.7701304	0.64781475	0.62005985	0.45454237	0.57497895	0.5446182	0.5794435	0.60225743	0.8849492	0.6666561	0.6202858	1
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking kanamycin as normal. There is no recommendation.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Avoid kanamycin. Take an alternate therapy.	For individuals with variants in the MT-RNR1 gene that place them at increased risk for aminoglycoside-induced hearing loss, it is generally recommended to avoid the use of aminoglycoside antibiotics such as kanamycin. Alternative antibiotics that do not carry the same risk of ototoxicity should be considered to prevent potential irreversible hearing damage.	0.7149324356706247	0.49411530553905875	0.4267016598194589	0.5444795615354773	0.7887209	0.6088733	0.48264697	0.63884825	0.77135456	0.51080847	0.47089657	0.62826407	0.7977369	0.42772728	0.41820803	0.5177992	0.68771476	0.6533365	0.5447252	0.69538647	1
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid kanamycin. Take an alternate therapy.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Proceed taking kanamycin as normal. There is no recommendation.	For individuals who are classified as normal risk for aminoglycoside-induced hearing loss based on their MT-RNR1 genotype, kanamycin may be used with standard dosing protocols, as there is no increased genetic susceptibility to ototoxicity. Nonetheless, regular monitoring of hearing function and renal function is recommended to promptly identify and manage any potential adverse effects.	0.6265421092195498	0.4442617705364379	0.42469025246809405	0.5826845092438608	0.6733788	0.45152903	0.4905007	0.57446384	0.6734583	0.510667	0.52820104	0.6544272	0.7056267	0.46866763	0.48679948	0.4966221	0.6212492	0.51939267	0.57403207	0.56533414	1
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid kanamycin. Take an alternate therapy.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Proceed taking kanamycin as normal. There is no recommendation.	For patients with uncertain risk of aminoglycoside-induced hearing loss due to potential MT-RNR1 mutations, caution is advised when administering kanamycin. Genetic testing to determine the presence of MT-RNR1 mutations, particularly the m.1555A>G mutation, is recommended before initiating treatment, as individuals with these mutations are at significantly higher risk of severe, irreversible ototoxicity. If a mutation is detected, alternative antibiotics that do not carry the same risk of hearing loss should be considered.	0.5816226514019508	0.4442617705364379	0.42469025246809405	0.5278654445556983	0.53971285	0.45152903	0.4905007	0.5061067	0.67045075	0.510667	0.52820104	0.57610536	0.6492471	0.46866763	0.48679948	0.41661757	0.5655832	0.51939267	0.57403207	0.48844397	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	For individuals identified as rapid metabolizers of CYP2C19, the clinical guidance would suggest considering a higher dose of lansoprazole or an alternative proton pump inhibitor (PPI) not significantly metabolized by CYP2C19, such as rabeprazole. This is due to the likelihood of reduced drug efficacy at standard doses because of faster metabolism. Always consult a healthcare provider for personalized medical advice.	0.467082708673358	0.4618732254591509	0.4340223530824725	0.6558010921794759	0.51832926	0.5101036	0.40146247	0.60911554	0.4295123	0.43865693	0.4294069	0.5877881	0.32188937	0.39795923	0.36851606	0.5169055	0.37093222	0.52924126	0.40537262	0.62531155	1
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	For individuals identified as likely poor metabolizers of CYP2C19, standard doses of lansoprazole may result in increased drug exposure and a potentially heightened risk of adverse effects. Clinical guidelines recommend considering a lower dose of lansoprazole or using an alternative proton pump inhibitor not significantly metabolized by CYP2C19, such as pantoprazole. It is essential to tailor therapy based on the individual's metabolic profile to ensure efficacy and minimize side effects.	0.3684823528076484	0.4415692772456328	0.4177318595080739	0.688857780311999	0.3721985	0.4223595	0.40915698	0.58314764	0.39788345	0.3880214	0.42315438	0.5415691	0.34956223	0.3922678	0.41773152	0.53596216	0.51338655	0.49732292	0.37711364	0.7109466	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	For individuals identified as Ultrarapid Metabolizers (UMs) for the CYP2C19 enzyme, clinical guidance suggests considering an alternative proton pump inhibitor (PPI) that is less dependent on CYP2C19 metabolism, such as esomeprazole or rabeprazole. This is because UMs may have reduced therapeutic response to lansoprazole due to increased clearance and lower plasma concentrations of the drug. Adjusting the treatment plan accordingly can help ensure adequate acid suppression and symptom control.	0.35608086304935455	0.45711498228336384	0.38184739094618025	0.599790659605163	0.35535803	0.6346298	0.48931384	0.47972107	0.32467428	0.6092481	0.51846784	0.48507443	0.3056466	0.5226105	0.4483411	0.4443454	0.31166503	0.5466819	0.34637892	0.6402513	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid lansoprazole. Take an alternate therapy.', 'Take lansoprazole with a reduced dose.', 'Take lansoprazole with an increased dose.']	Proceed taking lansoprazole as normal. There is no recommendation.	For a patient with an indeterminate CYP2C19 phenotype, dosing adjustments for lansoprazole, a proton pump inhibitor (PPI), typically are not specified due to the lack of clear genetic information. However, healthcare providers should monitor the patient for efficacy and any adverse effects, adjusting the dose if necessary based on clinical response. When possible, considering other clinical factors and possible alternative medications might be advisable.	0.24244653063455426	0.4679618523456921	0.23704759217871807	0.5903045082818261	0.12831816	0.315339	0.15860732	0.5261895	0.06615151	0.196159	0.08397603	0.59043103	-0.024640135	0.29971334	0.08771375	0.554051	0.2926736	0.53281885	0.3946633	0.5835497	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For a patient identified as a normal metabolizer with an activity score of 2.0 for CYP2C9, standard dosing of lornoxicam is generally appropriate. Normal metabolizers typically have regular enzyme activity, meaning they can process lornoxicam effectively and predictably. Therefore, no dose adjustments are typically necessary based solely on their CYP2C9 metabolizer status.	0.3554947293420398	0.41373041902339813	0.4277075831363146	0.6453653817924593	0.5151173	0.38846064	0.346195	0.53739023	0.48289302	0.47035366	0.31686828	0.60760164	0.42330363	0.3714915	0.39143813	0.5783388	0.3856433	0.443077	0.45283318	0.6369232	1
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For an individual who is an intermediate metabolizer (activity score = 1.5) for CYP2C9, caution is advised when prescribing lornoxicam. They may experience slower metabolism of the drug, leading to increased plasma levels and a higher risk of adverse effects. Dose adjustment and close monitoring for side effects are recommended to optimize therapeutic outcomes and minimize risks.	0.3865199009029904	0.41373041902339813	0.4277075831363146	0.6222462790741066	0.45064613	0.38846064	0.346195	0.6051532	0.45053723	0.47035366	0.31686828	0.6825786	0.37675235	0.3714915	0.39143813	0.5877343	0.4347966	0.443077	0.45283318	0.60217106	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	Clinical guidance for a patient who is indeterminate for CYP2C9 genotyping regarding lornoxicam use would generally recommend starting with the standard dosing regimen but with close monitoring for adverse effects, particularly gastrointestinal and renal issues. As the CYP2C9 genotype can influence lornoxicam metabolism, it is important to observe the patient for any signs of toxicity or reduced efficacy and adjust the dosage if necessary. Regular follow-up and possibly alternative pain management strategies might be considered based on clinical response.	0.2603502809576246	0.47006597786454063	0.24039404793535188	0.6668754623512382	0.20160803	0.39879048	0.2583364	0.6192418	0.13864101	0.29928493	0.2044519	0.6237137	0.023848513	0.3430517	0.12544459	0.5746357	0.2148827	0.49462235	0.3532696	0.5855368	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For individuals identified as intermediate metabolizers with an activity score of 1.0 for CYP2C9, clinical guidance often suggests caution when prescribing lornoxicam. Due to reduced metabolic capacity, there may be an increased risk of adverse effects from higher drug concentrations. Dose adjustments or alternative medications might be considered to mitigate these risks.	0.4479591152850915	0.4080056542722781	0.4421674292264462	0.6334393778516648	0.59270895	0.52421063	0.45007896	0.5974991	0.502339	0.5286274	0.3690702	0.64667404	0.4170984	0.3636173	0.38535556	0.5885771	0.498958	0.3587416	0.42705807	0.6081487	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	Individuals with a normal function genotype for SLCO1B1 (typically defined as the *1a/*1a or *1a/*1b genotypes) are expected to have a typical response to lovastatin. Clinical guidance generally does not necessitate dosage adjustments for such individuals, as they have a lower risk for statin-associated myopathy. It's important that they follow regular monitoring and clinical recommendations provided by their healthcare provider.	0.3683000509930757	0.3680136707653139	0.3441995673652946	0.6056634136611698	0.3097595	0.28405085	0.38512143	0.53005755	0.36668736	0.46173477	0.34138277	0.6100863	0.3944223	0.30372772	0.26445478	0.4865248	0.4647389	0.52720636	0.58332014	0.61313933	1
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	For individuals with increased function of the SLCO1B1 gene, standard dosing of lovastatin is generally recommended without modification. These individuals typically have reduced systemic exposure to the drug and a lower risk of statin-induced myopathy. As always, clinical decisions should also consider other patient-specific factors and monitoring for efficacy and side effects should continue as usual.	0.37661927151629465	0.3680136707653139	0.3441995673652946	0.6082626894831181	0.46853396	0.28405085	0.38512143	0.63569677	0.45856917	0.46173477	0.34138277	0.7300166	0.3681849	0.30372772	0.26445478	0.62499607	0.4778301	0.52720636	0.58332014	0.59767276	1
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	For individuals with an indeterminate SLCO1B1 genotype, the clinical recommendation for lovastatin use would generally proceed without specific adjustments driven by SLCO1B1 findings. However, since SLCO1B1 variants known as *5, *15, and *17 can increase the risk of statin-associated muscle symptoms (SAMS), clinicians should monitor for signs of myopathy and consider alternative statins or dosing adjustments if symptoms develop. Regular assessment of liver function and muscle symptoms should be conducted as per standard guidelines.	0.27412696016918503	0.4506944890612066	0.200337886496929	0.5899927150055739	0.20045145	0.3070175	0.15847011	0.56248486	0.10504383	0.21312553	0.09796449	0.58092475	0.014444254	0.3272289	0.11403362	0.50915486	0.2392484	0.5263305	0.41636434	0.551491	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.	['Proceed taking lovastatin as normal. There is no recommendation.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Avoid lovastatin. Take an alternate therapy.	For individuals with Possible Decreased Function of SLCO1B1, there is an increased risk of statin-associated myopathy when taking lovastatin. Clinical guidance would recommend considering alternative statins such as pravastatin or rosuvastatin, which are less dependent on the SLCO1B1 transporter, and using the lowest effective dose if lovastatin must be used. Regular monitoring for muscle-related symptoms is also advisable.	0.7101759659631895	0.7213938761137982	0.6558009763906334	0.6588215966649622	0.7010158	0.716754	0.6497324	0.66962284	0.68789166	0.79426247	0.76160735	0.6854207	0.59735346	0.56785214	0.59017074	0.571245	0.5615597	0.6932387	0.6043497	0.6213652	1
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	For patients who are deficient in glucose-6-phosphate dehydrogenase (G6PD), it is generally recommended to avoid the use of mafenide. The drug can induce hemolysis in G6PD-deficient individuals, leading to potentially severe consequences such as hemolytic anemia. It is crucial to identify alternative treatments to avoid this risk.	0.5708096020111896	0.48647954638521407	0.3775819350714695	0.5611125424419934	0.61970985	0.5759992	0.37785307	0.59681416	0.61910886	0.47978303	0.2654313	0.6133944	0.62001777	0.46378386	0.3401513	0.57713085	0.58573884	0.4833471	0.3955594	0.50014365	0
mafenide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when prescribing mafenide, as it has the potential to cause hemolysis in G6PD-deficient patients. It is recommended to either confirm G6PD status through further testing or alternatively, consider using other topical antimicrobial agents that are safer for individuals with suspected or confirmed G6PD deficiency.	0.5983878420556505	0.3795899424179429	0.3146545293281255	0.5799920269320884	0.46724752	0.21448557	0.221178	0.62408626	0.52020407	0.24836834	0.124411665	0.63937074	0.5538881	0.24246366	0.1924832	0.62223023	0.56867945	0.38702694	0.39681974	0.45115	0
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	For individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, particularly those at risk for Chronic Nonspherocytic Hemolytic Anemia (CNSHA), mafenide should be used with caution or avoided. Mafenide can induce hemolysis in G6PD-deficient patients, so alternate treatments might be necessary to avoid the risk of severe hemolytic reactions. Always consult with a healthcare provider to determine the safest and most appropriate treatment options.	0.43260215588113354	0.369260778890445	0.41209268652720676	0.5664456428736874	0.5795047	0.49657178	0.5036514	0.59955287	0.56170446	0.48548	0.40020892	0.6134027	0.4566702	0.39984766	0.34765235	0.6081106	0.5098049	0.30615044	0.40768027	0.47217953	0
mafenide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	For individuals with normal glucose-6-phosphate dehydrogenase (G6PD) activity, mafenide can generally be used as prescribed without increased risk of hemolytic anemia related to G6PD deficiency. However, as with any medication, it is important to monitor for side effects and follow the prescribing healthcare professional's guidelines.	0.5951782849153202	0.43123714569734845	0.2997913890209301	0.592327798260261	0.5213811	0.4481534	0.23981701	0.6097754	0.47035453	0.34508458	0.16066018	0.63047665	0.36726952	0.20597138	0.12792923	0.5915924	0.51137507	0.40791816	0.30661854	0.49660075	1
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For a patient identified as a normal metabolizer with an activity score of 2.0 for CYP2C9, standard dosing of meloxicam is appropriate. This genetic profile suggests the patient has typical enzyme activity for CYP2C9, which metabolizes meloxicam efficiently, allowing for standard therapeutic effects and risk of adverse events. Careful monitoring should still be implemented as per usual clinical guidelines.	0.3763422364424718	0.4093567670951658	0.40235702608687696	0.6035189167277957	0.35401452	0.36293304	0.34451762	0.47877738	0.32349586	0.44117254	0.2936089	0.567372	0.3452528	0.36278895	0.37953636	0.5355887	0.45374262	0.4726547	0.45383415	0.662181	1
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For a patient who is an intermediate metabolizer (IM) with a CYP2C9 activity score of 1.5, clinical guidelines suggest initiating meloxicam at the lowest recommended dose. Due to reduced enzyme activity, these patients may have increased exposure to the drug, thus requiring cautious dosing and careful monitoring for adverse effects such as gastrointestinal toxicity and impaired renal function. Regular assessment and adjustment of the dose may be necessary based on the patient's response and tolerance.	0.7833007391285888	0.6241105076865281	0.6760802183669804	0.592411772942523	0.614481	0.4756466	0.45348	0.5508576	0.58469725	0.6375218	0.4730623	0.5889162	0.6855367	0.61261976	0.6238072	0.6185346	0.6480914	0.6139773	0.5632675	0.6019452	0
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For a patient whose CYP2C9 genotype is indeterminate, the clinical guidance for meloxicam use often defaults to standard dosing and monitoring due to the lack of specific genotype data. However, practitioners should closely monitor for potential adverse effects and efficacy, as variations in CYP2C9 can influence meloxicam metabolism and the patient's response to the medication. Adjustments to dosing should be made based on clinical judgment and therapeutic monitoring.	0.2378135861540121	0.45395168083906384	0.21922545101477975	0.5770124178574146	0.13105707	0.27544275	0.12379988	0.511653	0.057793826	0.1511889	0.061338622	0.5502993	0.013032373	0.36191893	0.13929836	0.5469529	0.28989384	0.53668666	0.4205043	0.5853436	0
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking meloxicam as normal. There is no recommendation.', 'Avoid meloxicam. Take an alternate therapy.']	Take meloxicam with an altered dose.	For an individual classified as an intermediate metabolizer with a CYP2C9 activity score of 1.0, taking meloxicam may warrant dose adjustments or closer monitoring. This phenotype is associated with reduced metabolic capacity, which could lead to higher plasma concentrations of the drug and an increased risk of adverse effects. Clinical guidance typically recommends starting at the lower end of the dosing range and monitoring for efficacy and side effects.	0.7547747914246677	0.6420754538166199	0.6438447299175116	0.6657563365384859	0.6588877	0.5590076	0.53591454	0.52696526	0.76215106	0.53969234	0.6209737	0.45664844	0.6745996	0.5727233	0.5665212	0.5346008	0.7258293	0.6676766	0.5732453	0.68750125	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For a patient who is a Normal Metabolizer for TPMT and a Poor Metabolizer for NUDT15, clinical guidance would typically recommend starting at a significantly reduced dose of mercaptopurine, such as 10% or less of the usual dose, due to the increased risk of severe toxicity. The patient should be closely monitored for hematologic toxicity, and dose adjustments should be made based on their tolerance and blood counts.	0.7257435532276243	0.656033861424704	0.6531215378731485	0.6727395725656845	0.66833746	0.54011464	0.50656897	0.54695255	0.6549849	0.5443496	0.617	0.50907516	0.61856264	0.53400606	0.49136633	0.5876868	0.6400288	0.6409073	0.50744545	0.6583112	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For individuals who are intermediate metabolizers for both TPMT and NUDT15, a dose reduction of mercaptopurine is generally recommended to minimize the risk of myelosuppression. Clinical guidelines suggest starting at a lower dose, approximately 30-70% of the standard dosage, with careful monitoring of blood counts and adjusting the dose based on tolerance and therapeutic response. Regular follow-up and monitoring are crucial to manage potential toxicities and ensure effective treatment.	0.8032796928585592	0.6875104304921226	0.6657776061987652	0.6634419201088847	0.6974991	0.5255369	0.47550333	0.5451655	0.80196965	0.5455124	0.6310689	0.51835084	0.8379313	0.63834155	0.6251917	0.62715197	0.72578096	0.5916299	0.47121668	0.7047348	1
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For a patient who is a possible intermediate metabolizer for TPMT and a poor metabolizer for NUDT15, clinical guidance typically recommends a substantial reduction in the starting dose of mercaptopurine, even as low as 10% or less of the standard dose, with careful monitoring for toxicity and therapeutic response. This is due to significantly increased risk for myelosuppression and other adverse effects resulting from reduced inactivation of the drug. Regular blood count monitoring is essential to adjust dosing appropriately and ensure safety.	0.7669511757591047	0.656033861424704	0.6531215378731485	0.6908576346669595	0.59264374	0.54011464	0.50656897	0.5102607	0.67376345	0.5443496	0.617	0.503781	0.6139197	0.53400606	0.49136633	0.59672004	0.6681654	0.6409073	0.50744545	0.6895769	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For a patient who is a Poor Metabolizer for TPMT but a Normal Metabolizer for NUDT15, clinical guidance generally suggests starting with a significantly reduced dose of mercaptopurine to minimize the risk of severe myelosuppression. Typically, this may involve initiating treatment at 10% or less of the standard dose, with close monitoring of blood counts and potential dose adjustments based on therapeutic response and tolerance.	0.7562616706406748	0.6824092340964264	0.678523228009069	0.6580119511705418	0.7331402	0.52621776	0.4666165	0.52835166	0.6708289	0.56850994	0.64690125	0.49222037	0.69855595	0.5993989	0.56710446	0.5763549	0.67527455	0.673325	0.5324691	0.66948944	1
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	Methoxyflurane should be avoided in individuals with uncertain susceptibility for RYR1 and malignant hyperthermia susceptibility (MHS) for CACNA1S. Both genetic factors are associated with an increased risk of malignant hyperthermia, a potentially life-threatening reaction to certain anesthetics, including methoxyflurane. Therefore, alternative anesthetics that do not trigger malignant hyperthermia should be considered.	0.7103595660949431	0.4832833750282811	0.44367088102211133	0.6221060782123095	0.69677454	0.52831686	0.4143478	0.5951248	0.70529586	0.3992715	0.32240808	0.58370286	0.6728712	0.45769954	0.41020012	0.56211424	0.6851843	0.58519626	0.5607931	0.66873586	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	For a patient with indeterminate or no results for RYR1 and positive for CACNA1S concerning Malignant Hyperthermia Susceptibility, the use of methoxyflurane is generally contraindicated. Individuals with mutations in CACNA1S are at increased risk for malignant hyperthermia, a potentially life-threatening condition, when exposed to certain anesthetics like methoxyflurane. Thus, alternative non-triggering anesthetics should be considered.	0.7419983554052549	0.4839318504817565	0.44415626595215296	0.5692260073356656	0.77021044	0.5184895	0.4119039	0.57150865	0.77040523	0.3746874	0.2927024	0.50637186	0.75858074	0.42452854	0.3807415	0.54885566	0.7778686	0.56964153	0.5502052	0.5497557	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	Individuals with Malignant Hyperthermia Susceptibility (MHS) linked to RYR1 gene mutations or those with uncertain susceptibility related to CACNA1S should avoid the use of methoxyflurane. Methoxyflurane, like other volatile anesthetics, can trigger malignant hyperthermia, a potentially life-threatening condition, in susceptible individuals. Clinical guidelines recommend using alternative, non-triggering anesthetic agents for these patients.	0.7501190343444644	0.4832833750282811	0.44367088102211133	0.5538731973685084	0.76093364	0.52831686	0.4143478	0.6078536	0.76295346	0.3992715	0.32240808	0.57119817	0.79484046	0.45769954	0.41020012	0.5753285	0.67561847	0.58519626	0.5607931	0.63352776	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid methoxyflurane. Take an alternate therapy.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Proceed taking methoxyflurane as normal. There is no recommendation.	"Individuals with a ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S should approach methoxyflurane use with caution. Genetic testing for susceptibility to malignant hyperthermia (MH) may not provide definitive guidance in these cases, so clinical monitoring for signs of MH and consultation with a healthcare provider experienced in anesthetics and pharmacogenomics are recommended."	0.7569090447657448	0.44254844715601316	0.3755510898875167	0.5538311154864479	0.6716476	0.45844546	0.28589624	0.45965382	0.6954393	0.24951358	0.24346183	0.3867353	0.5836041	0.39962572	0.34295952	0.4791062	0.76707923	0.44583112	0.39463902	0.53015304	0
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking methylene blue as normal. There is no recommendation.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Avoid methylene blue. Take an alternate therapy.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), methylene blue is contraindicated due to the risk of triggering hemolytic anemia. Clinical guidance would advise against the use of methylene blue in these patients, as their condition makes them more susceptible to oxidative stress, which can lead to the rapid destruction of red blood cells.	0.24887402755407176	0.29396252494959985	0.2635735545962334	0.6233010734535237	0.3200496	0.40431276	0.3338392	0.6352407	0.18867195	0.21889381	0.2300791	0.64333785	0.19010475	0.18944	0.18988742	0.72223884	0.45558563	0.6267883	0.5424116	0.66846937	1
methylene blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid methylene blue. Take an alternate therapy.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Proceed taking methylene blue as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, methylene blue should be administered with caution due to the risk of hemolysis. Close monitoring for signs of hemolysis is recommended, and alternative treatments should be considered if available. Consulting with a healthcare professional for a thorough risk assessment is crucial in this scenario.	0.6227460852823831	0.39926667705511604	0.34025789233989445	0.6040628232749033	0.52837473	0.25596574	0.2768521	0.65069187	0.5465132	0.2835732	0.24537903	0.71403074	0.46635315	0.19279297	0.19199747	0.69532293	0.54695183	0.41993737	0.42208827	0.62317604	0
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking methylene blue as normal. There is no recommendation.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Avoid methylene blue. Take an alternate therapy.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), are at high risk of hemolysis when exposed to methylene blue. Clinical guidance strongly advises against the use of methylene blue in these patients due to the potential for severe hemolytic episodes. Alternative treatments should be considered to avoid this risk.	0.22249875944837674	0.29396252494959985	0.2635735545962334	0.5839566358763355	0.2867642	0.40431276	0.3338392	0.6085409	0.15528707	0.21889381	0.2300791	0.58106995	0.13983977	0.18944	0.18988742	0.7060788	0.48206285	0.6267883	0.5424116	0.680698	1
methylene blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	No reason to avoid ased on G6PD status	['Avoid methylene blue. Take an alternate therapy.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Proceed taking methylene blue as normal. There is no recommendation.	For individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) deficiency, taking methylene blue is generally considered safe at therapeutic doses. These individuals do not have an increased risk of hemolytic anemia that is associated with G6PD deficiency. However, caution should still be exercised, especially at higher doses or in combination with other oxidizing agents.	0.5705887787261165	0.4094021002240724	0.28886343401229864	0.6212917755821409	0.4249768	0.33019596	0.17593654	0.70634145	0.3647513	0.2158015	0.122321494	0.75431997	0.31021935	0.14012602	0.09004671	0.70649093	0.48173755	0.38158786	0.30839118	0.6711712	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, the use of nalidixic acid is generally contraindicated. This is because nalidixic acid can induce hemolytic anemia in people with G6PD deficiency, a condition that leads to the destruction of red blood cells. Therefore, alternative antibiotics that do not pose this risk should be considered for these patients.	0.6211617730789654	0.5102963233087527	0.3995030814456959	0.5584317446814077	0.5748208	0.5367552	0.33543587	0.6094231	0.59748274	0.43464684	0.25055793	0.64723074	0.56959295	0.44526783	0.3288478	0.59248155	0.5652291	0.5274701	0.41685203	0.63753587	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	For individuals with an indeterminate status for glucose-6-phosphate dehydrogenase (G6PD) deficiency, it is generally advisable to avoid the use of nalidixic acid. This antibiotic can increase the risk of hemolysis in G6PD-deficient patients. Alternative treatments that do not pose such a risk should be considered, with genetic testing recommended to confirm G6PD status if the use of such medications is necessary.	0.6120556046260627	0.41028201602843883	0.34138512113866976	0.5774285531256357	0.5086527	0.25943494	0.27332565	0.6561121	0.6674247	0.31100872	0.2369225	0.60567886	0.5716531	0.22788674	0.19734377	0.56779027	0.5797995	0.4442517	0.42799935	0.58668983	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	For individuals with G6PD deficiency, particularly those with Chronic Nonspherocytic Hemolytic Anemia (CNSHA), nalidixic acid is contraindicated. Use of this antibiotic can trigger acute hemolytic anemia due to the oxidative stress it imposes on red blood cells. Clinicians should choose alternative, non-oxidative stress-inducing medications for treating infections in these patients.	0.44610766070310653	0.41934796179015893	0.4490871397025546	0.5628714822952984	0.5404577	0.4938284	0.4958153	0.62400484	0.52654296	0.4820026	0.45384482	0.61458	0.50953597	0.39614537	0.36586258	0.55096954	0.53138137	0.3824438	0.4566885	0.6107134	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	Individuals who are normal for G6PD (Glucose-6-Phosphate Dehydrogenase) enzyme activity typically do not have the associated risk of hemolysis when exposed to oxidant drugs such as nalidixic acid. Thus, for a person with normal G6PD activity, clinical guidance does not require specific precautions related to G6PD deficiency when prescribing nalidixic acid. However, standard considerations for nalidixic acid's use, such as its contraindications, side effects, and potential for drug interactions, still apply.	0.6658294296562607	0.44993205836648464	0.32019268583958693	0.5737867536046799	0.5649096	0.38517892	0.1905008	0.58526075	0.40857074	0.25284716	0.1232888	0.6297892	0.38014856	0.16881055	0.08779632	0.5754925	0.59995806	0.45205277	0.34309897	0.6305644	1
neomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking neomycin as normal. There is no recommendation.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Avoid neomycin. Take an alternate therapy.	Individuals who have a genetic variant in the MT-RNR1 gene that puts them at increased risk for aminoglycoside-induced hearing loss should typically avoid using aminoglycosides, including neomycin, if alternative treatments are available. Clinical guidelines suggest that healthcare providers consider non-aminoglycoside antibiotics to mitigate the risk of irreversible ototoxicity in these patients.	0.7178274234475341	0.5170128410934319	0.43902898045025657	0.5250325884781697	0.79592955	0.60293967	0.48924625	0.61152434	0.7866429	0.5176673	0.5016423	0.57215226	0.79000324	0.4763912	0.44747832	0.48109967	0.6786572	0.6149113	0.50945026	0.6330813	1
neomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid neomycin. Take an alternate therapy.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Proceed taking neomycin as normal. There is no recommendation.	For individuals with a normal MT-RNR1 genotype, indicating a typical risk of aminoglycoside-induced hearing loss, there is no increased genetic predisposition to hearing loss from aminoglycosides like neomycin. Therefore, they can usually be prescribed neomycin without additional risk for aminoglycoside-induced ototoxicity. However, it's important to follow standard clinical considerations and monitoring due to the inherent risks of aminoglycosides.	0.5687288828784591	0.436805259352131	0.45868538317550017	0.5360507366214731	0.45726183	0.4583342	0.48983455	0.5345206	0.5750757	0.52771825	0.55508214	0.5387066	0.6707958	0.50227654	0.50675625	0.49424583	0.529378	0.4940156	0.5422487	0.53153884	0
neomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid neomycin. Take an alternate therapy.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Proceed taking neomycin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss related to MT-RNR1 mutations, it is generally advised to avoid aminoglycosides, including neomycin, due to the potential for severe ototoxicity. If aminoglycoside treatment is deemed necessary, alternative antibiotics should be considered, or genetic testing for MT-RNR1 mutations should be performed to better assess the risk.	0.6213303180193994	0.436805259352131	0.45868538317550017	0.4897137011457491	0.54966897	0.4583342	0.48983455	0.6146975	0.676724	0.52771825	0.55508214	0.57114005	0.7236935	0.50227654	0.50675625	0.50028616	0.5507013	0.4940156	0.5422487	0.5179213	0
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking netilmicin as normal. There is no recommendation.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Avoid netilmicin. Take an alternate therapy.	For individuals with an increased risk of aminoglycoside-induced hearing loss associated with MT-RNR1 variants, it is generally recommended to avoid the use of aminoglycosides, including netilmicin. Alternative non-aminoglycoside antibiotics should be considered to mitigate the risk of ototoxicity and preserve hearing function.	0.725777259283243	0.5081800664560344	0.43533232783108206	0.519761026824875	0.8091192	0.57104945	0.4572886	0.63389534	0.76941943	0.4305896	0.41669762	0.5886328	0.7949433	0.405359	0.39526176	0.5739275	0.6869393	0.59560007	0.4809334	0.6211641	1
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid netilmicin. Take an alternate therapy.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Proceed taking netilmicin as normal. There is no recommendation.	For individuals with a normal risk of aminoglycoside-induced hearing loss according to their MT-RNR1 genotype, netilmicin can be administered according to standard dosing protocols without additional precautions specific to hearing loss risk. Nonetheless, it remains important to monitor renal function and plasma drug levels to prevent potential nephrotoxicity and ototoxicity typically associated with aminoglycosides.	0.6408005379332152	0.4284412123096973	0.41428631836409213	0.5937622464331946	0.6338017	0.45805687	0.45130825	0.604331	0.6223609	0.4630871	0.47007787	0.6273803	0.69178814	0.46881813	0.46443865	0.4999215	0.6273094	0.45471826	0.5047259	0.5339352	0
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid netilmicin. Take an alternate therapy.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Proceed taking netilmicin as normal. There is no recommendation.	For individuals with an uncertain risk of aminoglycoside-induced hearing loss related to MT-RNR1 variants, caution is advised when considering netilmicin. It is generally recommended to explore alternative antibiotics if possible or to closely monitor auditory function if netilmicin use is unavoidable. Consultation with a clinical geneticist or a specialist in pharmacogenomics may provide more personalized guidance.	0.6050069813301862	0.4284412123096973	0.41428631836409213	0.5806054519413166	0.5681453	0.45805687	0.45130825	0.5608854	0.65530175	0.4630871	0.47007787	0.56090444	0.7103226	0.46881813	0.46443865	0.48927382	0.6035683	0.45471826	0.5047259	0.5482569	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	Use at standard doses with caution and with close monitoring for anemia	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), it is generally advised to avoid nitrofurantoin due to the increased risk of hemolytic anemia. G6PD deficiency can make red blood cells more vulnerable to oxidative damage induced by certain medications, including nitrofurantoin, leading to their premature destruction. Therefore, an alternative antibiotic should be considered for treating infections in these patients.	0.32990421883475923	0.387101450133549	0.4052466910355325	0.5719425088542901	0.5121697	0.522519	0.46297336	0.63818824	0.4885615	0.5286387	0.4036254	0.6196588	0.4368441	0.40946662	0.3082297	0.5767009	0.45360076	0.40740108	0.44536152	0.59938157	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, there is insufficient evidence to ensure safety or risk when taking nitrofurantoin. It is generally recommended to proceed with caution and consider alternative antibiotics, or to conduct G6PD deficiency testing to guide appropriate therapy. Consulting with a healthcare provider for a personalized risk assessment is advised.	0.5716873970287496	0.34926333492144146	0.28611565102392605	0.6504277314233714	0.49805567	0.2725551	0.28808877	0.7169261	0.53276277	0.33166814	0.27097312	0.77449626	0.5833582	0.2132039	0.17746516	0.6219482	0.5778079	0.40906742	0.38126978	0.63534987	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	Avoid	['Proceed taking nitrofurantoin as normal. There is no recommendation.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Avoid nitrofurantoin. Take an alternate therapy.	For individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, particularly those with Chronic Non-Spherocytic Hemolytic Anemia (CNSHA), the use of nitrofurantoin is generally contraindicated. Nitrofurantoin can trigger hemolysis in patients with G6PD deficiency, and alternative antibiotics that do not pose a risk for hemolytic anemia should be considered to avoid potentially severe complications.	0.16825774221608616	0.3005691797852066	0.2357660913345824	0.5981000994399237	0.22273085	0.37423956	0.32493457	0.6422209	0.14732477	0.22473016	0.2399553	0.6863194	0.100374766	0.26494846	0.24695277	0.6345169	0.35516334	0.51067966	0.43996444	0.6371373	1
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	For individuals who have a normal genotype for glucose-6-phosphate dehydrogenase (G6PD), there are no specific contraindications for taking nitrofurantoin. Nitrofurantoin can be prescribed and used as indicated for the treatment or prevention of urinary tract infections without the heightened risk of hemolytic anemia associated with G6PD deficiency.	0.5624422857698218	0.36693159426412836	0.2457900146282421	0.633022884884098	0.5182531	0.44078693	0.269966	0.6444111	0.4914813	0.33738163	0.21715666	0.68958986	0.38311097	0.1798882	0.100993395	0.5146677	0.5164889	0.4436887	0.32732594	0.6227562	1
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	Patients who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should use caution when taking norfloxacin, as the medication can increase the risk of hemolytic anemia. Clinical guidance typically advises avoiding norfloxacin in G6PD-deficient individuals when possible or closely monitoring for signs of hemolysis if its use is considered unavoidable. Alternative antibiotics that do not carry this risk should be considered.	0.5876658530081531	0.41963863061013507	0.32170793635523803	0.5962184474400426	0.5977335	0.46382824	0.25206774	0.56308246	0.5907722	0.31267026	0.12702455	0.5296692	0.52889633	0.3985021	0.28740144	0.606364	0.52536565	0.46547198	0.35617176	0.5809111	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	For individuals with an indeterminate status for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, norfloxacin should be used with caution. G6PD deficiency may increase the risk of hemolytic anemia when exposed to certain medications. It is advisable to monitor for signs of hemolysis, such as jaundice and dark urine, especially during or after initiating treatment with norfloxacin, and to seek alternative treatments if possible.	0.5800680039567251	0.3099475422170956	0.24670080838918584	0.5745206140547033	0.54423165	0.13171333	0.12475675	0.5145611	0.6217145	0.111671075	0.031879365	0.4708926	0.48275596	0.1869118	0.15330034	0.55113333	0.46298203	0.40342304	0.38039103	0.5468611	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), the use of norfloxacin should be approached with caution due to the risk of hemolysis. Clinical guidelines recommend avoiding norfloxacin in G6PD-deficient patients to prevent potential hemolytic episodes and suggest considering alternative antibiotics that have a safer profile for these individuals.	0.4527192249264578	0.34606818928904154	0.3893772566465747	0.5522945547236985	0.57928526	0.47659543	0.46238354	0.55521923	0.49859104	0.44834954	0.35976207	0.51124495	0.57961655	0.41963315	0.3625772	0.5631977	0.53438663	0.42166263	0.47665906	0.56045294	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	For an individual with normal glucose-6-phosphate dehydrogenase (G6PD) activity, there is no increased risk of hemolytic anemia when taking norfloxacin. Therefore, norfloxacin can be prescribed without additional concern for G6PD deficiency-related adverse effects. Nonetheless, it is still important to monitor for other common side effects associated with norfloxacin use.	0.5817901589349894	0.3663251993408382	0.2497966719033872	0.5811068286989721	0.5177426	0.34096554	0.16035789	0.53454715	0.41891423	0.19446607	0.06388267	0.44610944	0.3228117	0.139765	0.08049331	0.52606887	0.4499751	0.4030785	0.3007896	0.56064194	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	For a patient identified as an Ultrarapid Metabolizer (UM) with a CYP2D6 activity score of ≥3.75, it is recommended to avoid nortriptyline due to the risk of subtherapeutic plasma concentrations and lack of efficacy. Alternative medications not metabolized primarily by CYP2D6, such as those in the serotonin-norepinephrine reuptake inhibitor (SNRI) class or other tricyclic antidepressants (TCAs) with less reliance on CYP2D6, should be considered.	0.7136840750264558	0.5539332337773649	0.5185643014818234	0.6498749134342487	0.70355946	0.59421337	0.53958297	0.6444355	0.78354925	0.50010276	0.4762896	0.64496845	0.69128424	0.48090205	0.46487388	0.5735798	0.6633521	0.5963231	0.5515143	0.63192135	0
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid nortriptyline. Take an alternate therapy.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Proceed taking nortriptyline as normal. There is no recommendation.	For a patient identified as a normal metabolizer (activity score = 1.75) of CYP2D6 regarding nortriptyline, standard dosing guidelines can be followed. The normal metabolizer status indicates that the patient will likely have typical nortriptyline metabolism and response. However, monitoring for efficacy and adverse effects is still recommended, as individual responses can vary.	0.4071949050987687	0.48586007244775986	0.47727313192606696	0.6386806112190319	0.41651806	0.3388268	0.41150093	0.52820325	0.3768829	0.43394366	0.35340515	0.60546046	0.34508786	0.36809278	0.34603143	0.5111249	0.38826975	0.51391894	0.5276429	0.58819896	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer with a CYP2D6 activity score of 2.75, clinical guidance typically advises caution with nortriptyline due to the potential for subtherapeutic plasma levels and reduced efficacy. It is generally recommended to consider alternative medications not metabolized by CYP2D6 or to closely monitor the patient's response and plasma drug levels if nortriptyline is prescribed. Adjusting the nortriptyline dose may be necessary, but clinical decisions should be made based on careful monitoring and the patient's specific clinical situation.	0.6625298022194417	0.5539332337773649	0.5185643014818234	0.6476930300905005	0.7698523	0.59421337	0.53958297	0.59812266	0.7306195	0.50010276	0.4762896	0.6173349	0.6506939	0.48090205	0.46487388	0.49753663	0.6669355	0.5963231	0.5515143	0.6001508	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	For a patient who is an Ultrarapid Metabolizer with a CYP2D6 activity score of ≥4.0, it is recommended to avoid using nortriptyline. Due to their rapid metabolism through CYP2D6, these patients may have subtherapeutic drug levels, leading to inadequate response. Alternative medications not metabolized by CYP2D6 are preferred, or if nortriptyline is necessary, close monitoring and possible dose adjustment would be required.	0.6563295418007977	0.5539332337773649	0.5185643014818234	0.6317428099322083	0.7107744	0.59421337	0.53958297	0.64944214	0.6887832	0.50010276	0.4762896	0.6001017	0.6948717	0.48090205	0.46487388	0.531087	0.67173976	0.5963231	0.5515143	0.6576579	1
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	Individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD) should generally avoid taking ofloxacin due to the increased risk of hemolytic anemia. Ofloxacin and other quinolones can trigger red blood cell breakdown in people with G6PD deficiency. Alternative antibiotics that do not carry this risk should be considered for these patients.	0.5403832733675195	0.4073082038427261	0.2968745737750878	0.5222331055936483	0.58422613	0.52439594	0.32061028	0.6125221	0.583514	0.40802163	0.2311114	0.6207647	0.54286796	0.38465032	0.27130282	0.53949654	0.47509322	0.43098566	0.33088526	0.5766985	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, it is advisable to exercise caution when prescribing ofloxacin, as the drug has been associated with hemolysis in G6PD-deficient patients. Clinicians should consider alternative antibiotics that do not pose a risk of hemolysis or closely monitor the patient for hemolytic symptoms if ofloxacin is deemed necessary.	0.5488254924627778	0.3015775796198828	0.2275060579392735	0.5442021833291928	0.50805193	0.23022361	0.23508711	0.63397884	0.5485468	0.23781705	0.14877336	0.6492072	0.5292179	0.19479704	0.16254325	0.60272753	0.51801044	0.39192256	0.39242938	0.553029	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those at risk for chronic nonspherocytic hemolytic anemia (CNSHA), taking ofloxacin is generally contraindicated. Ofloxacin has been associated with triggering hemolytic anemia in G6PD-deficient patients. It is important to consider alternative antibiotics that are safer for this population to avoid hemolytic complications.	0.4211402034398067	0.3722279232955478	0.39823882251465387	0.55053055767284	0.52452785	0.47258347	0.47498977	0.5856926	0.4851864	0.43115827	0.40081966	0.6141715	0.51779044	0.4406681	0.4035031	0.5842736	0.5169248	0.41272187	0.49330425	0.5542329	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	For individuals who are normal (i.e., have no deficiency) in glucose-6-phosphate dehydrogenase (G6PD) activity, there are no specific additional precautions needed when taking ofloxacin. This antibiotic can be used as prescribed without increased risk of hemolytic anemia, which is a concern in G6PD-deficient individuals. However, standard monitoring and adherence to dosing guidelines remain important to manage potential side effects or drug interactions.	0.5411796216610494	0.3386573415241505	0.22096623346335686	0.6494161804078082	0.54231614	0.4036585	0.21641771	0.7129964	0.4730915	0.26453057	0.14745688	0.7000036	0.35794884	0.1290781	0.05306213	0.5786551	0.53972244	0.38018796	0.26939926	0.6052548	1
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	For an individual identified as an ultrarapid metabolizer of CYP2C19, standard doses of omeprazole may result in reduced efficacy due to increased drug clearance. Clinical guidelines suggest considering alternative proton pump inhibitors that are less dependent on CYP2C19 metabolism, such as esomeprazole or rabeprazole, or adjusting the omeprazole dose as needed to achieve the desired therapeutic effect.	0.3641969708752038	0.4454323819857296	0.36912897080624996	0.6624751266086316	0.43692335	0.63719136	0.47588378	0.6036838	0.399153	0.6020922	0.49424553	0.56466603	0.3747888	0.52940774	0.453827	0.5325288	0.34785724	0.5606365	0.34522527	0.6307952	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	For individuals identified as likely poor metabolizers of CYP2C19, the enzyme responsible for metabolizing omeprazole, clinical guidance typically suggests that standard doses of omeprazole are generally effective, but the patient may experience higher plasma levels and prolonged drug effects. As a result, poor metabolizers may have an enhanced therapeutic response, and dose adjustments or more frequent monitoring for efficacy and adverse effects may be warranted.	0.4260220749565652	0.431118623473782	0.41026860792589404	0.6401899142435912	0.3648206	0.42749757	0.3863197	0.57432854	0.3596324	0.39290285	0.40172052	0.5531819	0.36596173	0.40408832	0.42602524	0.51054925	0.42812186	0.51069117	0.39541352	0.5929971	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	For individuals identified as Likely Intermediate Metabolizers for CYP2C19 when taking omeprazole, clinical guidelines suggest that these patients may experience moderately reduced metabolism of the drug. This can lead to increased drug levels and prolonged action. Therefore, standard dosing is generally still appropriate, but clinicians might consider monitoring for increased drug effects or potential side effects and adjust the dose if necessary.	0.46062358591704516	0.431118623473782	0.41026860792589404	0.6742433845873355	0.44406512	0.42749757	0.3863197	0.6006326	0.40216774	0.39290285	0.40172052	0.5603714	0.41781914	0.40408832	0.42602524	0.48714095	0.44956455	0.51069117	0.39541352	0.66459996	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid omeprazole. Take an alternate therapy.', 'Take omeprazole with a reduced dose.', 'Take omeprazole with an increased dose.']	Proceed taking omeprazole as normal. There is no recommendation.	For a person with an indeterminate genotype for CYP2C19, the clinical guidance for omeprazole use would generally be to proceed with the standard dosing recommendations provided in product labeling. Since their specific enzyme activity is unknown, careful monitoring for therapeutic response and potential adverse effects is advised. If clinical response is not as expected, further pharmacogenetic testing or adjusting the dose might be considered.	0.24891317160117782	0.4505783381963025	0.19287095045098726	0.6028704312029476	0.16366947	0.34948722	0.17491753	0.5382852	0.09320247	0.2224891	0.094694875	0.5709938	-0.030380042	0.28686637	0.06165957	0.5448756	0.3148255	0.55088276	0.41253772	0.59420794	0
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	For individuals who are ultrarapid metabolizers with an activity score of ≥6.0 for CYP2D6, the clinical guidance for taking ondansetron would suggest that they may experience reduced therapeutic efficacy due to increased clearance of the drug. Alternative antiemetic agents that are not primarily metabolized by CYP2D6, such as granisetron or palonosetron, may be recommended to ensure effective nausea and vomiting control.	0.6093789305461953	0.6064120937930781	0.4734419763492406	0.6482440315243178	0.6302993	0.5319944	0.47772932	0.6162578	0.730591	0.41769275	0.39910686	0.61414546	0.7785949	0.5270997	0.5287408	0.6275321	0.71060216	0.5799418	0.52722955	0.6257157	1
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid ondansetron. Take an alternate therapy.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Proceed taking ondansetron as normal. There is no recommendation.	For an individual identified as a normal metabolizer with a CYP2D6 activity score of 1.75, standard dosing guidelines for ondansetron can be followed. This is because normal metabolizers generally have typical enzyme activity and are expected to metabolize the drug effectively, ensuring both efficacy and safety at standard doses. It's important to monitor for therapeutic response and any potential adverse effects, as with any medication administration.	0.4105370071653992	0.4896730095819196	0.5304752031389409	0.6281907167887429	0.41869506	0.40120316	0.525737	0.511497	0.4131728	0.51873624	0.524869	0.65586644	0.33933875	0.45777196	0.49198285	0.60460407	0.43104422	0.5024893	0.5728647	0.635056	1
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	For a patient identified as a CYP2D6 Ultrarapid Metabolizer with an activity score of 2.75, clinical guidance suggests that ondansetron may be less effective at standard doses due to increased metabolism. It may be advisable to consider alternative antiemetic medications that do not primarily rely on CYP2D6 for metabolism, or consult with a healthcare provider to discuss potential dose adjustments.	0.5606948064979658	0.6064120937930781	0.4734419763492406	0.6352249614770311	0.62424594	0.5319944	0.47772932	0.644905	0.6808007	0.41769275	0.39910686	0.62597036	0.69320375	0.5270997	0.5287408	0.57249343	0.6126728	0.5799418	0.52722955	0.62662894	1
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	For a patient identified as a CYP2D6 Ultrarapid Metabolizer (UM) with an activity score ≥5.0, it is recommended to avoid using ondansetron. Ultrarapid metabolizers may have reduced therapeutic efficacy due to rapid metabolism of the drug, leading to lower plasma concentrations. Alternative antiemetic medications not primarily metabolized by CYP2D6 should be considered.	0.5764824434293496	0.6064120937930781	0.4734419763492406	0.6398565065147183	0.7232932	0.5319944	0.47772932	0.6696668	0.68997914	0.41769275	0.39910686	0.6596451	0.71375036	0.5270997	0.5287408	0.5875697	0.61434036	0.5799418	0.52722955	0.61518794	1
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	If patient is oxcarbazepine-naïve, do not use oxcarbazepine.	['Proceed taking oxcarbazepine as normal. There is no recommendation.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Avoid oxcarbazepine. Take an alternate therapy.	For individuals who are HLA-B*15:02 positive, the clinical guidance is to avoid prescribing oxcarbazepine due to the significantly increased risk of severe cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. An alternative medication with a lower risk profile should be considered.	0.6342066628351759	0.7135790550383974	0.6881527451258563	0.6680851946563534	0.678868	0.6514912	0.53940594	0.6135575	0.6410303	0.71380687	0.6159231	0.5654404	0.61320716	0.80327135	0.7270234	0.5631608	0.6591202	0.7186559	0.59483653	0.6809921	1
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	Individuals who test positive for the HLA-B*15:02 allele are at an increased risk of developing severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), when taking oxcarbazepine. Therefore, clinical guidelines recommend avoiding the use of oxcarbazepine in HLA-B*15:02 positive patients to mitigate this risk. Alternatives that don't carry the same risk for SCAR should be considered.	0.6574081590231777	0.5043979438756131	0.5344224150315137	0.5620329778993264	0.5744942	0.5658956	0.5124112	0.5937562	0.6153669	0.6096384	0.4981693	0.5550733	0.52748865	0.49684122	0.5035804	0.45223525	0.5217875	0.5025414	0.51570123	0.5400447	0
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	Use oxcarbazepine per standard dosing guidelines.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	If an individual is HLA-B*15:02 negative, they are at a significantly reduced risk for developing oxcarbazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis compared to someone who is positive for this allele. Consequently, oxcarbazepine can generally be prescribed without additional special precautions related to this specific genetic marker, although monitoring for adverse reactions remains advisable as with any medication.	0.5748601183234532	0.7546955498099462	0.760685780590325	0.5751830215137489	0.42461663	0.7262312	0.7635482	0.5438511	0.48405138	0.84319997	0.87197757	0.55604243	0.39014816	0.8297167	0.78971976	0.41486531	0.58539027	0.79110354	0.7943649	0.55942935	1
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	Use oxcarbazepine per standard dosing guidelines.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, there is no increased genetic risk for oxcarbazepine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. Therefore, oxcarbazepine can be prescribed without special precautions related to this allele, although general monitoring for adverse effects is always recommended.	0.6075241611128598	0.7546955498099462	0.760685780590325	0.6280610566223692	0.45932403	0.7262312	0.7635482	0.63991725	0.49844694	0.84319997	0.87197757	0.58059496	0.39563	0.8297167	0.78971976	0.4443234	0.57600254	0.79110354	0.7943649	0.5614282	1
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	For individuals identified as Ultrarapid Metabolizers (UMs) for CYP2C19, standard doses of pantoprazole might result in reduced therapeutic efficacy due to faster drug metabolism. While specific clinical guidelines direct adjustments are limited for pantoprazole, considering an alternative proton pump inhibitor (PPI) not metabolized by CYP2C19, such as rabeprazole, may be beneficial. Consulting with a healthcare provider for personalized therapy adjustments is recommended.	0.361600299398036	0.46036628881789327	0.3805938698243083	0.6899534514300678	0.40701437	0.65451384	0.4859116	0.58414716	0.4037026	0.6395466	0.53436863	0.5821309	0.37302703	0.51645404	0.42759904	0.515941	0.35260156	0.5662754	0.36993787	0.65990776	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	For individuals who are likely poor metabolizers of CYP2C19, clinical guidance suggests that standard dosing of pantoprazole can generally be used without dose adjustments. Pantoprazole is primarily metabolized via CYP2C19, but poor metabolizers exhibit only slightly higher plasma levels, which usually does not necessitate major changes in dosing. However, monitoring for efficacy and adverse effects is advised.	0.3549979202134098	0.42783515005305905	0.40592745274181374	0.6641965362780207	0.40591326	0.46150437	0.42293596	0.47972402	0.45288295	0.44084656	0.46522775	0.56331027	0.3916881	0.3958696	0.3891765	0.54029727	0.4712492	0.53891414	0.42433175	0.6572874	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	For an individual who is an intermediate metabolizer for CYP2C19, standard dosing of pantoprazole is generally considered appropriate, as pantoprazole primarily undergoes non-CYP2C19 mediated metabolism. Clinical guidelines usually do not recommend any specific dose adjustments for pantoprazole based on CYP2C19 metabolizer status, but monitoring for therapeutic effectiveness and adverse effects should be conducted as with any medication.	0.37118562849649156	0.42783515005305905	0.40592745274181374	0.6601244782354625	0.4429418	0.46150437	0.42293596	0.5163478	0.49515986	0.44084656	0.46522775	0.5327039	0.46234903	0.3958696	0.3891765	0.5552209	0.46045274	0.53891414	0.42433175	0.61694264	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid pantoprazole. Take an alternate therapy.', 'Take pantoprazole with a reduced dose.', 'Take pantoprazole with an increased dose.']	Proceed taking pantoprazole as normal. There is no recommendation.	For individuals with an indeterminate CYP2C19 genotype, standard dosing of pantoprazole is typically recommended, as the guidelines generally apply standard doses to this group due to lack of specific data indicating altered metabolism. It's essential to monitor the patient for therapeutic efficacy and potential adverse effects, adjusting the dosage as clinically indicated.	0.23996895615897668	0.4439879908864724	0.2060539952911775	0.6678836013491593	0.1483883	0.3284786	0.18227132	0.56218153	0.118673995	0.22252685	0.112472035	0.6778525	0.018218532	0.29856524	0.09517778	0.5939066	0.3081722	0.5326224	0.38784862	0.5980077	0
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking paromomycin as normal. There is no recommendation.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Avoid paromomycin. Take an alternate therapy.	For individuals identified with an increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants, it is typically recommended to avoid the use of aminoglycosides, including paromomycin, whenever possible. Alternative antibiotics that do not carry the same risk for ototoxicity should be considered to mitigate the potential for hearing loss. Always consult healthcare professionals for personalized treatment plans based on specific genetic risks and clinical conditions.	0.7288375856330381	0.5106822880239688	0.4285185628870885	0.5983812034277227	0.83578205	0.6090968	0.48464417	0.6567752	0.7664052	0.4754906	0.47105178	0.586991	0.81317705	0.4146247	0.4179776	0.49710158	0.6305678	0.5933152	0.48953977	0.63172317	1
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid paromomycin. Take an alternate therapy.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Proceed taking paromomycin as normal. There is no recommendation.	For individuals who are at normal risk of aminoglycoside-induced hearing loss due to their MT-RNR1 genetic status, paromomycin can be prescribed without additional concerns related to this specific risk. However, it remains essential to monitor for general side effects as with any aminoglycoside use. Always consult with a healthcare provider for thorough evaluation and personalized medical advice.	0.6093113287575773	0.44548281031033354	0.46271528692336333	0.6265589458278386	0.52480805	0.4691963	0.47202793	0.6188379	0.58553094	0.53912383	0.52893585	0.6372685	0.70867205	0.49476042	0.47414574	0.5240884	0.5961106	0.53017235	0.5722973	0.58668435	0
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid paromomycin. Take an alternate therapy.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Proceed taking paromomycin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants, caution is advised when considering paromomycin. While paromomycin is an aminoglycoside, its ototoxicity profile may differ from other aminoglycosides. Genetic testing for specific MT-RNR1 variants associated with aminoglycoside-induced hearing loss is recommended before prescribing, to better guide clinical decision-making and mitigate potential risks.	0.5583474736951993	0.44548281031033354	0.46271528692336333	0.5847701859122046	0.44019702	0.4691963	0.47202793	0.47017345	0.52691925	0.53912383	0.52893585	0.52030915	0.6479535	0.49476042	0.47414574	0.40888253	0.5327361	0.53017235	0.5722973	0.5178398	0
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For individuals who are ultrarapid metabolizers (activity score ≥ 2.25) for CYP2D6, including those with an activity score of ≥6.0, the clinical guidance is typically to avoid paroxetine. Due to increased metabolism, these individuals would likely have reduced drug efficacy at standard doses, potentially requiring alternative treatments to achieve desired therapeutic outcomes. Consultation with a healthcare professional for alternative antidepressant therapy is recommended.	0.5079412970540556	0.4998528205180899	0.34633956705925195	0.6177503829413913	0.7458543	0.39904875	0.33855024	0.6063306	0.65171486	0.2325868	0.2382857	0.6489437	0.6316188	0.34230387	0.33780465	0.65360963	0.55880827	0.5248598	0.4494816	0.6945275	1
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid paroxetine. Take an alternate therapy.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Proceed taking paroxetine as normal. There is no recommendation.	For a person who is a Normal Metabolizer with an activity score of 1.75 for CYP2D6, standard dosing of paroxetine is generally recommended. This is because such individuals are expected to metabolize paroxetine at a typical rate, allowing for effective drug levels and minimizing the risk of adverse effects. It is still important to monitor for efficacy and side effects, and adjustments can be made based on clinical response.	0.4396894980323385	0.45628113748083265	0.4735275356348543	0.6048874522889423	0.45878083	0.3495537	0.3774395	0.4903726	0.44311735	0.375729	0.29313543	0.61943257	0.44803536	0.42626578	0.4125264	0.62021685	0.4584455	0.5126283	0.5601581	0.6546083	1
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For individuals who are ultrarapid metabolizers (UM) with a CYP2D6 activity score of 2.75, the use of paroxetine is generally not recommended. This is because their increased enzyme activity leads to significantly lower plasma concentrations of the drug, which can result in reduced efficacy. Alternative medications that are not primarily metabolized by CYP2D6 should be considered for these patients.	0.5496706186331919	0.4998528205180899	0.34633956705925195	0.5904512676630775	0.6422117	0.39904875	0.33855024	0.6032393	0.6240302	0.2325868	0.2382857	0.6099235	0.6310728	0.34230387	0.33780465	0.5894052	0.5883697	0.5248598	0.4494816	0.6662944	1
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For an ultrarapid metabolizer with a CYP2D6 activity score of ≥5.0, clinical guidance generally recommends avoiding paroxetine due to the risk of subtherapeutic drug levels, which may render the medication ineffective. Alternative treatments not significantly metabolized by CYP2D6 should be considered. If paroxetine must be used, close monitoring and potential dose adjustments based on clinical response are advised.	0.5353092944780272	0.4998528205180899	0.34633956705925195	0.6323851925310647	0.7318746	0.39904875	0.33855024	0.65096474	0.66285414	0.2325868	0.2382857	0.58814406	0.62645376	0.34230387	0.33780465	0.58334917	0.5386946	0.5248598	0.4494816	0.6457915	1
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking pegloticase as normal. There is no recommendation.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Avoid pegloticase. Take an alternate therapy.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of pegloticase is contraindicated. This is due to the increased risk of hemolysis and methemoglobinemia, serious side effects that can occur in G6PD-deficient individuals when exposed to the oxidative stress induced by pegloticase. Therefore, alternative gout treatments should be considered for these patients.	0.256544776327289	0.29798209054542835	0.2569559045705651	0.6432172189166908	0.33300477	0.37155733	0.29162398	0.62689966	0.1382305	0.1747964	0.18571635	0.64575505	0.08548251	0.17363565	0.17409736	0.6094063	0.44044092	0.5796388	0.47259387	0.67419857	1
pegloticase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid pegloticase. Take an alternate therapy.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Proceed taking pegloticase as normal. There is no recommendation.	For a patient with an indeterminate G6PD (glucose-6-phosphate dehydrogenase) status, caution is warranted when considering pegloticase therapy. It is recommended to either confirm G6PD deficiency status through further testing or avoid pegloticase due to the risk of hemolysis, which can occur in G6PD-deficient individuals. Clinicians should seek alternative gout treatments or ensure close monitoring if pegloticase use is deemed necessary.	0.6415544724247789	0.4144346370152838	0.37652409244113483	0.608071709386183	0.6120024	0.2793679	0.3210735	0.60740805	0.64045507	0.37694275	0.33661437	0.61957383	0.6396926	0.39990237	0.32525682	0.5768395	0.6080767	0.42390808	0.4283959	0.55701137	0
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking pegloticase as normal. There is no recommendation.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Avoid pegloticase. Take an alternate therapy.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, including those with chronic non-spherocytic hemolytic anemia (CNSHA), the use of pegloticase is contraindicated. Pegloticase can lead to severe hemolytic anemia and methemoglobinemia in G6PD-deficient patients. Therefore, alternative treatments for conditions like refractory chronic gout should be considered.	0.22966192322988793	0.29798209054542835	0.2569559045705651	0.6181813522846049	0.30514175	0.37155733	0.29162398	0.60595745	0.14075246	0.1747964	0.18571635	0.63246465	0.08097525	0.17363565	0.17409736	0.6037992	0.42296615	0.5796388	0.47259387	0.6769179	1
pegloticase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid pegloticase. Take an alternate therapy.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Proceed taking pegloticase as normal. There is no recommendation.	For individuals with normal glucose-6-phosphate dehydrogenase (G6PD) activity, there are no specific additional risks associated with taking pegloticase compared to the general population. Pegloticase can be administered following standard dosing guidelines. Monitoring is still essential to manage potential common side effects and to ensure treatment efficacy in managing chronic gout.	0.5728977887142462	0.42853417818463013	0.33599287042169923	0.6653456571273363	0.49670458	0.4098072	0.217561	0.6500516	0.44704124	0.28910205	0.16120887	0.7509161	0.3946892	0.2068913	0.09266206	0.6120454	0.5131207	0.43167853	0.32591045	0.6170245	1
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), should avoid taking phenazopyridine. This drug can induce hemolysis in G6PD-deficient patients, leading to potentially severe complications. Clinical guidance would recommend alternative treatments that do not pose a risk of hemolysis for managing their symptoms.	0.45097127199373765	0.3539091668975645	0.3927109184153717	0.546486581732172	0.5274173	0.5002355	0.5164551	0.639529	0.55007017	0.48254967	0.474049	0.58726877	0.5593449	0.39339694	0.3603239	0.5543719	0.5605302	0.42967528	0.48021817	0.6001922	0
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	For individuals who have normal glucose-6-phosphate dehydrogenase (G6PD) activity, there are no specific contraindications to taking phenazopyridine based on their G6PD status. Phenazopyridine can generally be used safely in these patients, but as with all medications, it should be taken under guidance from a healthcare professional to monitor for any potential side effects or interactions with other medications.	0.6434976154149604	0.4287327066912678	0.31568525801773767	0.6539855881590306	0.53083956	0.39865574	0.19810335	0.65831774	0.5130316	0.28774935	0.14585656	0.68758523	0.41948512	0.16834332	0.09964835	0.61044914	0.58312184	0.46084315	0.331821	0.60028565	1
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	"Individuals who are classified as ""Variable"" (heterozygous) for G6PD deficiency should avoid the use of phenazopyridine due to the increased risk of hemolytic anemia. Clinical guidance would recommend selecting alternative agents that do not pose a risk of triggering hemolysis in G6PD-deficient patients."	0.6711214085315498	0.48869851183414725	0.3837959319455644	0.5524323163208906	0.6024312	0.5575637	0.35187903	0.607508	0.6358453	0.49766034	0.3031375	0.5866165	0.6726171	0.44163874	0.33736953	0.52575374	0.58725077	0.5493739	0.41835925	0.53928626	0
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), using phenazopyridine is generally contraindicated. This is because phenazopyridine can induce hemolysis in patients with G6PD deficiency, leading to hemolytic anemia. Therefore, alternative treatments should be considered in these patients.	0.5985654756703627	0.48869851183414725	0.3837959319455644	0.5814792994499944	0.6211326	0.5575637	0.35187903	0.62152326	0.6394395	0.49766034	0.3031375	0.6256424	0.5928127	0.44163874	0.33736953	0.5551546	0.5594449	0.5493739	0.41835925	0.58103925	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	['Avoid phenytoin. Take an alternate therapy.', 'Take phenytoin with a reduced dose.', 'Take phenytoin with an increased dose.']	Proceed taking phenytoin as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, there is no increased genetic risk of developing phenytoin-induced Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Therefore, phenytoin can be prescribed without the elevated concern for these specific severe adverse drug reactions typically associated with the HLA-B*15:02 allele. However, standard monitoring for other potential side effects of phenytoin usage remains essential.	0.7955674986319348	0.5941313711752331	0.5563997669360304	0.5641646437286145	0.6930434	0.6312081	0.5283107	0.5987969	0.7795855	0.62854886	0.5542701	0.5696188	0.77054524	0.5241668	0.5305268	0.47339898	0.8047683	0.52779835	0.50937027	0.5689267	1
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking phenytoin as normal. There is no recommendation.', 'Avoid phenytoin. Take an alternate therapy.']	Take phenytoin with an altered dose.	For an individual with no HLA-B*15:02 genetic test result, clinical guidance for taking phenytoin suggests considering alternative medications to avoid the risk of severe cutaneous adverse reactions (SCARs), particularly in populations where the HLA-B*15:02 allele is common (e.g., individuals of Asian descent). If phenytoin is deemed necessary, it should be used with caution, and patients should be closely monitored for early signs of SCARs, such as Stevens-Johnson syndrome or toxic epidermal necrolysis.	0.7390457688757212	0.5854740858915999	0.5958967520919687	0.5908791731498229	0.5761563	0.5539176	0.6040654	0.46509328	0.6360018	0.5490833	0.6752889	0.4299728	0.6447047	0.54993606	0.53744864	0.5132263	0.661999	0.55776227	0.5125804	0.5226549	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking phenytoin as normal. There is no recommendation.', 'Avoid phenytoin. Take an alternate therapy.']	Take phenytoin with an altered dose.	In the absence of HLA-B genotyping results, phenytoin can still be prescribed, but clinicians should proceed with caution due to the risk of adverse reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Regular clinical monitoring for early signs of hypersensitivity is recommended, especially in populations with a higher prevalence of the HLA-B*15:02 allele, which is associated with increased risk of severe skin reactions to phenytoin.	0.7639133020499174	0.5851076454452884	0.5961573440046032	0.5789568220744883	0.6305868	0.54565316	0.5921931	0.41437992	0.6549818	0.5445964	0.6684654	0.41371253	0.637914	0.55336046	0.53762925	0.445462	0.67873776	0.55979866	0.51231253	0.5414808	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	['Avoid phenytoin. Take an alternate therapy.', 'Take phenytoin with a reduced dose.', 'Take phenytoin with an increased dose.']	Proceed taking phenytoin as normal. There is no recommendation.	If a patient tests positive for the HLA-B*15:02 allele, it is recommended to avoid prescribing phenytoin due to the significantly increased risk of serious cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Alternative medications with a lower risk profile should be considered for these patients. This guidance is in line with clinical guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC).	0.687293577396131	0.5608653544805681	0.5544001017735645	0.5686321012181356	0.5583085	0.59154713	0.52103406	0.62942576	0.5516165	0.64347273	0.5483784	0.5343595	0.52744865	0.5169034	0.5282492	0.5146638	0.47663343	0.48335138	0.4902078	0.59493935	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	For an individual who is a Normal Metabolizer with an activity score of 2.0 for CYP2C9, standard dosing of piroxicam is generally recommended. They are expected to metabolize the drug typically, which minimizes the risk of adverse effects due to altered drug levels. Therefore, no special dose adjustments are necessary based on CYP2C9 activity.	0.38327579945570156	0.43231982704298505	0.43786295664995545	0.6391862805216342	0.50727606	0.35056245	0.29469594	0.60726094	0.46860495	0.4132601	0.2480439	0.6821749	0.40815017	0.38000882	0.36730972	0.5945505	0.433675	0.467388	0.4555997	0.6398584	1
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	For someone identified as an Intermediate Metabolizer with a CYP2C9 activity score of 1.5 taking piroxicam, clinical guidelines would generally recommend considering an alternative medication, as there is an increased risk for adverse effects due to slower metabolism of the drug. If piroxicam must be used, it should be administered with caution and possibly at a reduced dose while closely monitoring for side effects such as gastrointestinal toxicity.	0.40218091211526635	0.43231982704298505	0.43786295664995545	0.6362136624221884	0.3662621	0.35056245	0.29469594	0.610563	0.37153324	0.4132601	0.2480439	0.645992	0.394614	0.38000882	0.36730972	0.5750875	0.4088266	0.467388	0.4555997	0.64300245	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	For patients with indeterminate CYP2C9 genotype, the clinical guidance for taking piroxicam, a nonsteroidal anti-inflammatory drug (NSAID), typically recommends caution. Given the uncertainty about the patient's metabolizer status, it may be advisable to consider alternative NSAIDs that are not significantly metabolized by CYP2C9 or to monitor the patient closely for adverse effects related to drug accumulation, such as gastrointestinal or renal toxicity. Clinicians may also consider starting at the lowest effective dose if piroxicam is deemed necessary.	0.29241507893791724	0.46262241622174644	0.23498001668003513	0.6572907317969492	0.16859159	0.37049466	0.2272154	0.5309499	0.089586146	0.26741773	0.18145466	0.51856595	0.02277227	0.32825956	0.080221005	0.5589475	0.3686305	0.5253647	0.3766552	0.66479105	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking piroxicam as normal. There is no recommendation.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Avoid piroxicam. Take an alternate therapy.	For a patient who is an intermediate metabolizer with an activity score of 1.0 for CYP2C9, clinical guidance suggests that a reduced dose of piroxicam or an alternative therapy may be appropriate. Intermediate metabolizers may have reduced clearance of piroxicam, leading to higher plasma levels and an increased risk of adverse effects. Close monitoring for signs of toxicity is recommended if piroxicam is used.	0.6247929979906206	0.6194366849470393	0.5103363520932606	0.6782646992850134	0.6989255	0.5393946	0.43539992	0.559895	0.68930054	0.32969302	0.27722454	0.5510812	0.66788447	0.42809734	0.38362703	0.5644556	0.6290253	0.5536652	0.5251735	0.6496582	0
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	For individuals with increased function of the SLCO1B1 gene, there is generally no need for dose adjustment of pitavastatin. This genetic variant may lead to enhanced transport of the drug into hepatocytes, potentially improving its efficacy. However, clinical response and patients' lipid levels should still be monitored to ensure the therapeutic goal is achieved without adverse effects.	0.3541080561225521	0.3738394401778674	0.3665385020649207	0.5872970157725838	0.38219076	0.29842973	0.37568787	0.5357387	0.39646715	0.44845253	0.33967733	0.5994871	0.31263757	0.3579497	0.31679413	0.45142755	0.4798097	0.4783974	0.569094	0.5304119	1
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	For individuals who have normal function for the SLCO1B1 gene, the clinical guidance for taking pitavastatin does not require any dosing adjustments. They are unlikely to experience altered pharmacokinetics or an increased risk of statin-associated side effects, such as myopathy. Therefore, standard dosing of pitavastatin can be safely followed in these patients.	0.3733992845237031	0.3738394401778674	0.3665385020649207	0.6818050326852793	0.4049228	0.29842973	0.37568787	0.6742085	0.43963805	0.44845253	0.33967733	0.72396594	0.34801862	0.3579497	0.31679413	0.5834778	0.49373356	0.4783974	0.569094	0.6801942	1
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	For patients who are indeterminate for SLCO1B1 genotype, standard clinical guidelines for prescribing pitavastatin generally apply. Pitavastatin is less impacted by SLCO1B1 variants compared to other statins, so no specific dosing adjustments are typically necessary. However, patients should still be monitored for any signs of adverse effects, particularly muscle-related symptoms, and clinicians should be aware of other potential drug interactions.	0.2258109417984347	0.4630801461764192	0.22187783001761704	0.650507998020179	0.11775837	0.2974844	0.14459728	0.59658986	0.07763128	0.18318969	0.07401037	0.65284085	0.0020547844	0.26902944	0.061543923	0.53105116	0.27542028	0.49070147	0.3865284	0.61887324	0
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	['Proceed taking pitavastatin as normal. There is no recommendation.', 'Avoid pitavastatin. Take an alternate therapy.']	Take pitavastatin with an altered dose.	For individuals with a Possible Decreased Function variant of the SLCO1B1 gene, the clinical guidance for taking pitavastatin generally does not require dose adjustment. Unlike certain other statins, pitavastatin is less reliant on the SLCO1B1 transporter for hepatic uptake, thus reducing the risk of statin-associated muscle symptoms. Nonetheless, monitoring for any signs of adverse effects remains prudent.	0.742698232130263	0.707962598951693	0.6749716719216314	0.6572341896163869	0.5873308	0.6625408	0.60888934	0.5146402	0.66650546	0.66534716	0.72140014	0.5587511	0.6481244	0.6414486	0.6054331	0.56387025	0.6601037	0.69705236	0.60709554	0.6761386	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking plazomicin as normal. There is no recommendation.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Avoid plazomicin. Take an alternate therapy.	For individuals at increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants, it is advised to avoid the use of aminoglycosides, including plazomicin, when alternative treatments are available. If the use of plazomicin is deemed necessary, careful clinical monitoring for ototoxicity is essential, and the potential benefits must be weighed against the risks of hearing loss.	0.6318002850271042	0.4472512092312358	0.3727989293258867	0.6056498046780614	0.79029226	0.5412148	0.4360197	0.63393795	0.70164895	0.35951802	0.36452246	0.56001943	0.76433533	0.38931897	0.3954724	0.5159174	0.68240863	0.5577428	0.44866768	0.6099636	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid plazomicin. Take an alternate therapy.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Proceed taking plazomicin as normal. There is no recommendation.	For individuals identified as normal risk for aminoglycoside-induced hearing loss based on MT-RNR1 gene status, the standard clinical guidance does not require specific alterations to the prescribing of plazomicin. They can be administered the drug according to the standard dosing recommendations. However, general monitoring for any signs of ototoxicity should still be conducted due to the potential for other, non-genetic risk factors.	0.5721124182842579	0.3899982173670886	0.3817365061863362	0.6373689732072055	0.64786726	0.42339244	0.42624426	0.61599326	0.6238534	0.4513895	0.44311866	0.62211955	0.66533065	0.48940736	0.4860718	0.51542264	0.6019538	0.45863158	0.50893945	0.61558837	1
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid plazomicin. Take an alternate therapy.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Proceed taking plazomicin as normal. There is no recommendation.	Individuals with uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 mutations should be cautious when considering plazomicin. Clinical guidance would generally recommend genetic testing to confirm the presence of MT-RNR1 variants linked to increased sensitivity. If a pathogenic variant is detected, alternative antibiotics should be considered to avoid the potential risk of irreversible ototoxicity.	0.5333836491715733	0.3899982173670886	0.3817365061863362	0.5375952132553774	0.51909304	0.42339244	0.42624426	0.50496024	0.6213688	0.4513895	0.44311866	0.5268183	0.6351562	0.48940736	0.4860718	0.449439	0.58315396	0.45863158	0.50893945	0.46036816	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	For individuals with increased function of the SLCO1B1 gene, there is generally no need to alter pravastatin therapy based on SLCO1B1 status alone. Increased function typically indicates enhanced transport and uptake of pravastatin into the liver, which may lead to effective lipid-lowering at standard doses. Consequently, these patients are not at increased risk for adverse drug reactions related to statin therapy and can be managed with usual dosages.	0.3215080554576517	0.3605569898414859	0.3542630150556501	0.5161242549253093	0.31358597	0.31167483	0.37594128	0.5327927	0.3689802	0.44127497	0.3295271	0.5839823	0.27299967	0.3474089	0.3156984	0.4746803	0.3999506	0.49523875	0.5714204	0.5402552	1
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	Clinical guidance for an individual with normal SLCO1B1 function (i.e., homozygous for the *1A allele) who is prescribed pravastatin generally indicates standard dosing without any special precautions. This genotype is associated with typical pravastatin metabolism and transport, leading to a usual efficacy and risk profile. Therefore, no dose adjustments or additional monitoring beyond standard clinical practice would typically be necessary.	0.4185175098605074	0.3605569898414859	0.3542630150556501	0.660540957653808	0.48845756	0.31167483	0.37594128	0.5737291	0.4864157	0.44127497	0.3295271	0.6601701	0.3640301	0.3474089	0.3156984	0.46567506	0.47424093	0.49523875	0.5714204	0.61018753	1
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	For individuals who are indeterminate for the SLCO1B1 gene, standard dosing of pravastatin is generally recommended as their SLCO1B1 genotype does not clearly indicate an increased risk for statin-associated myopathy. However, it is still important to monitor for any signs of muscle pain or weakness and to adjust the dose if necessary based on clinical response and tolerability. If any adverse effects occur, healthcare providers might consider alternative statins or non-statin lipid-lowering therapies.	0.23407758940460713	0.4604720300723354	0.21207025254258874	0.550349421737835	0.15075088	0.30104142	0.1422076	0.6049626	0.10846521	0.1877276	0.07142191	0.68324894	0.014584222	0.28907138	0.06006204	0.560517	0.29860446	0.5008195	0.40348327	0.58322996	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	For individuals with Possible Decreased Function of the SLCO1B1 gene taking pravastatin, clinical guidelines generally recommend starting with a lower dose and closely monitoring for signs of myopathy or muscle-related side effects. If muscle symptoms occur, adjusting the dose or considering alternative lipid-lowering therapies may be necessary to minimize adverse effects while managing cholesterol levels effectively.	0.7664897484255239	0.620144850658007	0.6545112391949791	0.582768482285533	0.7155244	0.53047866	0.54431134	0.595238	0.6772494	0.6562759	0.5162477	0.6833362	0.6578443	0.52027243	0.5000932	0.5935772	0.71058947	0.5667448	0.6025362	0.57031417	0
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.	['Proceed taking primaquine as normal. There is no recommendation.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Avoid primaquine. Take an alternate therapy.	For individuals who are G6PD-deficient, the use of primaquine should be approached with caution due to the heightened risk of hemolytic anemia. Clinical guidelines typically recommend either avoiding primaquine altogether or, if its use is necessary, closely monitoring for signs of hemolysis and using the lowest effective dose under medical supervision.	0.7072149163036193	0.6726552337278622	0.6680096506396304	0.5898233929746162	0.6714915	0.58287287	0.5400314	0.593622	0.7002508	0.58089745	0.5449776	0.6369864	0.6083815	0.6139145	0.56615275	0.6182477	0.5222287	0.5496724	0.53993255	0.58764315	0
primaquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid primaquine. Take an alternate therapy.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Proceed taking primaquine as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when prescribing primaquine due to the risk of hemolytic anemia. It is recommended to perform a quantitative G6PD test to confirm the enzyme activity level before initiating treatment. If testing is not possible, alternative antimalarial therapies with a lower risk of hemolysis may be considered.	0.6576387696672997	0.3957739150872026	0.3357205345318657	0.5915012620313084	0.65084815	0.2341523	0.2933162	0.53747165	0.6303382	0.29548275	0.21225011	0.5746548	0.6653565	0.28192836	0.21875142	0.6317658	0.6147881	0.4019604	0.39547744	0.5329789	0
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	Avoid primaquine	['Proceed taking primaquine as normal. There is no recommendation.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Avoid primaquine. Take an alternate therapy.	For individuals who are deficient in G6PD (glucose-6-phosphate dehydrogenase) and who have Chronic Nonspherocytic Hemolytic Anemia (CNSHA), the use of primaquine is generally contraindicated due to the high risk of hemolysis. Alternative antimalarial medications that do not pose a risk to G6PD-deficient patients should be considered, and any treatment plan should involve careful medical supervision.	0.6272977238954466	0.7941096806073801	0.7327787493016475	0.5877007077577501	0.64740324	0.7907023	0.6753638	0.5743712	0.56307554	0.81679296	0.7111111	0.5377732	0.6977464	0.85295165	0.7064869	0.63679487	0.647753	0.91153246	0.7195818	0.6016111	1
primaquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid primaquine. Take an alternate therapy.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Proceed taking primaquine as normal. There is no recommendation.	Individuals with normal G6PD activity can typically take primaquine without a heightened risk of hemolytic anemia, which is a concern in G6PD-deficient patients. Clinical guidelines would generally recommend standard dosing of primaquine for the treatment or prevention of malaria in these individuals, while monitoring for other potential side effects. However, it is important to conduct regular clinical assessments to ensure patient safety.	0.5917430502457461	0.44320085399607934	0.320001652324512	0.6399183768331491	0.47231522	0.3753424	0.19332863	0.5914087	0.4190457	0.25333205	0.11490496	0.6792363	0.38085926	0.186888	0.110461764	0.57869756	0.5478198	0.42969733	0.31606653	0.59272945	1
quinine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of quinine is generally contraindicated. This is because quinine can trigger hemolysis, leading to serious complications such as hemolytic anemia. It is critical for healthcare providers to explore alternative treatments for these patients.	0.5852643166986126	0.4967947110564648	0.37685150025040626	0.5705079131464421	0.5567989	0.53719854	0.3285966	0.6479776	0.5556326	0.4374044	0.26512942	0.6951581	0.5575229	0.42400327	0.3297743	0.552945	0.5556038	0.5053088	0.39155784	0.56419635	0
quinine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	For patients with an indeterminate G6PD status, caution is advised when considering the use of quinine. Since individuals with G6PD deficiency are at risk for hemolytic anemia when exposed to certain medications, including quinine, it is recommended to either confirm G6PD status through additional testing or to consider alternative treatments to mitigate the potential risk. Consultation with a healthcare provider for personalized assessment and decision-making would be prudent.	0.6610101991746745	0.40342793252349174	0.3370589114570923	0.5872644537801694	0.52968925	0.2657501	0.28618404	0.6421873	0.58661157	0.30287367	0.23640962	0.68962973	0.596843	0.23715203	0.20171905	0.5163016	0.5710954	0.40367126	0.3890513	0.5102374	0
quinine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic nonspherocytic hemolytic anemia (CNSHA), should avoid quinine due to the risk of triggering severe hemolytic anemia. A safer alternative should be chosen, and healthcare providers need to closely monitor and manage any use of medications that can induce hemolysis in G6PD-deficient patients.	0.47476306183786965	0.4036725417225148	0.4310828828951392	0.5236343463304143	0.5656779	0.4960569	0.47003403	0.6759843	0.5179272	0.43650675	0.4023614	0.6770296	0.46284974	0.3602717	0.32208076	0.53106785	0.5506719	0.4022845	0.46001694	0.5288186	0
quinine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) enzyme activity, taking quinine is generally considered safe and does not pose a risk of hemolytic anemia, which can occur in those with G6PD deficiency. However, as with any medication, it is important to follow dosing instructions and monitor for any adverse reactions. Always consult with a healthcare provider before starting quinine therapy.	0.6192045121974674	0.42819000638130583	0.30016950791040203	0.614905375558547	0.45701602	0.40508378	0.18798845	0.6741947	0.39812508	0.27897647	0.12627245	0.73569083	0.36605728	0.13878319	0.08471268	0.59896487	0.54162353	0.41710633	0.29671517	0.5721209	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking rasburicase as normal. There is no recommendation.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Avoid rasburicase. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking rasburicase due to the risk of severe hemolysis and methemoglobinemia. Clinical guidelines recommend alternative treatments for hyperuricemia in these patients to prevent potentially life-threatening complications.	0.2589185988829023	0.30641063544360625	0.25943499170577683	0.6128522080124095	0.36562577	0.43802193	0.3459865	0.62825173	0.20678821	0.24215324	0.23364854	0.6312434	0.16660866	0.18794441	0.17483377	0.62970454	0.5151603	0.59386873	0.47473112	0.6918325	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid rasburicase. Take an alternate therapy.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Proceed taking rasburicase as normal. There is no recommendation.	For an individual who is indeterminate for G6PD deficiency, the clinical guidance would be to avoid the use of rasburicase due to the risk of severe hemolytic anemia and methemoglobinemia. Alternative treatments that do not pose a risk for hemolysis in G6PD-deficient patients should be considered.	0.5984297639872258	0.39656991086299803	0.33292973587823566	0.6053016397899638	0.4089384	0.33025667	0.32421282	0.5831785	0.65143853	0.3262097	0.31580418	0.58311576	0.60986227	0.3295244	0.28478152	0.6048483	0.50439984	0.3680207	0.37297413	0.49205965	0
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking rasburicase as normal. There is no recommendation.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Avoid rasburicase. Take an alternate therapy.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, the use of rasburicase is contraindicated due to the risk of severe hemolysis and methemoglobinemia. Clinical guidelines advise against administering rasburicase to patients with G6PD deficiency and recommend alternative treatments for managing hyperuricemia associated with tumor lysis syndrome.	0.27430922009097375	0.30641063544360625	0.25943499170577683	0.6209309735599673	0.35550246	0.43802193	0.3459865	0.6065732	0.18264222	0.24215324	0.23364854	0.6258789	0.106684394	0.18794441	0.17483377	0.6197474	0.40411964	0.59386873	0.47473112	0.5960718	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid rasburicase. Take an alternate therapy.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Proceed taking rasburicase as normal. There is no recommendation.	For individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) activity, rasburicase can generally be prescribed without particular concern for hemolytic anemia, a serious complication that can occur in G6PD-deficient individuals. However, standard clinical monitoring and precautions should still be followed as with any chemotherapeutic agent. Always consult a healthcare provider for personalized advice.	0.6439268991460833	0.43253236665501205	0.3208549059716987	0.606745732957404	0.56618154	0.43342674	0.25304696	0.61009336	0.47228324	0.28556177	0.18659031	0.6380305	0.37936693	0.1643905	0.07426436	0.6345724	0.53996664	0.3957399	0.30261493	0.5862253	1
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking ribostamycin as normal. There is no recommendation.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Avoid ribostamycin. Take an alternate therapy.	For individuals at increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 genetic variants, clinical guidance typically advises avoiding the use of aminoglycosides, including ribostamycin, if possible. Alternative antibiotics that do not carry the same risk of ototoxicity should be considered to prevent irreversible hearing impairment.	0.7409721948896734	0.48833956935868106	0.4221317569519207	0.5830962110058255	0.82668984	0.6176445	0.48445666	0.6424377	0.7875147	0.4974237	0.47291005	0.58551747	0.826145	0.45414892	0.44387367	0.54347897	0.6619064	0.6050108	0.4826611	0.6434022	1
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid ribostamycin. Take an alternate therapy.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Proceed taking ribostamycin as normal. There is no recommendation.	For individuals with normal risk of aminoglycoside-induced hearing loss based on their MT-RNR1 genotype, there is no specific contraindication for using ribostamycin according to their genetic profile. However, it remains critical to monitor renal function and overall drug levels, as aminoglycosides, including ribostamycin, carry a risk of nephrotoxicity and ototoxicity that is dose-dependent and cumulative.	0.5868910983188556	0.43799749649876824	0.4383074833363336	0.6045726076414175	0.5568295	0.4458685	0.4887046	0.5878452	0.6173696	0.52710116	0.5449565	0.5915093	0.6555078	0.5056631	0.50599897	0.49218914	0.5222868	0.4805947	0.5332294	0.5273279	0
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid ribostamycin. Take an alternate therapy.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Proceed taking ribostamycin as normal. There is no recommendation.	Individuals with uncertain risk for MT-RNR1-related aminoglycoside-induced hearing loss should avoid taking ribostamycin due to the potentially severe ototoxicity associated with aminoglycosides in those with this genetic variant. Genetic testing to determine MT-RNR1 variant status is recommended to guide safer antibiotic use and prevent possible irreversible hearing loss.	0.5390911232782316	0.43799749649876824	0.4383074833363336	0.5463353300420312	0.47234243	0.4458685	0.4887046	0.5673597	0.59833044	0.52710116	0.5449565	0.54288477	0.6575199	0.5056631	0.50599897	0.43910173	0.52799547	0.4805947	0.5332294	0.52538806	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For a patient with normal function of ABCG2 and increased function of SLCO1B1, there is no need for a dosage adjustment when prescribing rosuvastatin. These genetic profiles suggest that the patient will metabolize the drug normally and should experience efficacy and safety similar to the general population. Thus, standard dosing guidelines for rosuvastatin are appropriate for this individual.	0.6387679304198045	0.5865816200693775	0.6182407535591358	0.6070807521195982	0.5903478	0.4243364	0.52305996	0.66384375	0.72379446	0.7216861	0.6284959	0.651233	0.6193699	0.52674925	0.5363809	0.53797615	0.65602434	0.66564703	0.7043523	0.5975582	1
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For a patient who has normal function for the ABCG2 gene and decreased function for the SLCO1B1 gene, prescribing rosuvastatin may require careful consideration. Since SLCO1B1 variants can lead to increased exposure to the drug and a higher risk of statin-associated side effects like myopathy, the clinician might consider starting with a lower dose of rosuvastatin and titrating upward as needed while monitoring for adverse effects.	0.6440201557703286	0.6027693991621845	0.6433591914629337	0.5222219560967523	0.65850294	0.5140376	0.5700909	0.5367613	0.6557417	0.68006384	0.55727243	0.6581306	0.6325138	0.5050037	0.49876928	0.5771013	0.6412482	0.574435	0.6064827	0.51128995	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For a patient with decreased function in the ABCG2 gene but normal function in the SLCO1B1 gene, clinical guidelines suggest that there may be an increased risk of rosuvastatin-associated side effects, particularly myopathy. It is recommended to consider lower starting doses and to monitor the patient for signs of toxicity, adjusting the dose as necessary to balance efficacy and safety.	0.5786495938022014	0.5865816200693775	0.6182407535591358	0.5322511912484827	0.5205749	0.4243364	0.52305996	0.58674484	0.60717964	0.7216861	0.6284959	0.66653055	0.5591222	0.52674925	0.5363809	0.52434206	0.6390305	0.66564703	0.7043523	0.579277	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For a patient with decreased function for ABCG2 and no result for SLCO1B1 regarding rosuvastatin use, clinical guidance suggests that they may be at an increased risk of higher plasma concentrations of the medication. This is linked to an increased risk of adverse effects, such as muscle toxicity. It would be prudent to consider using a lower starting dose of rosuvastatin and to monitor the patient closely for signs of adverse reactions.	0.7898005947618049	0.5743903681949449	0.6018017344721867	0.5396962527693696	0.6885923	0.5871856	0.48963356	0.603226	0.7927364	0.67801756	0.59198934	0.6795823	0.6771644	0.5029694	0.48327032	0.52344376	0.74741536	0.6010229	0.5738715	0.5779336	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	No recommendation	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For a patient with no result for CYP2B6 and an indeterminate status for CYP2C19, clinical guidance for sertraline use would follow standard dosing recommendations due to the lack of specific genetic information that would necessitate dosage adjustment. However, monitoring for efficacy and side effects should be emphasized, and adjustments should be made based on clinical response.	0.27921401469061086	0.4327824774902563	0.20945409364805853	0.6013212370207485	0.17392154	0.3150432	0.16553693	0.58572155	0.06542212	0.17384869	0.10388883	0.6773251	0.011571979	0.3057449	0.09174416	0.5319101	0.32244807	0.5215013	0.3970836	0.65466225	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For someone who is an Ultrarapid Metabolizer for CYP2B6 and has no result for CYP2C19, starting sertraline at standard doses is generally safe, as CYP2B6 is not a primary metabolizer of sertraline. However, since CYP2C19 does contribute to sertraline metabolism, it's important to monitor the patient closely for efficacy and side effects, adjusting the dose if necessary, considering there is no genotypic information available for CYP2C19.	0.3652397166078416	0.4630028899358478	0.49691091383335034	0.5825705051907246	0.39269125	0.38907063	0.42368975	0.6501566	0.41200003	0.48815998	0.40268913	0.6680638	0.35659924	0.44016293	0.4359481	0.57786644	0.41831493	0.51360846	0.58839625	0.5964718	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	Clinical guidance for someone who is Indeterminate for CYP2B6 and an Ultrarapid Metabolizer for CYP2C19 taking sertraline would generally focus on the CYP2C19 status, as it is more relevant for sertraline metabolism. As an ultrarapid metabolizer of CYP2C19, the individual may have lower plasma concentrations of sertraline, potentially reducing its efficacy. Clinicians might consider starting at a standard dose with close monitoring for effectiveness and side effects, adjusting the dose as necessary based on the clinical response.	0.4072481183051419	0.4630028899358478	0.49691091383335034	0.5842967136263566	0.39043877	0.38907063	0.42368975	0.5335451	0.38865194	0.48815998	0.40268913	0.6481954	0.4304818	0.44016293	0.4359481	0.5661531	0.36345974	0.51360846	0.58839625	0.5850262	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For a rapid metabolizer of CYP2B6 taking sertraline, dosage adjustments are generally not necessary based on CYP2B6 alone, as sertraline is primarily metabolized by CYP2C19. Since there is no result for CYP2C19, it would be prudent to monitor the patient's response and side effects closely, and adjust the dose based on clinical response and tolerability rather than genetic information.	0.33205111070884535	0.4630028899358478	0.49691091383335034	0.5666788665249181	0.34948474	0.38907063	0.42368975	0.6176421	0.39659184	0.48815998	0.40268913	0.635579	0.3172067	0.44016293	0.4359481	0.53170574	0.3464292	0.51360846	0.58839625	0.570743	0
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking sevoflurane as normal. There is no recommendation.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Avoid sevoflurane. Take an alternate therapy.	For an individual with no results available for RYR1 and a Malignant Hyperthermia Susceptibility finding for the CACNA1S gene, clinical guidance would typically advise avoiding the use of sevoflurane. Sevoflurane is known to trigger malignant hyperthermia, and any known susceptibility, such as that associated with CACNA1S, warrants the use of alternative anesthetic agents to mitigate the risk.	0.6797367731404651	0.4577322968908379	0.3950503790050188	0.5461012954767411	0.7261735	0.5242743	0.41952017	0.6370336	0.7622009	0.38997516	0.32202256	0.6345823	0.7662871	0.38056022	0.37776628	0.5450703	0.6480694	0.5110538	0.4875466	0.5320474	1
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking sevoflurane as normal. There is no recommendation.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Avoid sevoflurane. Take an alternate therapy.	For individuals with Malignant Hyperthermia Susceptibility (MHS) related to RYR1 or CACNA1S gene mutations, the use of sevoflurane should be contraindicated. These patients are at high risk of developing a potentially life-threatening hypermetabolic crisis if exposed to sevoflurane, a known trigger of malignant hyperthermia. Alternative anesthetics that do not trigger malignant hyperthermia, such as regional anesthesia or TIVA (total intravenous anesthesia) with non-triggering agents, should be considered.	0.7583611932882983	0.4545663107907299	0.390423410687307	0.5698219471792634	0.7241042	0.5301802	0.4270331	0.61636144	0.77406645	0.4028364	0.3430284	0.5976105	0.7926291	0.40479818	0.40274474	0.52286756	0.6895601	0.5206879	0.4927721	0.5562063	1
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid sevoflurane. Take an alternate therapy.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Proceed taking sevoflurane as normal. There is no recommendation.	Clinical guidance for someone with uncertain susceptibility for RYR1 and no result for CACNA1S concerning sevoflurane use would be to exercise caution. Sevoflurane can trigger malignant hyperthermia (MH) in susceptible individuals. Therefore, it may be prudent to consider alternative anesthetic agents and consult with a specialist in MH to evaluate potential risks further.	0.6471571639492427	0.404625231433635	0.35035865710471553	0.5947465489763015	0.66683567	0.44700626	0.3018782	0.61859804	0.6294297	0.28510997	0.27155432	0.6066163	0.51820046	0.34939775	0.28251505	0.534217	0.6296744	0.41315067	0.36498272	0.5215876	0
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid sevoflurane. Take an alternate therapy.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Proceed taking sevoflurane as normal. There is no recommendation.	For someone with no result for the RYR1 gene and uncertain susceptibility for the CACNA1S gene, clinical guidance remains precautionary. Sevoflurane is a known trigger for malignant hyperthermia (MH), and without definitive genetic information, it's prudent to avoid sevoflurane or use it in a setting equipped for rapid MH intervention, while considering alternative anesthetics that do not pose the same risk.	0.7207405039638368	0.42048804759396385	0.3688005636801659	0.5453788870052713	0.7284008	0.44580105	0.28976873	0.56583774	0.66052014	0.2849354	0.26839402	0.5067782	0.4872544	0.3944337	0.32558468	0.54763365	0.57650316	0.41290683	0.3670448	0.55768615	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	For individuals with increased function of the SLCO1B1 gene, the transport of simvastatin into hepatocytes may be enhanced. This condition could potentially lead to a decreased plasma concentration of the drug, which might reduce its efficacy in lowering LDL cholesterol. Clinicians may choose to monitor the lipid levels more closely and consider dose adjustments or alternative statin therapy if the therapeutic response is inadequate.	0.3082883465016281	0.35520323393516884	0.3625538167552265	0.4772406714608885	0.41639042	0.29368147	0.37379178	0.4697384	0.33505192	0.43996063	0.33405927	0.6044639	0.21890919	0.3681696	0.3272569	0.4949908	0.49942553	0.51872534	0.5893848	0.54481256	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	Individuals with normal function of the SLCO1B1 gene typically have standard transporter activity, which is responsible for the hepatic uptake of simvastatin. Clinical guidance suggests that these individuals can follow the standard dosing recommendations for simvastatin without increased risk of side effects, particularly myopathy. Regular monitoring and adherence to prescribed doses remain important to optimize therapeutic outcomes.	0.3584229634800619	0.35520323393516884	0.3625538167552265	0.5939971934548598	0.4762606	0.29368147	0.37379178	0.5454254	0.4097653	0.43996063	0.33405927	0.639208	0.29220733	0.3681696	0.3272569	0.47207946	0.5494272	0.51872534	0.5893848	0.62725073	1
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	If a patient is Indeterminate for the SLCO1B1 genotype, it suggests that the testing did not provide clear results regarding their risk for simvastatin-associated myopathy. Clinical guidance would recommend monitoring the patient closely for signs of muscle toxicity and considering alternative statins or lower doses if symptoms arise, as an indeterminate result doesn't guarantee normal function of the transporter protein. It might also be beneficial to conduct further genetic testing or rely on clinical factors and family history to guide therapy decisions.	0.2605735451964029	0.4625140376620879	0.2085460208797063	0.515035730583452	0.16443767	0.2978556	0.14447227	0.51873267	0.044254325	0.19657017	0.08326497	0.55931467	0.0047819987	0.31804746	0.080486454	0.3968069	0.32179448	0.52485126	0.40065327	0.5316322	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.	['Proceed taking simvastatin as normal. There is no recommendation.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Avoid simvastatin. Take an alternate therapy.	For individuals who have Possible Decreased Function of the SLCO1B1 gene, there is an increased risk of simvastatin-induced myopathy. Clinical guidance typically suggests considering a lower dose of simvastatin or choosing an alternative statin, particularly one less dependent on SLCO1B1 activity for hepatic uptake, such as pravastatin or rosuvastatin, to minimize the risk of adverse effects.	0.6738107512460096	0.7277971588287913	0.6528134150679131	0.60615092360577	0.68130344	0.73048836	0.6647571	0.6559317	0.6697921	0.81392723	0.7618964	0.6960423	0.5451434	0.5576565	0.56782985	0.6288907	0.5217945	0.66800714	0.5938259	0.6189625	1
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking streptomycin as normal. There is no recommendation.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Avoid streptomycin. Take an alternate therapy.	For individuals at increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants, clinical guidance strongly advises avoiding the use of streptomycin and other aminoglycosides unless no suitable alternatives are available. If treatment with an aminoglycoside is absolutely necessary, careful monitoring for ototoxicity and consideration of non-ototoxic antibiotics should be prioritized to mitigate the risk of hearing loss.	0.7691333442194268	0.5142258212686126	0.4284793099705051	0.5709898191402664	0.8220257	0.6081317	0.48939642	0.62670255	0.7852348	0.5112248	0.48077092	0.60563844	0.8381384	0.41462815	0.4065719	0.437755	0.6841966	0.5992292	0.5111725	0.6036563	1
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid streptomycin. Take an alternate therapy.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Proceed taking streptomycin as normal. There is no recommendation.	For individuals identified as being at normal risk for aminoglycoside-induced hearing loss due to their MT-RNR1 genetic status, clinical guidance generally does not require modifying the standard dose of streptomycin. However, it remains crucial to monitor hearing function regularly during treatment, as aminoglycosides can still pose a risk of ototoxicity irrespective of genetic predisposition.	0.6927006054412439	0.45422819547735455	0.45307174671684985	0.5764945626295636	0.5763153	0.45912617	0.49132943	0.6108075	0.6388001	0.5299307	0.5460022	0.56271213	0.72327846	0.47248167	0.4446279	0.4538872	0.59323716	0.53565234	0.5680272	0.5217312	1
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid streptomycin. Take an alternate therapy.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Proceed taking streptomycin as normal. There is no recommendation.	For patients with uncertain risk of aminoglycoside-induced hearing loss related to the MT-RNR1 gene, it is generally advisable to avoid the use of aminoglycosides such as streptomycin if alternative antibiotics are available. Genetic testing for MT-RNR1 variants known to confer increased risk of ototoxicity can provide clarity, and if high-risk variants are identified, stringent monitoring for hearing loss is recommended if streptomycin use cannot be avoided.	0.6152650030675348	0.45422819547735455	0.45307174671684985	0.5069325806057801	0.5022525	0.45912617	0.49132943	0.57896644	0.68362796	0.5299307	0.5460022	0.5523543	0.7016478	0.47248167	0.4446279	0.42329597	0.58694744	0.53565234	0.5680272	0.4914855	0
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	Individuals with uncertain susceptibility for RYR1 and malignant hyperthermia susceptibility for CACNA1S are at increased risk for developing malignant hyperthermia, a potentially fatal reaction, when exposed to triggering agents like succinylcholine. Clinical guidance generally recommends avoiding the use of succinylcholine in these patients, and suggests using alternative medications and vigilant monitoring to mitigate the risk.	0.6976425353281756	0.527814087888422	0.48228017872192	0.5132474400217678	0.7621847	0.58536065	0.49024773	0.5562825	0.768194	0.5190823	0.42098674	0.56427693	0.6862621	0.5455104	0.48073366	0.47004402	0.62982315	0.5365511	0.50722456	0.5533224	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	For a patient with no result for RYR1 but with susceptibility to malignant hyperthermia (MH) indicated by a CACNA1S variant, the use of succinylcholine should be approached with caution. Succinylcholine is known to trigger MH in susceptible individuals, so alternative anesthetics that do not carry this risk should be considered, and if succinylcholine must be used, rigorous monitoring and preparedness for MH management are essential.	0.7827015828916993	0.5234694651738674	0.4817853108071822	0.5751200671248222	0.83633775	0.57796425	0.49079117	0.5466748	0.8583296	0.4955142	0.39472172	0.4661103	0.8440803	0.5378755	0.46728277	0.49988928	0.790888	0.5330462	0.50714344	0.5622064	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	For individuals with Malignant Hyperthermia Susceptibility (MHS) due to mutations in the RYR1 gene, the use of succinylcholine is contraindicated because it can trigger a life-threatening hypermetabolic reaction. For those with uncertain susceptibility related to CACNA1S variants, caution is also advised, and alternative non-triggering anesthetics should be considered to avoid potential malignant hyperthermia episodes. It is crucial to properly screen and manage anesthetic plans for these patients to ensure safety.	0.8272264135803076	0.527814087888422	0.48228017872192	0.5439428610311717	0.765188	0.58536065	0.49024773	0.4851887	0.8474909	0.5190823	0.42098674	0.45496672	0.8256268	0.5455104	0.48073366	0.46429178	0.7788783	0.5365511	0.50722456	0.5470723	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid succinylcholine. Take an alternate therapy.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Proceed taking succinylcholine as normal. There is no recommendation.	Clinical guidance for a patient who has no result for RYR1 and uncertain susceptibility for CACNA1S regarding succinylcholine would generally involve caution. While there is no definitive genetic evidence to suggest a heightened risk of malignant hyperthermia (MH), the uncertain status for CACNA1S means there remains possible risk. It would be prudent for healthcare providers to consider alternative medications and closely monitor the patient if succinylcholine use is necessary.	0.6717727977063933	0.4012847013331125	0.3691897245764412	0.5855514755056138	0.6906143	0.49628866	0.31289098	0.47131747	0.68564075	0.33169323	0.3286617	0.4756078	0.5848725	0.42874748	0.34859177	0.4500818	0.7435993	0.41059837	0.34475026	0.55791104	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	For individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD), the use of sulfadiazine is generally contraindicated due to the increased risk of hemolytic anemia. Alternative antibiotics with no risk of inducing hemolysis should be considered in these patients. Always consult with a healthcare professional for personalized medical advice.	0.6305540651727859	0.49409310659631833	0.38567168209215	0.5763996094639688	0.5793098	0.55285794	0.34279808	0.6597771	0.56901073	0.47429895	0.2665436	0.70398164	0.5322038	0.44109833	0.3475649	0.61146545	0.4815217	0.4953315	0.3599021	0.6233912	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when prescribing sulfadiazine due to the risk of hemolytic anemia. Since the G6PD enzyme plays a critical role in protecting red blood cells from oxidative damage, it is recommended to consider alternative medications or conduct further testing to clarify G6PD status. Close monitoring for signs of hemolysis is essential if sulfadiazine is administered.	0.6670264589827734	0.41211662832204105	0.3489397021930356	0.551595119673864	0.6026668	0.25197884	0.28623995	0.58200884	0.6421346	0.32540876	0.23879947	0.64954305	0.6372995	0.25633618	0.24435584	0.5689155	0.62109476	0.44424903	0.4111406	0.5857838	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	For individuals deficient in glucose-6-phosphate dehydrogenase (G6PD) with chronic non-spherocytic hemolytic anemia (CNSHA), the use of sulfadiazine is generally contraindicated. Sulfadiazine, a sulfonamide antibiotic, can trigger hemolysis in G6PD-deficient patients, potentially leading to severe anemia and other complications. It is recommended to consider alternative antibiotics that are safer for G6PD-deficient individuals.	0.4133192226888928	0.3683210736983723	0.41165556589554164	0.5366116103777646	0.5753769	0.48263654	0.4828907	0.6153624	0.548499	0.4822018	0.42708778	0.6507264	0.49892017	0.4086935	0.37994298	0.570273	0.5255792	0.4005608	0.4407929	0.5805213	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	For individuals who have normal G6PD (glucose-6-phosphate dehydrogenase) activity, sulfadiazine can generally be used without specific dosing adjustments or increased risk of hemolytic anemia, which is a major concern for those with G6PD deficiency. However, as with any medication, it is important to monitor for any adverse reactions and consult with a healthcare provider for personalized medical advice.	0.6593669978512077	0.44098857563454497	0.32580317638210055	0.6046070704908855	0.5251378	0.403317	0.20066725	0.65796715	0.4659711	0.2926803	0.13621284	0.7149949	0.43593353	0.19492838	0.13273613	0.6054601	0.5217001	0.4200052	0.2845944	0.593901	1
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	For a patient who is deficient in glucose-6-phosphate dehydrogenase (G6PD), taking sulfadimidine is not recommended due to the risk of hemolytic anemia. G6PD deficiency impairs the ability of red blood cells to handle oxidative stress, which can be exacerbated by sulfonamide medications like sulfadimidine, leading to red cell breakdown. Therefore, alternative treatments that do not pose this risk should be considered.	0.5974300722000991	0.5366443753840053	0.4172271170802881	0.6358756908901471	0.59355015	0.56382734	0.37480518	0.6326878	0.6319745	0.5065424	0.31411874	0.65460086	0.60599697	0.4707895	0.38082504	0.61574966	0.5534632	0.53090537	0.4009732	0.6183846	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when considering sulfadimidine due to the potential risk of hemolytic anemia associated with G6PD deficiency. It is generally recommended to avoid the medication or seek alternative treatments, and if use is deemed necessary, close monitoring for signs of hemolysis is essential.	0.6586786526069647	0.4630560778176447	0.3867991396176147	0.6233609558425216	0.5103375	0.2764976	0.34482363	0.62777674	0.60425717	0.38954467	0.34922948	0.665748	0.53553414	0.2797548	0.26608437	0.6701794	0.5434612	0.45811012	0.41824174	0.6031975	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	In individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic nonspherocytic hemolytic anemia (CNSHA), the use of sulfadimidine (also known as sulfamethazine) is generally contraindicated. This medication can trigger hemolytic anemia in these patients, leading to a potentially dangerous drop in hemoglobin levels. It is crucial for healthcare providers to consider alternative therapies that are safer for G6PD-deficient patients.	0.4389282615563801	0.4209225930462725	0.43827578042200527	0.5703538489901007	0.53401405	0.48220828	0.52227277	0.58390653	0.518604	0.48777655	0.47218665	0.59834653	0.51167893	0.4433251	0.40773273	0.56647676	0.5343787	0.3986235	0.44751632	0.58477056	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	For an individual who is normal for glucose-6-phosphate dehydrogenase (G6PD) enzyme activity, taking sulfadimidine typically carries a standard risk, as they are not prone to hemolytic anemia associated with G6PD deficiency. However, it is always important to monitor for any adverse reactions and consult with a healthcare provider before starting the medication, as other factors such as allergies or concurrent medications may affect its safety and efficacy.	0.6276198175633514	0.47151580356404366	0.34642321593753733	0.6486867877338386	0.5366087	0.41365242	0.22407989	0.6803077	0.4984557	0.32886207	0.1757294	0.7240892	0.41307235	0.22115462	0.15708718	0.6353415	0.5681419	0.45304385	0.3298614	0.6310233	1
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	For an individual with normal glucose-6-phosphate dehydrogenase (G6PD) activity, there are no special precautions needed when taking sulfamethoxazole/trimethoprim. They can use this medication as prescribed, as they are not at increased risk for hemolytic anemia, a concern primarily for those with G6PD deficiency. However, standard side effect monitoring remains essential.	0.617383576690926	0.4306443638139204	0.3247689733049191	0.63927083051286	0.5670624	0.41712707	0.20478147	0.7323365	0.5156173	0.30901244	0.14787404	0.72869277	0.35222974	0.16224156	0.09979022	0.58244205	0.5085508	0.4082015	0.28756562	0.6526724	1
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	For individuals with a variable (intermediate) G6PD enzyme activity, caution is advised when prescribing sulfamethoxazole/trimethoprim (SMX/TMP) due to the risk of hemolytic anemia. While the degree of risk may not be as high as in those with G6PD deficiency, close monitoring for signs of hemolysis is recommended. Alternatives should be considered if clinically appropriate, particularly in patients with a known history of hemolysis.	0.636997048956412	0.4705058638684977	0.37906068861041886	0.577544331077345	0.6258874	0.5506341	0.3296366	0.5608499	0.614161	0.46586427	0.25076166	0.5916278	0.5909543	0.40578195	0.30630967	0.5998459	0.51143694	0.466226	0.33565807	0.6044153	0
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	Patients who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid the use of sulfamethoxazole/trimethoprim, as this medication can cause oxidative stress leading to hemolytic anemia in individuals with G6PD deficiency. It is important to consider alternative antibiotics that do not pose this risk. Clinical decisions should involve monitoring for hemolytic symptoms and choosing safer treatment options.	0.6461599912088423	0.4705058638684977	0.37906068861041886	0.559977253001948	0.6067306	0.5506341	0.3296366	0.66954637	0.5924965	0.46586427	0.25076166	0.61347777	0.57478213	0.40578195	0.30630967	0.5613721	0.5340553	0.466226	0.33565807	0.5866731	0
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	For individuals with an indeterminate status for G6PD deficiency, caution is recommended when considering the administration of sulfamethoxazole/trimethoprim. Clinical guidance typically involves careful monitoring for hemolytic anemia, as G6PD deficiency can increase the risk for this adverse effect. It may also be prudent to consider alternative antibiotics if the risk of G6PD deficiency is suspected but not confirmed.	0.6445657266226109	0.4036652776421411	0.3479839129552009	0.6173234904735838	0.55868185	0.24292305	0.27221867	0.63431215	0.5861343	0.315268	0.23093794	0.68664855	0.5678809	0.2193713	0.19654308	0.566759	0.5893256	0.43268222	0.36607432	0.6093832	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	If an individual is normal for G6PD (glucose-6-phosphate dehydrogenase), they generally do not have an increased risk of hemolytic anemia when taking sulfanilamide. However, it is still important to monitor the patient for any adverse reactions, as sulfanilamide can have other side effects and individual responses to medications can vary. Always consult with a healthcare provider before starting any new medication.	0.5937938244249217	0.4343700432793431	0.2947795499277937	0.6123699045185744	0.45656988	0.4056054	0.21576686	0.5734324	0.3847503	0.29410857	0.13966405	0.60644025	0.44156682	0.19536656	0.1379577	0.523398	0.51258314	0.437908	0.3261619	0.5590672	1
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	For an individual who is Indeterminate for G6PD deficiency, caution should be exercised when considering the use of sulfanilamide, as it can precipitate hemolytic anemia in those with G6PD deficiency. Close monitoring for signs of hemolysis (such as fatigue, jaundice, and dark urine) is recommended, and alternative medications should be considered whenever possible. If sulfanilamide must be used, it is critical to proceed with careful clinical supervision.	0.6155709214846439	0.4182746565908878	0.33729696844813817	0.5990137093329163	0.554545	0.22919756	0.28116187	0.5631248	0.6560627	0.29972067	0.2222008	0.62764955	0.5682418	0.25603768	0.24801755	0.5386896	0.50488544	0.44852558	0.44223008	0.5232503	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	For individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, particularly those with Chronic Nonspherocytic Hemolytic Anemia (CNSHA), the use of sulfanilamide should be contraindicated. Sulfanilamide can induce hemolytic anemia in G6PD-deficient patients, and its use should be avoided to prevent potentially severe hemolytic episodes. It is essential for these patients to inform their healthcare providers of their G6PD deficiency to ensure that alternative treatments are considered.	0.4411306078804525	0.4041840488988126	0.42074429790244183	0.5525120485205286	0.52955616	0.49054238	0.5201581	0.62532455	0.52679634	0.49501613	0.45352992	0.59671277	0.47709587	0.39184275	0.36526337	0.4947549	0.5189416	0.39136568	0.46028605	0.5652373	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	For individuals who are G6PD-deficient, taking sulfanilamide is generally contraindicated. This is because sulfanilamide, a sulfonamide antibiotic, can induce oxidative stress, leading to hemolytic anemia in those with G6PD deficiency. Clinical guidance typically advises avoiding sulfanilamide and selecting alternative antibiotics that do not carry the same risk.	0.6109196371881424	0.5001107078985911	0.37375390210550646	0.6109503421745147	0.62625134	0.5555609	0.36481413	0.6474901	0.6699794	0.47597387	0.26766637	0.6783055	0.6168077	0.44162732	0.36039737	0.5628784	0.57741386	0.506491	0.3976718	0.61367655	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), it is recommended to avoid sulfasalazine due to the increased risk of hemolytic anemia. This is because G6PD deficiency makes red blood cells more vulnerable to oxidative stress, which can be exacerbated by sulfasalazine. Clinical alternatives should be considered, and any use of sulfasalazine in such patients should be closely monitored if deemed absolutely necessary.	0.5904060763891714	0.454761608173271	0.34050768287039546	0.536942037066218	0.6141428	0.5211813	0.31954464	0.5956169	0.5911821	0.4119653	0.20937975	0.58926165	0.5649706	0.4059127	0.31599593	0.5774137	0.5669331	0.47757736	0.35316658	0.56149936	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For individuals with indeterminate G6PD status, caution is advised when prescribing sulfasalazine due to the potential risk of hemolytic anemia. It is recommended to consider alternative medications or closely monitor for signs of hemolysis, weighing the benefits and risks of therapy. Genetic testing to ascertain G6PD status conclusively could further guide treatment decisions.	0.6672256562800739	0.3616340990132798	0.30436571600079243	0.5382059636055311	0.62195843	0.2402507	0.27568257	0.55864763	0.63771605	0.27466792	0.19229496	0.5886011	0.61168045	0.21604878	0.2027477	0.5738846	0.59487945	0.4199025	0.3860419	0.5745003	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For an individual with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, specifically Chronic Non-Spherocytic Hemolytic Anemia (CNSHA), sulfasalazine should generally be avoided. Sulfasalazine is known to trigger hemolytic anemia in G6PD-deficient patients due to oxidative stress, and the risk of severe hemolysis is heightened in those with CNSHA. Clinical alternatives should be considered, and if sulfasalazine is deemed necessary, close monitoring for hemolysis is essential.	0.42658543400877275	0.37233782366052026	0.4072278126853995	0.5085744885384672	0.50583094	0.4658889	0.47853336	0.6603972	0.517596	0.43297738	0.37736353	0.5696699	0.54879624	0.4247376	0.38877144	0.5752798	0.51299655	0.41632393	0.46072897	0.577647	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For individuals with normal glucose-6-phosphate dehydrogenase (G6PD) activity, sulfasalazine can generally be prescribed without specific restrictions related to G6PD deficiency. However, clinicians should still monitor for potential adverse reactions as part of routine medical care, as sulfasalazine can cause a range of side effects unrelated to G6PD status.	0.6245978180703291	0.38913060984950526	0.26991477255176216	0.5749734271060449	0.4995448	0.38723877	0.19100542	0.5991516	0.4724951	0.25948122	0.105310656	0.5710496	0.3867889	0.16246423	0.09714504	0.55920446	0.52222323	0.4087324	0.28224456	0.581396	1
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	Patients who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking sulfisoxazole, as this medication can precipitate hemolysis in these individuals. Clinical guidance typically advises selecting alternative antibiotics that do not pose a risk of causing hemolytic anemia in G6PD-deficient patients.	0.6089292081034078	0.4776053441656646	0.3572792340137502	0.5723308352009365	0.60613424	0.521006	0.31720397	0.66431373	0.5905433	0.41421908	0.21777071	0.63588274	0.58028185	0.41013876	0.30259517	0.5790766	0.51529133	0.47607094	0.35071957	0.56391937	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, the clinical guidance is to exercise caution when prescribing sulfisoxazole. Given the potential for hemolytic anemia in G6PD-deficient individuals when exposed to sulfa drugs like sulfisoxazole, it may be prudent to consider alternative antibiotics or ensure close monitoring for signs of hemolysis. Genetic testing to confirm G6PD status might also be recommended to tailor a safer treatment plan.	0.6441311895468548	0.37962200061456314	0.30808743873921896	0.5783375802098668	0.5354067	0.21456246	0.2426911	0.6084062	0.6157007	0.24887781	0.16867976	0.6095778	0.6051399	0.23579325	0.20944287	0.54555625	0.57963926	0.43196598	0.4036893	0.5611266	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), use of sulfisoxazole is generally contraindicated. Sulfisoxazole can precipitate hemolytic anemia in G6PD-deficient patients, therefore, alternative antibiotics should be considered to avoid hemolysis.	0.4436775739844802	0.37925551666284074	0.41648910957060004	0.5465306352428283	0.54760754	0.46666807	0.4705049	0.6108059	0.5310387	0.4460879	0.38614416	0.6304414	0.53194976	0.45544776	0.40924263	0.5511913	0.5133397	0.3974429	0.45411095	0.5559161	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	For individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) activity, there is no increased risk of hemolysis when taking sulfisoxazole. Therefore, standard dosing and administration guidelines for sulfisoxazole can be followed. However, as with any medication, patients should be monitored for any adverse reactions.	0.5536036043412307	0.419649122489722	0.2882677919284511	0.6408424676622105	0.45658046	0.38482702	0.18866698	0.674735	0.4117384	0.26523647	0.11324816	0.668573	0.33415118	0.16146298	0.09198319	0.578454	0.5213912	0.41952357	0.29587677	0.6165423	1
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	For individuals who are possible intermediate metabolizers for CYP3A5 (*1/*3, *1/*6, or *1/*7), clinical guidance suggests starting tacrolimus at a higher initial dose than the standard recommendation, typically 1.5 to 2 times higher. This adjustment is recommended because intermediate metabolizers may have increased clearance of tacrolimus, necessitating higher doses to achieve therapeutic levels, with frequent monitoring to adjust the dose as needed.	0.5912432913182578	0.4616834447000675	0.4362495880492575	0.7044001436291253	0.6895542	0.5866446	0.4795239	0.59676385	0.59356636	0.49911952	0.47183117	0.56893575	0.70668083	0.5063754	0.40307587	0.55060464	0.6232282	0.48400515	0.31489778	0.6818497	1
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Indeterminate for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	No recommendation	['Avoid tacrolimus. Take an alternate therapy.', 'Take tacrolimus with a reduced dose.', 'Take tacrolimus with an increased dose.']	Proceed taking tacrolimus as normal. There is no recommendation.	For an individual who is Indeterminate for CYP3A5 (meaning it is unclear whether they are a normal or poor metabolizer), the clinical guidance for tacrolimus would recommend starting with the standard initial dosing regimen. Subsequent dosing should be closely monitored and adjusted based on therapeutic drug monitoring to achieve the desired blood concentration, as CYP3A5 status can influence tacrolimus metabolism and therefore its efficacy and toxicity.	0.23125227914011579	0.4431192666617696	0.1962160416717064	0.6763083017180772	0.19967768	0.3410242	0.20064467	0.51318914	0.16024715	0.24524479	0.14249896	0.6611303	0.013040867	0.32175273	0.09869818	0.6147425	0.31412217	0.5299339	0.40260872	0.6516123	0
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	For an individual identified as an Intermediate Metabolizer of CYP3A5 taking tacrolimus, clinical guidance generally recommends increasing the starting dose of tacrolimus by 1.5 to 2 times the typical starting dose to achieve the desired therapeutic level, while also conducting careful monitoring of drug levels and kidney function. This adjustment compensates for reduced enzyme activity and helps avoid subtherapeutic drug levels.	0.6128721985743308	0.4616834447000675	0.4362495880492575	0.711386624797437	0.73605	0.5866446	0.4795239	0.656572	0.6721129	0.49911952	0.47183117	0.6031659	0.62649554	0.5063754	0.40307587	0.5454368	0.67481035	0.48400515	0.31489778	0.70238364	1
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Normal Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	For individuals identified as normal metabolizers (expressers) of CYP3A5, clinical guidance suggests starting tacrolimus at higher doses compared to non-expressers, due to the increased metabolism of the drug. Such patients typically require about 1.5 to 2 times the standard starting dose to achieve therapeutic drug levels, with subsequent dose adjustments based on therapeutic drug monitoring and clinical response.	0.5607139157003991	0.4616834447000675	0.4362495880492575	0.6530671630371154	0.66157323	0.5866446	0.4795239	0.60996395	0.60102105	0.49911952	0.47183117	0.56965744	0.60510415	0.5063754	0.40307587	0.5599389	0.6471732	0.48400515	0.31489778	0.68173414	1
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	Avoid use	['Proceed taking tafenoquine as normal. There is no recommendation.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Avoid tafenoquine. Take an alternate therapy.	Individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD) should avoid taking tafenoquine due to the risk of hemolytic anemia, which can be fatal in G6PD-deficient patients. Tafenoquine is contraindicated for these individuals, and alternative treatments for malaria prophylaxis or radical cure should be sought.	0.20180936914110348	0.28266737706399203	0.2424079324782934	0.6313296801524071	0.34981906	0.36137226	0.2774274	0.598481	0.19259937	0.15206675	0.16466653	0.5940012	0.15990543	0.19780403	0.19426876	0.5762366	0.41589767	0.53825694	0.44704333	0.6455446	1
tafenoquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid tafenoquine. Take an alternate therapy.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Proceed taking tafenoquine as normal. There is no recommendation.	For an individual with an indeterminate result for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, cautious use of tafenoquine is advised due to the risk of hemolytic anemia. A confirmatory G6PD test should be conducted prior to initiating tafenoquine therapy. If G6PD deficiency is confirmed, alternative treatments should be considered.	0.6360108649830037	0.393089109099031	0.33422251347699206	0.6001213968157678	0.62838954	0.19516173	0.21879297	0.54851663	0.649938	0.17707741	0.10083932	0.5646099	0.565081	0.18699531	0.14543094	0.5319496	0.5621797	0.430844	0.4059942	0.47186652	0
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	Avoid use	['Proceed taking tafenoquine as normal. There is no recommendation.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Avoid tafenoquine. Take an alternate therapy.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with congenital non-spherocytic hemolytic anemia (CNSHA), should avoid taking tafenoquine. Tafenoquine can induce hemolysis in G6PD-deficient individuals, leading to severe hemolytic anemia. Therefore, G6PD testing is recommended before prescribing tafenoquine, and alternative medications should be considered for those with G6PD deficiency.	0.19166488024537723	0.28266737706399203	0.2424079324782934	0.5791440246118229	0.33794087	0.36137226	0.2774274	0.64598566	0.15902033	0.15206675	0.16466653	0.60679954	0.13261664	0.19780403	0.19426876	0.5384343	0.38717416	0.53825694	0.44704333	0.5984221	1
tafenoquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid tafenoquine. Take an alternate therapy.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Proceed taking tafenoquine as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) activity, tafenoquine can be used safely for the treatment or prevention of malaria. Routine monitoring for hemolytic anemia is generally not necessary in these patients, as they are not at increased risk for tafenoquine-induced hemolysis. Nonetheless, as with any medication, they should be monitored for other potential side effects.	0.557046606284014	0.42259606475035444	0.3047555703188695	0.6570589893780581	0.49289295	0.39961833	0.2058283	0.5688671	0.2869469	0.26932788	0.11702481	0.55204505	0.28136277	0.13655831	0.06740723	0.5053744	0.4215332	0.42233628	0.30055097	0.54162306	1
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For someone who is a normal metabolizer with a CYP2D6 activity score of 2.0, standard clinical guidance would generally support the use of tamoxifen without dosage adjustment. This individual is expected to metabolize tamoxifen effectively into its active metabolites, particularly endoxifen, which is crucial for the drug's therapeutic effect in breast cancer treatment. Therefore, the standard dosing regimen for tamoxifen is typically appropriate for these patients.	0.6813590474487147	0.6741140690515157	0.664771565113239	0.5488246647251677	0.6320426	0.7435186	0.6722197	0.4918104	0.6643284	0.7313675	0.6874338	0.5288582	0.654453	0.7392635	0.6696129	0.46589342	0.7496023	0.79819125	0.77450246	0.58744603	1
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (activity score = 2.5) for CYP2D6, clinical guidance typically suggests caution when using tamoxifen. Due to the increased metabolic activity, tamoxifen may be converted too rapidly into its active metabolite, potentially leading to reduced effectiveness of the drug. Alternative treatments or careful monitoring may be recommended to ensure therapeutic efficacy.	0.6943032007539963	0.6741140690515157	0.664771565113239	0.5893072178046909	0.7297344	0.7435186	0.6722197	0.5929773	0.7427893	0.7313675	0.6874338	0.5960167	0.6532473	0.7392635	0.6696129	0.46735224	0.712698	0.79819125	0.77450246	0.6170049	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For individuals who are Ultrarapid Metabolizers with a CYP2D6 activity score of ≥3.25, clinical guidance suggests reconsidering the use of tamoxifen due to the potential for reduced therapeutic efficacy. As tamoxifen's conversion into its active metabolites is highly dependent on CYP2D6, and Ultrarapid Metabolizers might excessively convert the drug, resulting in lower availability of active metabolites, alternative therapies or additional monitoring could be appropriate.	0.6896707760593156	0.6741140690515157	0.664771565113239	0.5777541183671089	0.67931354	0.7435186	0.6722197	0.58128697	0.70542175	0.7313675	0.6874338	0.5938108	0.64570427	0.7392635	0.6696129	0.49225217	0.7135556	0.79819125	0.77450246	0.62800854	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For a patient who is a normal metabolizer (activity score of 1.75) of CYP2D6 taking tamoxifen, standard dosing is typically recommended. This CYP2D6 phenotype generally indicates that the patient has sufficient enzymatic activity to convert tamoxifen into its active metabolites, thereby maintaining optimal therapeutic effectiveness. Regular monitoring and adherence to prescribed dosages should ensure effective treatment.	0.6926111477086048	0.6741140690515157	0.664771565113239	0.5455607517360178	0.6635438	0.7435186	0.6722197	0.44983694	0.73807496	0.7313675	0.6874338	0.56182843	0.71339756	0.7392635	0.6696129	0.46249235	0.73763335	0.79819125	0.77450246	0.5500235	1
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	For patients with an indeterminate CYP2C9 status, clinical guidance typically involves monitoring for potential side effects and adjusting doses based on clinical response and tolerability, due to the varied enzymatic activity that can alter tenoxicam metabolism. Close monitoring for adverse effects like gastrointestinal issues or signs of toxicity is recommended, and alternative therapies may be considered if the patient exhibits negative reactions. Consulting with a healthcare professional for personalized management and possibly conducting more specific genetic testing could be beneficial.	0.24641398348127522	0.45549037908208784	0.24614018057835055	0.6072471637979558	0.13821304	0.28179795	0.14689119	0.5183257	0.08122219	0.14983788	0.071839415	0.595855	-0.024087403	0.34113693	0.11707452	0.51209277	0.25786504	0.55544454	0.41888833	0.6020699	0
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	For an individual who is a normal metabolizer (activity score = 2.0) for CYP2C9, the clinical guidance for taking tenoxicam generally does not require dose adjustment due to expected normal enzyme activity. This means they are likely to metabolize tenoxicam at the standard rate, resulting in typical efficacy and safety profiles. As with any medication, it is important to monitor for therapeutic effectiveness and any potential adverse effects.	0.4045059480354623	0.43137110084097624	0.43317168704404146	0.682652710960124	0.4411513	0.37811524	0.3729335	0.5301938	0.44236037	0.4783564	0.3365829	0.5640206	0.40882975	0.39204037	0.40393975	0.5632743	0.45122087	0.48403755	0.46221796	0.6592838	1
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking tenoxicam as normal. There is no recommendation.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Avoid tenoxicam. Take an alternate therapy.	For individuals identified as Poor Metabolizers with an activity score of 0.0 for CYP2C9, the activity of the enzyme CYP2C9 is significantly reduced or absent, leading to decreased clearance of tenoxicam. Therefore, clinical guidance recommends considering alternative nonsteroidal anti-inflammatory drugs (NSAIDs) that are not metabolized by CYP2C9 to reduce the risk of adverse effects, such as prolonged drug exposure and increased risk of toxicity.	0.6597686055937696	0.5851060746176674	0.484081942471341	0.6062746197630617	0.728404	0.6312463	0.5491793	0.59837687	0.7565808	0.44854802	0.41460106	0.59366035	0.6305287	0.35341328	0.3262374	0.53928757	0.6935577	0.5569536	0.52573466	0.68057704	1
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	Patients identified as intermediate metabolizers with an activity score of 1.5 for CYP2C9 may have a moderately reduced metabolism of tenoxicam, potentially leading to higher plasma levels of the drug. Clinical guidance generally recommends close monitoring for adverse effects and may suggest a dose reduction to mitigate the risk of toxicity. It is advisable to consult with a healthcare provider for personalized dosing recommendations.	0.4247093880762873	0.43137110084097624	0.43317168704404146	0.6336795023356446	0.41985428	0.37811524	0.3729335	0.5475225	0.38294017	0.4783564	0.3365829	0.6019094	0.387826	0.39204037	0.40393975	0.5644477	0.46172297	0.48403755	0.46221796	0.5840611	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For an individual who is a Normal Metabolizer for TPMT but a Poor Metabolizer for NUDT15, the clinical guidance would recommend a reduced starting dose of thioguanine to decrease the risk of toxicity. Close monitoring for adverse effects, such as myelosuppression, would also be advised due to the impaired ability to metabolize thioguanine effectively through the NUDT15 pathway.	0.7294780642397976	0.6743777498658091	0.6739901993629687	0.6553520341229299	0.67760116	0.58721167	0.5339574	0.5783883	0.6345327	0.57932216	0.6469989	0.5116453	0.62068737	0.5916697	0.5719942	0.5763954	0.6313125	0.64058524	0.5567079	0.6611444	1
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For a patient identified as a Possible Intermediate Metabolizer for TPMT and a Normal Metabolizer for NUDT15, it is generally recommended to prescribe thioguanine with caution. Clinicians might start at a lower dose or opt for more frequent monitoring to avoid potential toxicity, as intermediate TPMT activity can lead to higher concentrations of thioguanine metabolites, increasing the risk of myelosuppression. Regular monitoring of blood counts and thioguanine metabolite levels is advised to ensure safe and effective dosing.	0.7238381398951164	0.6942473925877668	0.6671470331959455	0.6527600576588304	0.54481786	0.5512906	0.5244281	0.5169377	0.6212773	0.5617464	0.63988155	0.5019275	0.60389155	0.5995758	0.5753321	0.59192085	0.6295155	0.618008	0.5470049	0.6137376	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For a patient who is a normal metabolizer of TPMT (thiopurine S-methyltransferase) and an intermediate metabolizer of NUDT15 (nucleoside diphosphate-linked moiety X-type motif 15), clinical guidance would suggest starting thioguanine at normal initial doses but under close monitoring. Dose adjustments may become necessary based on tolerance and any signs of myelosuppression, as an intermediate metabolizer of NUDT15 can have increased risk of toxicity. Regular blood count monitoring is essential to ensure safety and efficacy.	0.7739557888739301	0.6942473925877668	0.6671470331959455	0.6352356221795373	0.6505412	0.5512906	0.5244281	0.54733914	0.72801834	0.5617464	0.63988155	0.53389406	0.6134708	0.5995758	0.5753321	0.5603306	0.6794424	0.618008	0.5470049	0.629747	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For an individual who is an intermediate metabolizer for TPMT and a possible intermediate metabolizer for NUDT15, it is recommended to reduce the standard dose of thioguanine to 30-70% and monitor closely for toxicity. Both TPMT and NUDT15 enzymes play critical roles in metabolizing thioguanine, and reduced activity can significantly increase the risk of myelosuppression and other adverse effects. Regular blood count monitoring is essential to adjust the dosage as needed.	0.7428896318538929	0.6942473925877668	0.6671470331959455	0.654836404701623	0.59878594	0.5512906	0.5244281	0.5226213	0.6967015	0.5617464	0.63988155	0.53558606	0.6398155	0.5995758	0.5753321	0.59126055	0.6693407	0.618008	0.5470049	0.65495956	0
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking tobramycin as normal. There is no recommendation.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Avoid tobramycin. Take an alternate therapy.	Individuals with certain variants in the MT-RNR1 gene are at increased risk for aminoglycoside-induced hearing loss. For those with such genetic predispositions, alternative antibiotics should be considered instead of aminoglycosides such as tobramycin to avoid potential ototoxicity. Genetic testing for MT-RNR1 variants can help guide antibiotic selection in these patients.	0.6752161589505814	0.5476688334099847	0.4323345697345123	0.4594391699097912	0.6499437	0.59542096	0.4749798	0.4860151	0.7113412	0.48701894	0.47801688	0.4671447	0.71035415	0.40880623	0.39415637	0.37396008	0.5909916	0.62957263	0.51017684	0.53819424	1
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid tobramycin. Take an alternate therapy.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Proceed taking tobramycin as normal. There is no recommendation.	For individuals identified as having normal risk based on their MT-RNR1 genetic testing, standard dosing and monitoring for tobramycin can be followed, as they do not possess the genetic variants associated with increased risk of aminoglycoside-induced hearing loss. Clinicians should still adhere to general guidelines for aminoglycoside use, incorporating regular monitoring of drug levels and kidney function to minimize potential toxicity.	0.6536511426336149	0.46278889384433863	0.4613069044437061	0.5973248565302144	0.63675	0.46600628	0.4814185	0.5739578	0.64507204	0.54020387	0.53728217	0.59875166	0.66805774	0.46048653	0.4700062	0.50472486	0.56403184	0.5228594	0.55286264	0.55081755	0
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid tobramycin. Take an alternate therapy.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Proceed taking tobramycin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss due to variants in the MT-RNR1 gene, caution is advised when considering the use of tobramycin. Genetic testing to confirm the presence of risk-associated variants in MT-RNR1 could provide clarity and aid in the decision-making process. If the individual is at increased genetic risk, alternative antibiotics should be considered to avoid potential ototoxicity.	0.5574365725552671	0.46278889384433863	0.4613069044437061	0.5160633765957575	0.48658282	0.46600628	0.4814185	0.45919234	0.6123745	0.54020387	0.53728217	0.5753399	0.6398142	0.46048653	0.4700062	0.41613764	0.59954923	0.5228594	0.55286264	0.47321635	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	Individuals with normal G6PD (glucose-6-phosphate dehydrogenase) enzyme activity generally do not have an increased risk of hemolysis when taking tolbutamide. Therefore, they can use tolbutamide as prescribed without additional precautions related to G6PD deficiency. However, patients should always follow their healthcare provider’s advice and monitor for any adverse effects.	0.6227388671596211	0.3978715225371441	0.26623399455833563	0.5954605791363468	0.5276786	0.39871144	0.21813262	0.6397463	0.4723253	0.2890023	0.15585126	0.6645498	0.44469586	0.18447715	0.1237425	0.51789075	0.58577794	0.43831187	0.3309244	0.5321137	1
tolbutamide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	Clinical guidance for someone with variable G6PD levels (Glucose-6-Phosphate Dehydrogenase deficiency) regarding tolbutamide use would advise caution. G6PD deficiency can increase the risk of hemolytic anemia with certain medications, including sulfonylureas like tolbutamide. Therefore, it is recommended to monitor closely for signs of hemolysis and consider alternative treatments if possible.	0.6125603642743038	0.4795004323743753	0.3477702332090405	0.5255572357769963	0.6200645	0.5720664	0.41603467	0.52099544	0.62896985	0.51813716	0.37049937	0.5950508	0.60372627	0.43208045	0.3473115	0.47942874	0.53142715	0.5191674	0.40989113	0.42071685	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	For individuals with G6PD deficiency, tolbutamide should be used with caution or avoided, as it can induce hemolysis in these patients. Regular monitoring of hemoglobin levels and signs of hemolysis is advised if tolbutamide must be used. It may be prudent to consider alternative antidiabetic medications that do not pose a risk of hemolysis in G6PD-deficient patients.	0.6129798014444342	0.4795004323743753	0.3477702332090405	0.5399740738059425	0.636231	0.5720664	0.41603467	0.6290846	0.64190376	0.51813716	0.37049937	0.6725234	0.6198764	0.43208045	0.3473115	0.5413428	0.5127241	0.5191674	0.40989113	0.47276217	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	For individuals with an Indeterminate status for G6PD (Glucose-6-Phosphate Dehydrogenase) deficiency, there is not enough information to predict their exact enzyme activity. When prescribing tolbutamide, a sulfonylurea used for managing type 2 diabetes, healthcare providers should carefully monitor for signs of hemolysis as a precaution, particularly at the initiation of treatment. Empirical evidence is limited, so the decision must be individualized, considering clinical judgment and potential alternative therapies.	0.6573366146411989	0.3674451738801272	0.29136042505834625	0.5129438674283845	0.6306939	0.26330706	0.3401234	0.51493925	0.67376775	0.34107542	0.32032183	0.5064062	0.6275209	0.24749395	0.24025297	0.47535986	0.6264193	0.43693367	0.41461125	0.53228045	0
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking toluidine blue as normal. There is no recommendation.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Avoid toluidine blue. Take an alternate therapy.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of toluidine blue is generally contraindicated. G6PD deficiency can increase the risk of hemolysis when exposed to oxidative agents such as toluidine blue. Therefore, it is important for healthcare providers to avoid prescribing or administering toluidine blue to patients known to have G6PD deficiency.	0.2572241485114922	0.2980446336423948	0.2584023072366985	0.6176129226827838	0.31511533	0.37050304	0.28443608	0.68933	0.19405541	0.14705415	0.16725342	0.6916129	0.17234792	0.18024425	0.18333058	0.6570902	0.41943178	0.6264256	0.53623605	0.6270985	1
toluidine blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid toluidine blue. Take an alternate therapy.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Proceed taking toluidine blue as normal. There is no recommendation.	For individuals who are classified as G6PD Indeterminate, there is a potential risk of hemolysis when using oxidizing agents like toluidine blue. Clinical guidance would generally advise caution; alternative diagnostic or therapeutic options that do not pose a risk of inducing hemolytic anemia should be considered. Healthcare providers may recommend conducting further tests to clarify the individual's G6PD status before administering such agents.	0.6149579267868497	0.38046713247243874	0.3319291540459879	0.5964755347126779	0.5058694	0.25050306	0.29103774	0.6010154	0.55768824	0.29739705	0.25317505	0.61114967	0.50526386	0.17507719	0.15172201	0.5976197	0.593255	0.44400343	0.41728577	0.579971	0
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking toluidine blue as normal. There is no recommendation.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Avoid toluidine blue. Take an alternate therapy.	Individuals with Central Nervous System Hemolytic Anemia (CNSHA) due to G6PD deficiency should avoid exposure to toluidine blue. This dye can trigger hemolytic episodes in patients with G6PD deficiency, potentially leading to severe anemia and related complications. Therefore, clinical guidance strongly recommends the use of alternative agents that do not have oxidative stress-inducing properties in these patients.	0.22279642819754614	0.2980446336423948	0.2584023072366985	0.525695254478012	0.25696427	0.37050304	0.28443608	0.6560313	0.10217134	0.14705415	0.16725342	0.6141917	0.13685267	0.18024425	0.18333058	0.60217047	0.48468542	0.6264256	0.53623605	0.6769599	1
toluidine blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	No reason to avoid ased on G6PD status	['Avoid toluidine blue. Take an alternate therapy.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Proceed taking toluidine blue as normal. There is no recommendation.	For an individual who has normal glucose-6-phosphate dehydrogenase (G6PD) activity, there are generally no specific clinical concerns when taking toluidine blue. However, it is crucial to follow standard dosing recommendations and observe for any unusual side effects, as individual responses to medications can vary. Always consult a healthcare professional before starting new medications to ensure it is appropriate for your specific health context.	0.5484853380767751	0.3832973724406889	0.27439065600628215	0.6460873086146802	0.38386932	0.3332946	0.17082961	0.7229658	0.35724622	0.20651574	0.10903177	0.79582554	0.2453959	0.1498567	0.09597397	0.74211985	0.40225846	0.39933273	0.30317935	0.6060169	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Use tramadol label recommended age- or weight-specific dosing.	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	For someone classified as a Normal Metabolizer with an activity score of 2.25 for CYP2D6, the typical clinical guidance for taking tramadol is that standard dosing regimens are generally appropriate. Normal metabolizers effectively convert tramadol to its active metabolite, offering effective pain relief with a standard dose. However, as always, individual response and potential side effects should be monitored by a healthcare provider.	0.5468874087694818	0.6038994949920677	0.6141755963826413	0.6147438517624075	0.5778057	0.5441053	0.60032505	0.52750975	0.60430115	0.7159648	0.6857438	0.6176299	0.61722094	0.717866	0.6263256	0.6079398	0.58514065	0.649606	0.6656346	0.61386925	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	['Proceed taking tramadol as normal. There is no recommendation.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Avoid tramadol. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer with a CYP2D6 activity score of 2.75, clinical guidance would recommend caution or avoidance when prescribing tramadol. Ultrarapid metabolizers convert tramadol more quickly to its active metabolite, O-desmethyltramadol, increasing the risk of serious side effects such as respiratory depression. Alternative pain management strategies should be considered to avoid potential adverse effects.	0.5879192365650254	0.65166882131708	0.6042582884576166	0.5674435150710234	0.6091056	0.7926296	0.6635241	0.5284436	0.62376076	0.8252405	0.69806117	0.5654315	0.66989064	0.70845723	0.6453412	0.6625111	0.57266134	0.8070759	0.6973669	0.58595073	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	No recommendation	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	For patients whose CYP2D6 status is indeterminate, clinical guidance generally recommends caution when prescribing tramadol. Due to variability in CYP2D6 enzyme activity, such patients may have unpredictable responses to tramadol, ranging from insufficient pain control to increased risk of adverse effects. It may be advisable to consider alternative analgesics that do not rely heavily on CYP2D6-mediated metabolism or to closely monitor the patient's response if tramadol is used.	0.2406161132036417	0.4600213841923948	0.19723027660599546	0.5685721348139088	0.17844808	0.29108873	0.1541182	0.58857036	0.033548962	0.15144742	0.060811922	0.58814216	0.0373754	0.3331763	0.09190323	0.62731904	0.38767964	0.51242226	0.40023413	0.60258585	0
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	For an individual who is an intermediate metabolizer with a CYP2D6 activity score of 0.5, the use of tramadol requires caution. Due to reduced enzymatic activity, they may have diminished conversion of tramadol to its active metabolite, leading to decreased analgesic efficacy. Alternative pain management strategies or medications not reliant on CYP2D6 metabolism should be considered to ensure effective pain control.	0.5347899026798265	0.587250480160361	0.5907024537820077	0.5383278014659192	0.5587797	0.6682551	0.6443482	0.54851395	0.544821	0.73243827	0.67626715	0.59429014	0.57832336	0.6370095	0.54356027	0.5843728	0.5112293	0.5737987	0.5163027	0.5485771	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	For a patient identified as an intermediate metabolizer with an activity score of 0.75 for CYP2D6 and a rapid metabolizer for CYP2C19, the metabolism of trimipramine may be altered. Adjustments in dosing may be necessary to achieve therapeutic efficacy while minimizing adverse effects due to altered drug levels. Close monitoring and potentially selecting an alternative medication may be recommended depending on the clinical response and side effect profile.	0.8184668702961354	0.7205071124789763	0.6967962886416269	0.6406317270722143	0.73017687	0.6132038	0.5084726	0.5273384	0.82049924	0.6125775	0.5228842	0.6631179	0.823778	0.60412467	0.5893733	0.61967695	0.80793214	0.67121416	0.63971174	0.64653033	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	For someone who is an Intermediate Metabolizer (activity score = 0.25) for CYP2D6 and a Poor Metabolizer for CYP2C19, the use of trimipramine might require careful consideration due to the potential for reduced metabolism and increased risk of adverse effects. Trimipramine is metabolized primarily by these enzymes; therefore, dose adjustments and close monitoring for side effects, particularly central nervous system effects, are advisable. Consulting with a healthcare professional for potential alternative medications or tailored dosing is recommended.	0.7640184713644256	0.7771476589904226	0.7680207899772258	0.6608958383141303	0.6433788	0.6677426	0.55407435	0.5607656	0.68719476	0.665936	0.58458394	0.7190299	0.60796887	0.62257713	0.5840695	0.6199146	0.66308194	0.67260283	0.58920425	0.64701146	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	For someone with no available result for CYP2D6 and an activity score that is also unavailable, alongside being a rapid metabolizer for CYP2C19, the clinical guidance for taking trimipramine should consider standard dosing due to the unknown CYP2D6 status. However, close monitoring is advised, particularly for efficacy and adverse effects, due to the CYP2C19 rapid metabolism potentially affecting the drug's overall pharmacokinetics. Adjustments may be needed based on the clinical response and tolerability.	0.6279154215201324	0.5792876271934558	0.5271472954129592	0.6222917740585443	0.6940157	0.52675956	0.43399516	0.53224885	0.647701	0.44597912	0.3908305	0.67004687	0.6170535	0.52155083	0.50305074	0.59494835	0.6048147	0.59707296	0.51390237	0.6026036	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid trimipramine. Take an alternate therapy.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Proceed taking trimipramine as normal. There is no recommendation.	For a patient identified as a normal metabolizer with an activity score of 1.5 for CYP2D6 and no result for CYP2C19, standard dosing of trimipramine is generally appropriate, as their CYP2D6 function is sufficient to metabolize the drug effectively. However, due to the lack of CYP2C19 information, it would be prudent to monitor the patient closely for any adverse effects or therapeutic inefficacy and adjust dosage if necessary. It is always recommended to consider comprehensive genotypic data and clinical factors before making final dosing decisions.	0.42564764590373066	0.4863876319797294	0.4991228368314869	0.6687294960982524	0.3911033	0.34320813	0.4081172	0.5571552	0.37554145	0.47519058	0.3911542	0.68929887	0.36720583	0.47008038	0.4813083	0.5846216	0.4383425	0.54109067	0.5978351	0.6280185	0
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (activity score ≥6.0) for CYP2D6, the clinical guidance would recommend avoiding the use of tropisetron due to the risk of reduced efficacy. This is because ultrarapid metabolizers may process the drug too quickly, leading to subtherapeutic levels and insufficient antiemetic effect. Alternative medications less dependent on CYP2D6 metabolism should be considered.	0.5936213432486125	0.5835268545103266	0.47303160652976484	0.6661288678152191	0.7159858	0.47649994	0.4419063	0.6135564	0.7524845	0.36477804	0.40524304	0.6260789	0.73536986	0.46304816	0.50664824	0.6024156	0.6424061	0.6042384	0.56028277	0.6753044	1
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid tropisetron. Take an alternate therapy.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Proceed taking tropisetron as normal. There is no recommendation.	For someone who is a normal metabolizer with an activity score of 1.75 for CYP2D6, clinical guidance would generally indicate that standard dosing of tropisetron is appropriate. This metabolizing status suggests that they will process the drug as expected, with no need for dose adjustments due to concerns about enhanced or reduced metabolic activity.	0.4458688163710131	0.516534548537015	0.5169334524902284	0.6515952359601662	0.42660037	0.41645208	0.5192625	0.559215	0.4235235	0.5008607	0.4915854	0.6914585	0.3766326	0.49092492	0.50587296	0.59690624	0.42654684	0.46484816	0.56466436	0.59145135	1
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	For someone identified as an Ultrarapid Metabolizer (UM) with an activity score of 2.75 for CYP2D6, which metabolizes tropisetron, the clinical guidance suggests they might experience reduced efficacy of the drug due to accelerated metabolism. This could result in subtherapeutic drug levels, leading to inadequate symptom control. Alternative antiemetics not extensively metabolized by CYP2D6, such as ondansetron or granisetron, may be considered.	0.616126219012393	0.5835268545103266	0.47303160652976484	0.5900856867761844	0.49753025	0.47649994	0.4419063	0.5221677	0.75723946	0.36477804	0.40524304	0.5772031	0.69917774	0.46304816	0.50664824	0.4542522	0.65302694	0.6042384	0.56028277	0.633476	1
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	For individuals identified as CYP2D6 ultrarapid metabolizers (activity score ≥5.0), taking tropisetron may result in reduced efficacy due to increased metabolic clearance. Clinical guidance often recommends considering an alternative antiemetic agent that is not significantly metabolized by CYP2D6 to ensure effective symptom control.	0.5836356625930116	0.5835268545103266	0.47303160652976484	0.6766691986483917	0.64873827	0.47649994	0.4419063	0.61943096	0.6932114	0.36477804	0.40524304	0.62605304	0.7290304	0.46304816	0.50664824	0.5724265	0.63890976	0.6042384	0.56028277	0.67557603	1
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For an individual identified as an Ultrarapid Metabolizer with a CYP2D6 activity score of ≥3.5, the clinical guidance would be to avoid the use of venlafaxine due to the risk of subtherapeutic drug levels and inadequate response. Alternative antidepressants that are not primarily metabolized by CYP2D6, such as escitalopram or sertraline, should be considered.	0.6040860245178581	0.644248746656721	0.5854100535380422	0.5648654663382672	0.57451445	0.5338721	0.3698864	0.6010925	0.5533914	0.6544883	0.5178928	0.50312847	0.53993875	0.6193784	0.52694565	0.5254987	0.5402758	0.66103476	0.52958214	0.61662287	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For an individual who is a normal metabolizer with a CYP2D6 activity score of 1.75, standard dosing guidelines for venlafaxine generally apply. Normal metabolizers typically process the drug efficiently and are expected to achieve therapeutic effects without unusual risk of adverse effects. Clinical monitoring as per usual care standards should be followed.	0.381718907132166	0.4708254935308498	0.4944210664684275	0.6482740987342263	0.44022992	0.39294913	0.43581223	0.52583176	0.40272826	0.50705934	0.40087855	0.6124365	0.38427383	0.47035256	0.49559298	0.5901156	0.40057358	0.545141	0.5885901	0.63378143	1
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For individuals who are ultrarapid metabolizers (UMs) with a CYP2D6 activity score of 2.75, the clinical guidance regarding venlafaxine usage suggests that these patients may have an increased conversion of venlafaxine to its active metabolite, resulting in potentially reduced efficacy. An alternative medication not metabolized by CYP2D6 may be recommended, or venlafaxine dosage may need careful adjustment under close monitoring of therapeutic drug levels and clinical response. Consulting with a healthcare provider specialized in pharmacogenomics would provide the most personalized and accurate approach.	0.6359497392131277	0.644248746656721	0.5854100535380422	0.579709408684736	0.41701838	0.5338721	0.3698864	0.54393667	0.6459676	0.6544883	0.5178928	0.49123693	0.5506429	0.6193784	0.52694565	0.49234006	0.55335873	0.66103476	0.52958214	0.59988064	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For individuals identified as CYP2D6 Ultrarapid Metabolizers (UMs) with an activity score of ≥4.0, clinical guidance generally suggests using an alternative medication to venlafaxine if possible. UMs are likely to metabolize venlafaxine too quickly, potentially leading to reduced efficacy due to lower plasma concentrations of the active metabolite, O-desmethylvenlafaxine (ODV). Therefore, considering an alternative antidepressant that is less dependent on CYP2D6 metabolism may be preferred.	0.6038302138810132	0.644248746656721	0.5854100535380422	0.5787125188519513	0.40065646	0.5338721	0.3698864	0.5616503	0.58099735	0.6544883	0.5178928	0.5011466	0.5073938	0.6193784	0.52694565	0.514667	0.5263754	0.66103476	0.52958214	0.60066915	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	For individuals with a G6PD deficiency, high doses of vitamin C (ascorbic acid) can precipitate hemolysis and should be avoided. Clinical guidance generally recommends caution with vitamin C supplementation, especially in doses exceeding 500 mg per day. It is advisable for patients to consult their healthcare provider before taking vitamin C supplements.	0.605652280375167	0.4530491447979341	0.3086773055509428	0.543376092612317	0.58718073	0.49443772	0.2869438	0.6476442	0.5780295	0.3930725	0.2049738	0.6529329	0.5633869	0.42404598	0.3162838	0.6110096	0.54216385	0.46612504	0.38801512	0.5489845	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	For an individual with an indeterminate status for glucose-6-phosphate dehydrogenase (G6PD) deficiency, caution is advised when taking high doses of vitamin C. Although routine dietary intake of vitamin C is generally considered safe, high doses may pose a risk for hemolysis in G6PD-deficient individuals. It is recommended to consult a healthcare provider before taking large amounts of vitamin C supplements.	0.6121510880427732	0.3463488797369956	0.25406358202995927	0.5189166787391061	0.4516738	0.19731872	0.21267378	0.64930826	0.50073034	0.22739428	0.17187023	0.6686321	0.40350536	0.18388677	0.15508582	0.6046702	0.43223655	0.35586616	0.36363068	0.59900415	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), should exercise caution when taking high doses of vitamin C, as it has the potential to induce hemolysis. While typical dietary intake of vitamin C is generally safe, doses exceeding 1000 mg/day should be avoided without medical supervision. Regular monitoring and consultation with healthcare providers are essential to manage risk.	0.476308291275367	0.3512040468873965	0.38163011984965345	0.5077532420265694	0.52606195	0.4344965	0.43427587	0.6148467	0.4512884	0.3810941	0.37049732	0.6571983	0.46558782	0.28539318	0.24695516	0.61631525	0.5401698	0.38313934	0.43508217	0.61001444	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	Individuals with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme levels generally do not have G6PD deficiency and can safely take vitamin C within recommended dietary limits. Clinical guidance suggests that they do not face an increased risk of hemolytic anemia associated with vitamin C consumption, unlike those with G6PD deficiency who may need to be cautious with high doses.	0.6603783975910842	0.3859070158334298	0.23369164048637306	0.5273726473069693	0.46415445	0.33424133	0.14917247	0.60596377	0.42470694	0.21868818	0.08659527	0.6126793	0.4294069	0.16924903	0.10133482	0.59674025	0.5036831	0.3842258	0.29911327	0.60512245	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), taking vitamin K should be approached with caution, particularly intravenous formulations, as they might increase the risk of hemolysis. It is recommended to consult a healthcare professional before starting any vitamin K supplementation to ensure safe management and avoid potential complications related to G6PD deficiency.	0.576265669386222	0.47501739067051013	0.33179988189873705	0.5871565384909346	0.5834113	0.5270561	0.32932243	0.64812803	0.60742104	0.43850276	0.254809	0.69685775	0.5769129	0.4333759	0.34540677	0.6513078	0.53886026	0.47779936	0.3998872	0.5506456	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals with an indeterminate G6PD (glucose-6-phosphate dehydrogenase) status, cautious use of drugs that may precipitate hemolysis is recommended due to potential G6PD deficiency. However, vitamin K is generally considered safe and does not typically trigger hemolytic events in G6PD-deficient individuals. It is still advisable to consult with a healthcare provider for personalized medical advice.	0.6575371011962532	0.36048308470507007	0.2647857721506815	0.49681224832542575	0.5284618	0.2332723	0.25797138	0.63708824	0.5965861	0.29695123	0.23800881	0.63529766	0.53116715	0.21016854	0.19161749	0.5518584	0.51599455	0.34533143	0.3607073	0.53649545	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency who experience Chronic Nonspherocytic Hemolytic Anemia (CNSHA) should generally avoid vitamin K supplements, especially in synthetic forms like vitamin K3 (menadione), which can exacerbate hemolysis. However, vitamin K1 (phylloquinone) and vitamin K2 (menaquinone) have not been shown to pose the same risk and can be safely included in the diet. Always consult with a healthcare provider before starting any new supplements.	0.4199338717935785	0.3777663797910543	0.4139123206713564	0.5351713924449123	0.4687862	0.43144685	0.4303917	0.6370747	0.43423676	0.38260683	0.35706958	0.63438886	0.38316357	0.30072802	0.2888585	0.6147079	0.46071464	0.3988476	0.46758947	0.53288484	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals with normal G6PD enzyme activity, there are generally no specific pharmacogenomic contraindications or special precautions needed when taking vitamin K. They can use vitamin K as prescribed for indications such as reversing the effects of anticoagulants like warfarin, or addressing vitamin K deficiency, without increased risk for hemolytic anemia, which can be a concern in those with G6PD deficiency.	0.6372528712826275	0.40275047664842	0.2574267683750323	0.6068291825012888	0.44226	0.36030218	0.16898845	0.648649	0.4306864	0.24453539	0.101157606	0.662448	0.39097515	0.16376248	0.10161227	0.5984546	0.48338053	0.3848919	0.29952303	0.59068185	1
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	No recommendation	['Avoid voriconazole. Take an alternate therapy.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Proceed taking voriconazole as normal. There is no recommendation.	Clinical guidance for an individual with an indeterminate CYP2C19 genotype regarding voriconazole should involve therapeutic drug monitoring (TDM) to ensure optimal dosing, as CYP2C19 metabolism significantly affects voriconazole levels. Because the indeterminate status implies unknown enzyme activity, close monitoring of drug concentrations and patient response is recommended to adjust dosing and minimize adverse effects or therapeutic failure.	0.21933596746136955	0.4455232856732073	0.21188961765860967	0.5885731608356977	0.083155766	0.3322561	0.17737858	0.52561045	0.048287265	0.2217329	0.11324045	0.6128591	-0.09107549	0.2889275	0.06293388	0.456258	0.24684492	0.50118655	0.36249557	0.54079974	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.	['Proceed taking voriconazole as normal. There is no recommendation.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Avoid voriconazole. Take an alternate therapy.	For individuals identified as ultrarapid metabolizers of CYP2C19, it is generally recommended to avoid the use of voriconazole due to the likelihood of subtherapeutic drug levels, which can lead to ineffective treatment. Alternative antifungal agents that are not significantly metabolized by CYP2C19 should be considered to ensure effective management of the fungal infection. If voriconazole must be used, therapeutic drug monitoring is essential to adjust the dose and ensure adequate drug exposure.	0.7322903079770329	0.7363010412312784	0.571944090432645	0.682942448731733	0.7107525	0.69853616	0.58659106	0.6885777	0.7735982	0.7335008	0.6654613	0.6185479	0.7574333	0.62062955	0.5397119	0.57295376	0.82013166	0.6731476	0.59010226	0.68024355	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Initiate therapy with recommended standard of care dosing	['Avoid voriconazole. Take an alternate therapy.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Proceed taking voriconazole as normal. There is no recommendation.	For individuals who are intermediate metabolizers (IM) of CYP2C19, clinical guidance suggests an increased risk of higher voriconazole concentrations and associated toxicity. Therefore, alternative antifungal agents that do not depend on CYP2C19 metabolism, such as isavuconazole or posaconazole, are recommended. If voriconazole is necessary, close monitoring of drug levels and patient response is advised to adjust dosages appropriately.	0.4089103009026042	0.4988635947310312	0.4739205566232929	0.6201699785249483	0.41902503	0.4721097	0.49840656	0.5889405	0.3747079	0.53591084	0.45065174	0.60911304	0.33206233	0.40004098	0.33257806	0.5333753	0.3987881	0.49174157	0.51202404	0.5986083	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	['Proceed taking voriconazole as normal. There is no recommendation.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Avoid voriconazole. Take an alternate therapy.	For individuals identified as Poor Metabolizers (PMs) for CYP2C19, voriconazole dosage adjustments are typically recommended due to the decreased clearance of the drug, which can lead to higher plasma concentrations and an increased risk of adverse effects. Clinical guidelines generally suggest alternative antifungal therapy or consider reducing the voriconazole dose and closely monitoring for side effects and therapeutic drug levels.	0.7782331871639524	0.7293043454782862	0.6248677398839856	0.64219992839489	0.6363111	0.71913785	0.6085643	0.575773	0.8173235	0.6723702	0.6184731	0.6190832	0.7546368	0.601125	0.539354	0.5492387	0.7233984	0.6367206	0.56936795	0.63461155	1
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	For individuals identified as Intermediate Metabolizers with a CYP2D6 activity score of 0.75, caution is advised when prescribing vortioxetine. This is because reduced CYP2D6 activity may lead to decreased clearance of the drug, potentially increasing the risk of adverse effects. Clinical guidelines suggest a lower starting dose and close monitoring for signs of toxicity or other side effects.	0.46084006488157303	0.5076852353817526	0.5230715940737068	0.6045479877770816	0.39636096	0.40537333	0.44112	0.5898791	0.37272713	0.512008	0.43013254	0.6569759	0.4093063	0.5017084	0.5267878	0.63053846	0.47110263	0.5229069	0.6068345	0.6339576	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	['Proceed taking vortioxetine as normal. There is no recommendation.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Avoid vortioxetine. Take an alternate therapy.	For someone who is an Ultrarapid Metabolizer with a CYP2D6 activity score of ≥3.0, clinical guidance indicates that they may experience lower plasma concentrations of vortioxetine, potentially reducing the drug’s efficacy. It may be necessary to monitor the patient closely for therapeutic response and consider alternative treatments if adequate symptom control is not achieved.	0.7765240573884663	0.7034353195833725	0.6783166653460384	0.6325270770772584	0.73182243	0.61908376	0.55448776	0.62288517	0.7615702	0.6243583	0.5784005	0.6647605	0.69790846	0.660748	0.63511544	0.57647705	0.7063391	0.61376745	0.5884796	0.66385007	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	For individuals identified as intermediate metabolizers of CYP2D6 with an activity score of 1.0 taking vortioxetine, clinical guidance suggests cautious dose adjustments may be necessary. Although specific dosage recommendations can vary, it's generally advised to monitor the patient closely for potential adverse effects and therapeutic efficacy, and adjust the dose accordingly to achieve optimal treatment response.	0.4766192294248918	0.5076852353817526	0.5230715940737068	0.6255766228713721	0.47646305	0.40537333	0.44112	0.54572	0.43549487	0.512008	0.43013254	0.68297315	0.45699543	0.5017084	0.5267878	0.61026925	0.5526193	0.5229069	0.6068345	0.63063467	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	For an individual identified as an intermediate metabolizer with a CYP2D6 activity score of 0.5, clinical guidance would typically recommend careful monitoring when prescribed vortioxetine. This is because intermediate metabolizers may have reduced enzyme activity leading to higher plasma concentrations of the drug, which can increase the risk of adverse effects. Dose adjustments may be considered depending on the patient's response and tolerance to the medication.	0.4403048246684643	0.5076852353817526	0.5230715940737068	0.600946363976582	0.39205626	0.40537333	0.44112	0.52939975	0.37851003	0.512008	0.43013254	0.62922275	0.38581133	0.5017084	0.5267878	0.61801076	0.45751134	0.5229069	0.6068345	0.5995786	0
